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RESUMO 
O tecido ósseo é um tecido conjuntivo especializado que contém células 
(osteoblastos, osteoclastos, osteócitos) e minerais depositados numa matriz 
orgânica de colagénio. A remodelação contínua do osso possibilita a sua 
reparação, crescimento e adaptação. Numa vida, muitas anomalias podem levar a 
alterações neste processo que é controlado de modo fino, resultando numa 
grande diversidade de doenças ósseas e anomalias esqueléticas (como a 
osteoporose). O desenvolvimento de novas terapias para as doenças ósseas é de 
grande relevância visto que muitas destas alterações têm uma crescente 
prevalência na população humana envelhecida. 
A remodelação óssea é um processo complexo que é regulado de forma 
apertada. Para além do envolvimento de fatores sistémicos, intervêm diversos 
fatores locais, tais como o 5’-trifosfato de adenosina (ATP) e os seus derivados 
(como a adenosina). Foi demonstrado que células ósseas osteoprogenitoras 
(como as células mesenquimatosas) e os osteoblastos libertam constitutivamente 
nucleótidos (como por exemplo o ATP) quando são sujeitas a estímulos 
mecânicos ou em situações patológicas, como a hipoxia e a inflamação. Os 
nucleótidos podem ser libertados por vários mecanismos: (1) lesão celular e 
tecidular (incluindo locais de lesão óssea), (2) por exocitose e (3) por intermédio 
de canais ou poros membranares na ausência de lise celular, incluindo neste 
último mecanismo as junções estreitadas. Uma vez libertados, os nucleótidos e 
seus derivados podem ativar recetores purinérgicos que são importantes 
moduladores da formação óssea, embora a sua ação seja ainda amplamente 
desconhecida. Os recetores para as purinas e pirimidinas podem ser classificados 
em dois tipos: recetores P1 (A1, A2A, A2B e A3), que são ativados pela adenosina, 
e recetores P2, ativados pelos nucleótidos de adenina e uracilo (e.g. ATP, ADP, 
UTP, UDP). Estes podem ser subdivididos em recetores P2X ionotrópicos (canais 
iónicos ativados por ligandos) e recetores P2Y metabotrópicos (acoplados a 
proteínas G). A ativação dos recetores purinérgicos é balanceada pela atividade 
de ecto-nucleotidases expressas na membrana das células, que promovem o 
metabolismo extracelular dos nucleótidos, levando à formação dos respetivos 
nucleósidos 5’-di- e mono-fosfatos, nucleósidos, fosfatos e pirofosfatos. 
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Existem evidências de que a sinalização purinérgica exerce um efeito local 
complexo nas células ósseas. Contudo, existe uma enorme controvérsia em torno 
da importância de cada recetor purinérgico e das enzimas metabolizadoras dos 
nucleótidos, bem como em saber de que modo a interação entre estes 
intervenientes promove a remodelação óssea. Infelizmente, muitos dos estudos 
derivam da utilização de modelos animais e do uso de células humanas 
imortalizadas, sendo ainda escassos os trabalhos realizados em células humanas 
não modificadas (osteoprogenitoras e osteoblastos). 
Visto que a sinalização purinérgica tem sido associada a diferentes patologias 
ósseas, torna-se imprescindível o seu estudo na tentativa de clarificar os 
mecanismos moleculares responsáveis pela atuação dos nucleótidos e 
nucleósidos na remodelação óssea em situação fisiológica e na doença. O 
sucesso deste estudo poderá resultar na descoberta de novos alvos terapêuticos 
para as patologias ósseas. Este projeto foi delineado para avaliar a expressão 
diferencial dos recetores P2 nas células humanas osteoprogenitoras / 
osteoblastos atendendo à idade e género dos doentes. Foi, ainda, decidido 
documentar as respostas funcionais destas células na presença de nucleótidos no 
meio extracelular e investigar o envolvimento de alguns subtipos de recetores P2 
na libertação de ATP e na plasticidade membranar responsável pelos fenómenos 
de diferenciação/proliferação celular. Devido à sua relevância no controlo da 
atividade purinérgica, estudou-se a influência das NTPDases na proliferação, 
diferenciação e mineralização das células osteoprogenitoras. Especificamente, 
neste projeto investigou-se: (1) a expressão e o papel funcional dos recetores 
sensíveis a nucleótidos de uracilo (P2Y2, P2Y4, e P2Y6) em células 
osteoprogenitoras / osteoblastos, visto que o seu papel na diferenciação 
osteogénica era desconhecido; (2) a expressão e função dos recetores 
ionotrópicos P2X7 na osteogénese humana, explorando os mecanismos 
moleculares envolvidos no sentido de esclarecer alguma controvérsia sobre o 
papel destes recetores existente na literatura, no que toca às células humanas; 
(3) a importância das NTPDases na proliferação e diferenciação das células 
osteoprogenitoras da medula óssea em mulheres jovens e com idade pós-
menopáusica. 
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As amostras de medula óssea foram obtidas de mulheres pós-menopáusicas 
sujeitas a artroplastia da anca como resultado de osteoporose primária. Para 
comparação, foram obtidas amostras da medula óssea proveniente de mulheres 
jovens sujeitas a colheita de enxerto ósseo para correção cirúrgica de escoliose 
ou fraturas traumáticas. O isolamento das células estromais mesenquimatosas 
foi demonstrado por análise imunofenotípica por citometria de fluxo; estas 
células apresentavam marcadores encontrados caracteristicamente em células 
mesenquimatosas multipotentes da medula óssea, nomeadamente os 
marcadores CD105, CD73, CD117 e CD29, não apresentando marcação para 
células estaminais hematopoiéticas, nomeadamente CD14 e CD45.  
Relativamente ao objetivo (1), verificou-se que a incubação das células 
estromais mesenquimatosas da medula óssea (MSCs) provenientes de mulheres 
pós-menopáusicas com UTP ou UDP promove a sua diferenciação osteogénica, 
traduzindo-se num aumento de atividade da fosfatase alcalina (ALP) para níveis 
semelhantes aos observados em mulheres jovens, sem contudo se observar 
qualquer efeito na proliferação celular. Os nucleótidos de uracilo aumentam de 
forma dependente da concentração os níveis de cálcio intracelular ([Ca2+]i) em 
MSCs. No entanto, estes efeitos tornam-se menos evidentes com o tempo das 
células em cultura (7>21 dias). A ativação seletiva de recetores P2Y6 com o 
análogo estável do UDP, PSB 0474, mimetizou os efeitos do UTP e do UDP, 
enquanto o análogo estável do UTP, UTPγS, foi desprovido de efeito. O 
antagonista seletivo do recetor P2Y6, MRS 2578, preveniu o aumento dos níveis 
intraceulares de [Ca2+]i e a diferenciação osteogénica provocada pelo UDP em 
todos os períodos de cultura analisados. As MSCs demonstram imuno-reatividade 
para os recetores P2Y2, P2Y4, e P2Y6. Enquanto a expressão do recetor P2Y6 se 
mantém constante ao longo do período de cultura (7~21 dias), a expressão dos 
recetores P2Y2 e P2Y4 é mais evidente em células mais diferenciadas (7<21 
dias). O catabolismo extracelular dos nucleótidos de uracilo, UTP e UDP, foi maior 
em células menos proliferativas e mais diferenciadas (7<21 dias), que é justificado 
pelo aumento da expressão das NTPDases1, -2 e -3 nas populações de células 
mais diferenciadas (7<21 dias). 
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No que concerne ao objetivo (2), verificámos que o ATP e o agonista do recetor 
P2X7 aumentam os níveis intracelulares de [Ca2+]i em MSCs, paralelamente à 
formação de poros membranares permeáveis à sonda TO-PRO-3. A ativação dos 
recetores P2X7 promove a formação reversível de microvesículas na membrana 
plasmática e a formação de bolhas (zeiose) em MSCs. Apesar da diferenciação 
osteogénica promovida pelas alterações na dinâmica membranar ser 
independente do [Ca2+]i, ela parece envolver a atividade da PLC (fosfolipase C), 
da PKC (proteína cinase C) e da Rho-cinase secundárias à ativação do recetor 
P2X7. O agonista P2X7, BzATP, antecipa a diferenciação osteogénica (aumento 
da atividade ALP e da expressão dos fatores de transcrição Runx-2 e Osterix) e 
promove a mineralização das culturas de MSCs. 
Quanto ao objetivo (3), demonstrámos que o catabolismo extracelular dos 
nucleótidos de adenina e uracilo leva a uma perda da atividade dos recetores 
P2Y6 e P2X7 em MSCs de mulheres pós-menopáusicas quando comparado com 
as mulheres jovens. Verificou-se que a expressão da NTPDase3 aumenta com o 
tempo das células em cultura nas mulheres pós-menopáusicas, sendo que esta 
enzima está ausente em MSCs de mulheres jovens. A inibição seletiva da 
NTPDase3 com o fármaco, PSB 06126, aumenta 3.6 vezes os níveis endógenos 
de ATP em culturas de MSCs de mulheres pós-menopáusicas avaliadas ao dia 7. 
A inibição da NTPDase3 favorece a atividade da ALP e promove a expressão de 
marcadores de osteogénese, Runx-2 e Osterix, ao longo do tempo de cultura. É, 
ainda, de realçar que a inibição da atividade da NTPDase aumentou de forma 
significativa (P<0.05) a formação de nódulos de mineralização nas culturas de 
MSCs comparativamente as mesmas culturas na ausência dos inibidores. Este 
efeito positivo na osteogénese foi totalmente prevenido na presença de apirase 
(CD39), a enzima que converte nucleótidos de adenina (ATP) e uracilo (UTP) nos 
seus derivados monofosfatados, AMP e UMP respectivamente. O antagonismo 
seletivo de recetores P2X7 e P2Y6 atenuou (P<0.05) de igual forma os efeitos dos 
inibidores da NTPDase3 na osteogénese. 
Concluindo, neste trabalho demonstra-se que os nucleótidos de uracilo são 
importantes reguladores da diferenciação de células osteoprogenitoras, 
predominantemente por intermédio da ativação de recetores P2Y6 sensíveis ao 
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UDP por um mecanismo associado ao aumento dos níveis de [Ca2+]i. A ação 
endógena dos nucleótidos de uracilo pode ser balanceada por NTPDases 
específicas que irão determinar se as células osteoprogenitoras se diferenciam ou 
proliferam; verificou-se, ainda, que o recetor P2X7 é um importante regulador da 
diferenciação osteogénica e da consequente mineralização das MSCs humanas 
em cultura. Os mecanismos dependentes da ativação P2X7 podem envolver 
oscilações do [Ca2+]i e alterações na dinâmica membranar (formação de poros e 
de bolhas) por mecanismos dependentes da atividade da PLC, PKC e Rho-
cinase; estes processos controlam a expressão de marcadores envolvidos na 
diferenciação osteogénica, tais como o Runx-2 e o Osterix. Demonstrou-se, ainda, 
que a expressão da NTPDase3 controla a atividade dos recetores P2 nas MSCs 
em mulheres pós-menopáusicas. A expressão da NTPDase3 parece aumentar 
com a idade, facto que pode contribuir para reduzir dos níveis endógenos de 
nucleótidos de adenina e de uracilo na medula óssea das mulheres pós-
menopáusicas e, deste modo, a ativação de importantes promotores da 
osteogénese, nomeadamente os recetores P2X7 e P2Y6.  
O conhecimento de alvos reguladores da diferenciação osteogénica 
anteriormente ignorados permitem agora o desenvolvimento de novas estratégias 
terapêuticas para controlar as doenças ósseas em que a erosão se sobrepõe à 
formação de novo osso, tais como a osteoporose, a artrite reumatoide e 
osteogénese imperfecta.  
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ABSTRACT 
Bone is a specialized connective tissue, containing cells (osteoblasts, 
osteoclasts and osteocytes) and inorganic mineral salts deposited within an 
organic collagen matrix. The continuous remodelling of the bone allows it to repair, 
to grow and adapt. Throughout life, many abnormalities in such balanced process 
may result in a huge variety of bone disorders and skeletal abnormalities (such as 
osteoporosis). The development of new therapeutic approaches is of major 
importance since some bone disorders are highly prevalent and in increasing 
incidence on an ageing population.  
Bone turnover is a complex and finely tuned process. To the importance of 
systemic factors that regulate bone turnover, we must include the role of local 
factors such as adenosine 5’-triphosphate (ATP) and its derivatives (such as 
adenosine). It was previously found that bone cells, such as osteoprogenitors 
(mesenchymal stem cells, MSCs) and osteoblasts constitutively release 
nucleotides (e.g. ATP) when submitted to mechanical stress or under pathological 
conditions, such as hypoxia and inflammation. Nucleotides may be released into 
the extracellular milieu through distinct mechanisms: (1) cytosolic release of ATP 
from sites of tissue and cell damage (including sites of bone injury), (2) exocytic 
release and (3) via intrinsic plasma membrane channels or pores in the absence 
of cytolysis, which includes hemichannels controlled release. Once released, 
nucleotides and their derivatives may act on purinoceptors, which are important 
(yet largely unknown) bone turnover regulators. The receptors for purines and 
pyrimidines are classified into two groups: P1 receptors (A1, A2A, A2B, A3), which 
are primarily activated by adenosine, and P2 receptors, which respond to adenine 
and uracil nucleotides (e.g. ATP, ADP, UTP, UDP). The latter may be further 
subdivided into P2X ligand-gated ion channels and P2Y G-protein-coupled 
receptors. Purinoceptors activation may be terminated by ecto-nucleotidases and 
other ecto-phosphatases bound to the plasma membrane, which rapidly hydrolyse 
extracellular nucleotides to their respective nucleoside 5’-di- and mono-
phosphates, nucleosides and free phosphates or pyrophosphates. 
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Current evidence shows that purinergic signalling exerts complex local effects in 
bone microenvironment. However, controversy still exists around the functional 
relevance of each purinergic receptor and enzyme on bone cells and how they 
may interact to promote bone remodelling. In this regard, most of the studies 
derive from using animal models and immortalized cell lines and less in non-
modified human cells (osteoprogenitors / osteoblasts).  
Since purinergic signalling has now been implicated in many bone disorders, it 
is of great importance to explore these potential targets for future therapies, 
clarifying the molecular mechanisms operating upstream and downstream 
receptors activation in both health and disease conditions. To this end, this project 
was designed to evaluate changes in the expression of P2 receptors in human 
osteoprogenitors / osteoblasts taking into consideration age and gender of the 
patients, to document functional responses to extracellular nucleotides, to 
investigate the involvement of P2 receptors on ATP release and cell-membrane 
plasticity (required for osteoblast proliferation/differentiation), and study the impact 
of NTPDases in such mechanisms. Specifically, this project aimed at investigating: 
(1) the expression and function of uracil nucleotide-sensitive receptors (P2Y2, 
P2Y4, and P2Y6) in osteoprogenitors / osteoblasts, since their role in osteogenic 
differentiation was largely unknown; (2) the expression and function of P2X7 
receptors on osteogenic differentiation of osteoprogenitors / osteoblasts in culture, 
exploring the molecular mechanisms involved; in literature, the role of the human 
P2X7 receptor is still controversial; (3) the role of the activity of NTPDases in the 
management of cell differentiation and/or proliferation, in both health and disease 
conditions; this topic is, so far, largely unknown particularly in non-modified human 
osteoprogenitor cells.  
Bone marrow specimens were obtained from postmenopausal female patients 
undergoing total hip arthroplasty as a result of primary osteoarthrosis. For 
comparison purposes, it was also used bone marrow from younger female patients 
requiring bone engraftment for spinal fusion to correct scoliosis or to repair 
traumatic bone fractures. Isolation of MSCs was proven by immunophenotypic 
analysis (flow cytometry), showing positivity for markers of bone marrow-derived 
mesenchymal stromal cells, namely CD105, CD73, CD29 and CD117, in the 
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absence of the expression of haematopoietic stem cell markers, such as CD14 
and CD45. 
Regarding goal (1), it was demonstrated that the application of UTP and UDP 
promotes osteogenic differentiation of postmenopausal bone marrow MSCs in 
culture measured as increases in alkaline phosphatase (ALP) activity to levels 
which are observed in younger patients, with no effects on cell proliferation. Uracil 
nucleotides concentration-dependently increase intracellular calcium ([Ca2+]i) in 
MSCs; their effects become less evident with the time (7>21 days) in culture. 
Selective activation of P2Y6 receptors with the stable UDP analogue, PSB 0474, 
mimicked the effects of both UTP and UDP, whereas UTPγS was devoid of effect. 
Selective blockade of P2Y6 receptors with MRS 2578 prevented [Ca2+]i rises and 
osteogenic differentiation caused by UDP at all culture time points. MSCs are 
immunoreactive against P2Y2, P2Y4, and P2Y6 receptors. While the expression of 
P2Y6 receptors remains fairly constant (7~21 days), P2Y2 and P2Y4 become 
evident only in less proliferative and more differentiated cultures (7<21 days). The 
rate of extracellular UTP and UDP inactivation was higher in less proliferative and 
more differentiated cell populations. It was also found that immunoreactivity 
against NTPDase1, 2, and 3 raises as cells differentiate (7<21 days).  
Concerning the objective (2), ATP, and the P2X7 receptor agonist, BzATP, 
increased [Ca2+]i in parallel to the formation of TO-PRO-3 permeable membrane 
pores. The two P2X7 agonists elicited reversible cell microvesiculation and plasma 
membrane blebbing (zeiosis). Differentiation-inducing plasma membrane 
dynamics was Ca2+-independent, but involved the PLC (phospholipase C), PKC 
(protein kinase C) and Rho-kinase pathway downstream P2X7 receptor activation. 
BzATP anticipated osteogenic differentiation (increases in ALP activity and in the 
expression of Osterix and Runx-2 transcription factors) and favoured 
mineralization of MSC cultures. 
Regarding goal (3), it was found that that enzymatic inactivation of extracellular 
nucleotides leads to a loss of function of P2Y6 and P2X7 purinoceptors in MSCs 
from postmenopausal women as compared to younger females. Interestingly, the 
expression of NTPDase3 increased with the culture time of MSCs from 
postmenopausal women; this enzyme was not expressed in the cells from younger 
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female patients. Selective inhibition of NTPDase3 with PSB 06126 increased by 
3.6-fold the endogenous levels of ATP in MSC cultures from postmenopausal 
woman at day 7. NTPDase3 inhibition also increased the ALP activity and 
promoted the expression of osteogenic markers, both Runx-2 and Osterix, 
throughout the culture period. Under these circumstances, mineralization of bone-
nodules increased (P<0.05) when compared to the control situation at culture day 
43. The osteogenic differentiating effect of NTPDase3 inhibition was fully 
prevented by apyrase (CD39), the enzyme that converts directly nucleoside 
trisphosphates into their monophosphate derivatives. Selective blockade of P2X7 
and P2Y6 receptors also attenuated (P<0.05) the osteogenic effect of NTPDase3 
inhibitors.  
In conclusion, we demonstrated in this study that uracil nucleotides are 
important regulators of osteogenic differentiation of MSCs via the activation of 
UDP-sensitive P2Y6 receptors coupled to increases in [Ca2+]i. The endogenous 
actions of uracil nucleotides may be balanced through the action of specific 
NTPDases determining whether osteoblast progenitors are driven into proliferation 
or differentiation. In addition, data show that the P2X7 receptor is an important 
regulator of osteogenic differentiation and subsequent mineralization of human 
MSCs in culture. The mechanisms by which the P2X7 receptor control bone 
formation might involve intracellular [Ca2+]i oscillations and membrane cell 
dynamics (pore formation and blebbing) due to downstream activation of PLC, 
PKC and Rho-kinase-dependent pathways controlling osteogenic markers, like 
Runx-2 and Osterix. Here, we show for the first time that NTPDase3 is an 
important modulator of the activity of P2 purinoceptors in MSCs from 
postmenopausal woman. Age-related overexpression of NTPDase3 may 
contribute to reduce the endogenous amounts of adenine and uracil nucleotides, 
thus compromising the activation of important inducers of osteogenesis, such as 
P2X7 and P2Y6 receptors.  
These previously unrecognized targets for local regulation of osteogenic 
differentiation of bone marrow MSCs may prompt for novel therapeutic strategies 
to control human ossification disorders where bone destruction exceeds bone 
formation (e.g., osteoporosis, rheumatoid arthritis, osteogenesis imperfecta).  
1.Introduction 
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1. INTRODUCTION 
1.1. Stem cells and the stem cell niche 
1.1.1. Adult stem cells – an introduction 
Stem cells are the foundation cells for every organ and tissue in the body. Stem 
cells are cells with the ability to grow and to differentiate into more than 200 cell 
types. These are able to divide and to give rise to identical daughter cells (known 
as symmetrical division) and to differentiate into specific cells of somatic tissues 
(Avery et al., 2006). Stem cells may be found in: early embryos (commonly known 
as embryonic stem cells) and adult tissues (known as adult stem cells).  
Stem cells can be classified with respect to their potency, that is, the 
competency of each cell to differentiate into a specialized type of tissue cells of the 
body. There are five class of potency for stem cells: totipotent, pluripotent, 
multipotent, oligopotent and unipotent (see e.g., Kaveh et al., 2011). Totipotent 
stem cells are able to give rise to all embryonic somatic cells and germ cells; they 
can generate a viable embryo (including extraembryonic support tissues such as 
the placenta). These cells result from the fusion of an ovum and sperm cell. Cells 
that result from the 1st divisions of the fertilized egg are totipotent cells (Volarevic 
et al., 2011). Pluripotent cells descend from totipotent cells and can give rise to 
cells of the three germ layers: endoderm, mesoderm, and ectoderm; they have no 
contribution to extraembryonic membranes or the placenta. Multipotent cells give 
rise to cells of a particular lineage or closely related family (Behr et al., 2010), that 
is, they can differentiate into a number of cells but from a germ layer. Oligopotent 
stem cells can differentiate into a few specialized cells and unipotent cells are 
limited to one cell type, although with the ability of self-renewal (Mitalipov and 
Wolf, 2009). Stem cells are part of an individual entire lifetime. Embryonic stem 
cells are the cells that are derived from the inner cell mass of an early stage of the 
embryo known as blastocyst (which consists of 50-150 cells, after 4-5 days post 
fertilization). Adult stem cells reside in most mammalian tissues, and the extent to 
which they contribute to normal homeostasis and repair is widely variable. Stem 
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cells have been found in many tissues and organs including epidermis, liver and 
bone (Kao et al., 2008). It is believed that the main role of adult stem cells is to 
replace damaged and injured tissues (Volarevic et al., 2011).  
Among adult stem cells, we can find the haematopoietic stem cells (HSCs), 
epithelial stem, muscle stem, neural stem and mesenchymal stem cells (MSCs) 
(Kao et al., 2008; Kaveh et al., 2011). In the bone marrow reside mainly HSCs and 
MSCs. HSCs are the blood-forming cells, that is, they are ultimately responsible 
for the constant renewal of blood with the production of billions of new blood cells 
each day. They can also be found in cord blood, foetal liver, adult spleen, and 
peripheral blood. Mature haematopoietic cells are traditionally categorized into two 
distinct lineages: the lymphoid and the myeloid. The lymphoid lineage consists of 
T, B and natural killer (NK) cells, while the myeloid lineage includes a number of 
morphologically, phenotypically and functionally distinct cell types such as different 
subclasses of granulocytes (neutrophils, eosinophils and basophils), monocytes–
macrophages, erythrocytes, megakaryocytes and mast cells (for a review, see 
Iwasaki and Akashi, 2007). HSCs usually express surface markers that can be 
used for their identification, namely Sca-1, CD14, CD34 and CD45. MSCs are 
multipotent, self-renewable cells that can be found not only in the bone marrow, 
but also in all postnatal organs and tissues, namely adipose tissue, umbilical cord 
blood and compact bone (Porada et al., 2006; Volarevic et al., 2010). These are a 
rare-population of non-haematopoietic stromal cells, able to differentiate into 
mesenchymal tissues such as bone, cartilage, adipose tissue and muscle (Augello 
et al., 2010). They are also able to differentiate into non-mesenchymal cells such 
as neurons (Kopen et al., 1999). In addition, they have a high proliferative 
capability, while retaining their undifferentiated state (Banfi et al., 2002; Bruder et 
al., 1997). MSCs show variable levels of expression of several markers, namely 
CD105 (SH2), CD90, CD73 (or ecto 5’-nucleotidase), stromal antigen 1, CD44, 
CD166 (vascular cell adhesion molecule), CD54/CD102 (intracellular adhesion 
molecule), CD49 and c-Kit (or CD117) (Baddoo et al., 2003; Boiret et al., 2005; 
Cognet and Minguell, 1999; Dennis et al., 2002; Gronthos et al., 2003; Pittenger et 
al., 1999; Sivasubramaniyan et al., 2012). However, some variations may be found 
1.Introduction 
 
PhD thesis – José Bernardo Noronha Matos (2011-2014) 20   
depending on the species, the tissue from where they were isolated and, of 
course, due to the ex vivo manipulations (Augello et al., 2010; Augello and De 
Bari, 2010; Jones et al., 2002). MSCs are able to leave their bone marrow niche 
and circulate through the bloodstream, assisting in repair of tissues when required 
(Bobis et al., 2006). 
Adult stem cells have captured attention with the promise of tissue repair and 
the treatment of degenerative diseases, among others. The challenge is to 
stimulate stem cells in vivo or in vitro to develop various numbers of specialized 
cells that may represent sources of cells suitable for transplantation in a cell-based 
therapy. Hopefully these may be used to treat genetic and degenerative diseases, 
among others (Volarevic et al., 2011).  
1.1.2. Adult stem cells and therapy – summary of promising applications in 
the context of bone tissue engineering 
As mentioned earlier, MSCs are able to differentiate into osteoblasts, the bone 
forming cells (Friedenstein et al., 1966; Luria et al., 1987). The possibility to use 
such cells in bone repair in known bone disorders, such as osteoporosis and 
rheumatoid arthritis, has been proposed previously. In particular, bone tissue 
engineering (BTE) has emerged as a promising field. BTE refers to the 
implantation of a scaffolds seeded with appropriate number of cells, plus growth 
factors at the bone defect site. The cells and the scaffold itself are the two key 
points in BTE. Bone marrow mesenchymal stem cells are a type of cells usually 
chosen in BTE in order to reconstruct bone defects since these have easy 
harvesting technique and are capable of proliferating and differentiating into bone 
forming cells (for a review, see Kaveh et al., 2011). Another consideration is the 
source of such osteoprogenitor cells: autologous, allogenic or xenograft.  
Concerning the scaffold, this is usually three dimensional and highly porous with 
an interconnected pore network for cell growth and flow transport (nutrients, 
metabolic waste). Is biocompatible and bioresorbable. In addition, it should be 
capable of osteogenesis and osteoconduction (Moore et al., 2001). Its source can 
be synthetic such as poly lactic acid and poly glycolic acid bleds, bioactive glass 
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particles, hydroxyapatite/chitosan-gelatin networks, ceramic or glasses and 
bioactive glass or natural such as autograft or allograft, collagen, glycosamin 
glycans (Kaveh et al., 2009; Moore et al., 2001; Nuttelman et al., 2005; Vats et al., 
2003). The scaffolds may be seeded with cells and cultured before surgery or the 
cells are seeded into the matrix and immediately implanted at the time of surgery 
(Kaveh et al., 2011). 
Another interesting approach is the direct injection of cells (with or without 
signalling molecules) into the defect site. This may be a useful technique when the 
damage in the tissue is confined to a small area. Yu and co-workers have shown 
that the injection of polylactic acid-polyglycolic acid copolymer/collagen type I 
microspheres combined with bone MSCs improves intertrochanteric bone quality 
in osteoporotic female rats. In this work, rats were ovariectomized to establish the 
osteoporotic animal model. The animals that received the microspheres with the 
bone marrow MSCs had improved bone mineral density when compared to control 
animals that were treated with microspheres alone or PBS. This suggested that 
such approach may provide a promising minimally invasive surgical tool for 
enhancement of bone fracture healing or prevention of fracture occurrence (Yu et 
al., 2012).  
The next chapters will describe the MSC’s potential to differentiate into 
osteoblasts, the bone forming cells, since this is one of the main topics of this 
work. It relies on the possibility of using MSCs as osteoblast precursor cells in 
bone regeneration, namely in known bone disorders such as osteoporosis and 
rheumatoid arthritis. 
1.1.3. The bone marrow microenvironment: a stem cell niche 
As mentioned earlier, non-embryonic or adult stem cells have been identified in 
many organs and tissues. Some authors suggest that there is a single quiescent 
population of stem cells residing in a specialized niche of a given tissue (e.g., bone 
marrow, brain, skin, skeletal muscle, adipose tissue) (Porada et al., 2006). The 
main properties of stem cells, namely the ability of differentiating into diverse 
specialized cells in the body and self-renewal, are believed to be maintained and 
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regulated by a specific microenvironment referred as niche. This local environment 
specifies the location of stem cells within tissues, as well as the cellular and 
molecular components that determine their activity (Rando, 2006). In other words, 
a stem cell niche is the microenvironment where the adult stem cell resides. It also 
includes the cells that surround them and the extracellular matrix, which are both 
believed to provide signals that keep the stem cell quiescent or, instead, modulate 
their activation. In this last case, stem cells undergo either symmetric division or 
asymmetric division, i.e. they give rise to daughter cells that are both stem or they 
produce one stem and other daughter cell that is already committed to 
differentiate. In fact, stem cell-function is regulated in a complex way, involving the 
cell-autonomous regulation to local environment stimuli of the stem-cell niche, the 
surroundings of the tissue, the so called systemic milieu of that organism, and the 
external environment (Figure 1) (Rando, 2006). The bone marrow is a key 
reservoir of stem cells. Here, cells interact with each other by releasing growth 
factors and cytokines, allowing cell survival and maintenance, as well as cell 
proliferation and/or differentiation (for a review, see Isern and Mendez-Ferrer, 
2011).  
We will focus our introduction in MSCs, since this work it is based on the ability 
of these cells to differentiate into osteoblasts, the bone forming cells.  
MSCs seem to play a significant role in bone marrow microenvironment. One of 
their main roles is to create a tissue framework, assuring the mechanical support 
for the haematopoietic cell system. In addition, quiescent or stimulated cells can 
secrete a number of extracellular matrix proteins (e.g., fibronectin, laminin, 
collagen and proteoglycans) (Devine and Hoffman, 2000). Besides these proteins, 
MSCs (and to some extent, cells that derive from this lineage, like osteoblasts) 
also produce and secrete haematopoietic and non-haematopoietic growth factors, 
chemokines and cytokines, regulating haematopoiesis. This is depicted in Figure 
2, showing a scheme of bone marrow as a stem cell niche. They secrete 
interleukins, namely IL-1a, IL-1b, IL-6, IL-7, IL-8, IL-11, IL-14, IL-15, macrophage 
colony stimulating factor, granulocyte-macrophage colony stimulating factor, 
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leukaemia inhibitor factor, stem cell factor, foetal liver tyrosine kinase-3, 
thrombopoietin and hepatocyte growth factor (for a review, see Bobis et al., 2006).  
 Recent works have also suggested that co-transplantation of human MSCs and 
HSCs resulted in accelerated haematopoietic recovery in animal models and 
humans (Fibbe and Noort, 2003; Koc et al., 2000; Lane et al., 1999). It was found 
that transplanted MSCs in mice tibia integrate into the functional components of 
haematopoietic microenvironment and actively participate in the haematopoietic 
cell development, since 4-10 weeks later, MSCs differentiate into pericytes, 
myofibroblasts, osteocytes and endothelial cells, resulting in increased numbers of 
primitive human haematopoietic stem cells in the bone marrow microenvironment 
(Muguruma et al., 2006). In fact, many studies point towards an interaction 
between MSCs and HSCs. It was also found, for instance, that osteopontin 
production by MSCs significantly prevents HSCs proliferation (Denhardt and Guo, 
1993). However, without mineralization, HSCs do not function properly (Adams et 
al., 2006). These findings support the concept that MSCs actively regulate the 
function of HSCs. The question remains whether HSCs influence the development 
and maintenance of the bone marrow niche. Recent reports suggest that HSCs 
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Figure 1. The stem cell niche. Stem cell niche is the microenvironment where adult stem 
cells reside. It includes the surroundings, cells and extracelullar matrix, which will provide 
the necessary signals for their quiescence or activation. External environmental influences 
also play a role, filter down through these levels to modulate stem cell fuction. See text for 
details (adapted from Rando, 2006). 
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regulate bone formation through the production of BMP-2 and BMP-6 (Jung et al., 
2008). Another particular example came from Liao and co-workers recent work. 
They have shown that in vitro, low dose of haematopoietic stem progenitor cells 
(HSPCs) co-cultured with MSCs in combination with dexamethasone accelerates 
the osteogenic progression of MSCs. They observed an earlier peak in alkaline 
phosphatase activity (an enzyme involved in the mineralization process) and 
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Figure 2. The bone marrow microenvironment. The stem cell niche is composed of several 
members of the bone marrow stem cell system. Recent studies demonstrate that endosteal 
osteoblasts and their precursors like mesenchymal stem cells (MSCs) play a critical role in the 
creation of a stem cell niche and thereby likely regulate stem cell maintenance, proliferation 
and maturation.  In particular, osteoblasts and their precursors play a pivotal role in 
haematopoiesis by secreting chemokines and cytokines depicted in the figure. This will be 
important for the lineage commitment of haematopoietic stem cells (HSCs) (myeloid or 
lymphoid progenitor cells), leading to the differentiated cells displayed in the picture. G-CSF, 
granulocyte colony stimulating factor; M-CSF, macrophage colony stimulating factor; IL, 
interleukin; OPG, osteoprotegerin, SDF-1, stromal derived factor 1, TNF- α, tumor necrosis 
factor alpha  (adapted from Taichman, 2005). 
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enhanced calcium deposition compared to MSC-cultures alone (Liao et al., 2011). 
The cellular mechanism is, however, still unknown.  
Osteoblasts, which derive from the mesenchymal stem cell lineage, also play an 
important role in the bone marrow stem cell niche. Evidences came from different 
works in which several animal models were used, in which was studied a 
transcription factor, Runx-2, which belongs to the runt domain gene family. RUNX-
2-deficient mice lack intramembranous and endochondral bone formation because 
osteoblasts don’t mature (Komori et al., 1997). These animals are dwarfed, unable 
to breathe and die immediately after birth (Takarada et al., 2013). The lack of 
osteoblast maturation leads to a total lack of bone marrow through the entire 
skeleton. In the embryos, the animals develop excessive medullary 
haematopoiesis in the livers and spleens and large haematopoietic foci in the 
periportal area (Deguchi et al., 1999).These authors have shown that the migration 
of the haematopoietic precursors was apparently perturbed by a lack of bone 
marrow cavity in Runx-2-/- embryos (Deguchi et al., 1999). Other evidences 
reinforce the role of osteoblasts in the bone marrow microenvironment. These 
cells express, similarly to marrow endothelial cells, the stromal derived factor 
(SDF-1), which they constitutively release. When deleted in animal models, 
together with its receptor, CXCR4, marrow engraftment by haematopoietic cells is 
not observed (Aiuti et al., 1999; Peled et al., 1999). Some authors have also 
suggested that the production of SDF-1 by osteoblasts is an important mechanism 
for the selective attraction of circulating osteoclast precursors to bone and their 
migration within the marrow to appropriate perivascular stromal sites for RANKL 
differentiation (see below) into resorptive osteoclasts (Yu et al., 2003).  
Other studies have also implicated osteoblasts as critical regulators of 
haematopoiesis. Zhang and co-workers have shown that bone morphogenic 
proteins (BMP), which may be produced and released by osteoblasts, regulate 
HSC development. They found that the conditional inactivation of the BMP 
receptor type IA (BMPRIA) in mutant mice leads to an increase in the number of 
HSCs when compared to the wild-type mice (Zhang et al., 2003). Calvi and co-
workers also showed that parathyroid hormone (PTH), in osteoblasts 
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overexpressing the PTHR, enhances osteoblastic growth and simultaneously 
increases the number of HSCs in the marrow (Calvi et al., 2003). They also 
showed that the treatment of healthy animals with PTH similarly expands the HSC 
population in the marrows, since there is an expansion of osteoblast precursors. 
Again, administrating PTH to wild-type animals before HSC transplantation 
improves their survival. These results point to osteoblasts as stem cell-supportive 
cells in such niches.   
Stem cells are able to maintain their undifferentiated state within the niche 
(Bobis et al., 2006). In the particular case of MSCs, some findings suggest that 
these cells decision to differentiate or to stay quiescent is regulated by Wnt family 
members. Its signalling is known to prevent differentiation process by inducing 
high levels of oct-3/4, rex-1 and the homeodomain transcription factor Nanog, 
which are known as gatekeepers for embryonic stem (ES) cell pluripotency (Sato 
et al., 2004). On the other hand, BMP-pathways play a role in the 
proliferation/differentiation process of stem cells, which raises the hypothesis that 
these factors are important for MSCs growth in their niche.  
When needed, stem cells like MSCs may be recruited from the bone marrow to 
other tissues, circulating in blood, after particular stimuli (Bobis et al., 2006). They 
are kept in the cell niche since they express a number of adhesion molecules, 
which are also important for the niche function itself. These include N-cadherin/β-
catenin, VCAM/integrin and osteopontin/β1 integrin (for a revision, see Bobis et al., 
2006). Osteoblasts themselves express many adhesion molecules that may also 
be used during cell-cell contact with HSCs. Some of these include VLA-4 (α4β1) 
receptors (expressed on CD34+ cells) and the vascular cell adhesion molecule-1 
(VCAM-1) (expressed by bone marrow stromal cells) (Simmons et al., 1994). 
Other structures are involved, namely CD34, CD44, CD164, intracellular cell 
adhesion molecules (ICAM-1, ICAM-3), very late antigen-4 (VLA-4), among others 
(for a revision, see Verfaillie, 1998). Some cell-associated or matrix-bound 
cytokines, like IL-3, stem cell factor (SCF) and transforming growth factor α1 (TGF- 
α1) may themselves serve as adhesion molecules (Gordon, 1991; Hardy and 
Minguell, 1995; Toksoz et al., 1992). When migrating to other tissues, MSCs are 
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able to support the regeneration process. Such cases were documented in 
regenerating bone (where they differentiate into bone forming cells, the 
osteoblasts) (Benayahu et al., 1989), in cartilage repair (Caplan et al., 1997), 
muscle (De Bari et al., 2003), heart (Shake et al., 2002) and migration throughout 
the forebrain and cerebellum (where they differentiate into astrocytes) (Kopen et 
al., 1999). Homing of MSCs is possible thanks to the expression of chemokine 
receptors which will help them in trafficking to various tissues. An example is the 
CXCR4, the receptor for SDF-1, which is produced by stromal cells (Stoicov et al., 
2013; Yang et al., 2013). Using such signalling mechanisms, MSCs detected in 
the bloodstream, are able to migrate and colonize various tissues (Gao et al., 
2001).  
1.2. Mesenchymal stem cells and osteogenic differentiation 
1.2.1. Mesenchymal stem cells: in vitro induction of osteogenesis 
When cells from the whole bone marrow are plated in plastic culture dishes with 
10% of foetal calf serum supplemented medium, one finds that there is a 
population of haematopoietic non-adherent cells together with a rare population of 
plastic-adherent cells (in a proportion of 1:10000 nucleated cells in the bone 
marrow, varying from individual to individual) (Friedenstein et al., 1970). After 
medium change, only the adherent cells will remain. These will start to proliferate 
and can differentiate into mature cells of mesenchymal lineages such as 
osteoblasts (Friedenstein et al., 1970; Friedenstein et al., 1976). In fact, this ability 
to adhere to plastic is one of the criteria for the minimal identification of 
mesenchymal stem cells (MSCs) by the International Society for Cell Therapy in 
2006 (Dominici et al., 2006). When assessed by the FACS analysis, these cells 
should also have the following cell phenotype: CD73+, CD90+, CD105+, CD45-, 
HLA-DR-, CD14- or CD11b-, CD79a- or CD19- (Dominici et al., 2006).  
Osteoblasts are the bone forming cells and, as mentioned earlier, these derive 
from MSCs. In vivo, MSCs are believed to be in close relation with other cells, 
namely haematopoietic stem cells, forming the stem cell niche (see section 1.1.3). 
In order to promote the osteogenic differentiation of human MSCs in vitro, these 
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should be incubated with ascorbic acid, β-glycerophosphate and dexamethasone 
(in addition to foetal bovine serum) added to the culture medium (Jaiswal et al., 
1997; Pittenger et al., 1999). Ascorbic acid is known to play a role in the collagen 
synthesis, since it is a cofactor for proline and lysine hydroxylases, both involved 
in the hydroxylation of collagen. Ascorbic acid seems to be essential for normal 
bone formation, since ascorbic acid was previously shown to increase alkaline 
phosphatase and osteocalcin mRNAs in osteoblast cultures (Franceschi and Iyer, 
1992) and that this induction is blocked by inhibitors of collagen triple-helix 
formation. In addition, osteoblasts were shown to express a Na+-dependent 
transporter specific for ascorbic acid which is essential for maintenance of 
intracellular ascorbate concentrations (Dixon et al., 1991; Franceschi et al., 1995) 
which, in turn, will influence the proliferation and alkaline phosphatase expression 
(Franceschi and Iyer, 1992; Franceschi et al., 1994). β-glycerophosphate is a 
substrate for alkaline phosphatase, producing an increase in phosphate content, 
which may be incorporated in the bone matrix (Bellows et al., 1991) together with 
Ca2+. It functions as an organic phosphate donor and has been used in culture 
media for MSC differentiation to osteoblast-type cells (see e.g., Jaiswal et al., 
1997). Besides this, the free inorganic phosphate may induce increases in mRNA 
and protein expression of osteogenic markers like osteopontin and regulation of 
Runx-2 (Beck et al., 2000; Fujita et al., 2001). Dexamethasone is a synthetic 
corticosteroid. It mimics the actions of several glucocorticoids located naturally in 
the body (cortisol, estradiol, testosterone, vitamin D3, thyroxine and retinoic acid) 
(Kaveh et al., 2011). Glucocorticoid-activated genes work through gene activator 
proteins. These, when not associated to glucocorticoids, remain in the cytosol. 
When present, glucocorticoids bind to their glucocorticoid receptors (nuclear 
receptor subfamily 3, group C, member 1 - NR3C1) and to the activator proteins, 
migrate to the nucleus and bind to the regulatory region of each gene regulated in 
this manner. Dexamethasone supports osteogenic differentiation (Liu et al., 2002) 
by binding to some special regulatory proteins in the cell and then activating 
transcription of osteoblast-specific genes, like those coding for alkaline 
phosphatase, which is an enzyme required for matrix mineralization, converting 
1.Introduction 
 
PhD thesis – José Bernardo Noronha Matos (2011-2014) 29   
pyrophosphate (PPi, a known inhibitor of mineralization) into inorganic phosphate 
(Cheng et al., 1994). It is worth noting that dexamethasone in vivo, in long-term 
intake cases, results in osteoporosis and osteopenia (bone degeneration and loss) 
(Baylink, 1983). This apparent contradiction is based on the fact that chronic 
glucocorticoid intake leads to an inhibition of MSCs proliferation and may activate 
the action of osteoclasts. It was shown that <10-8 M stimulated receptor activator 
of NF-B ligand (RANKL)-induced osteoclast formation synergistically with 
transforming growth factor β (Takuma et al., 2003). So, regimens of 
dexamethasone may limit the amount of osteoprogenitors sources (Kaveh et al., 
2011), resulting in an unbalanced bone formation versus bone resorption. Besides 
this, glucocorticoids are known to reduce Ca2+ absorption in the intestine, leading 
to an increase in circulating PTH, ultimately resulting in Ca2+ mobilization from 
bone (Fucik et al., 1975). This topic will be further discussed in section 1.3.2 which 
refers to bone metabolism description.  
Dexamethasone treated cultures have increased ALP activity when compared 
to control cultures (Fernandes et al., 1997), consistent with other observations 
showing that long-term treatment of bone-derived cells with physiological 
concentrations of glucocorticoids induces their differentiation into cells with an 
osteoblast phenotype (Benayahu et al., 1989;  Cheng et al., 1994). Fernandes and 
co-workers also revealed that dexamethasone treated cultures show randomly 
located multi-layered cell three-dimensional nodules, and that these appear to be 
important for in vitro mineralization of alveolar bone cells (Fernandes et al., 1997).  
Besides the previous indicated factors, the standard procedure for in vitro 
culture of MSCs is based on supplementing cell culture media with foetal bovine 
serum (FBS). This contains growth factors and extracellular matrix molecules that 
enhance cell attachment to plastic surfaces, enhancing cell proliferation and 
differentiation. It provides several important biological molecules such as albumin, 
antichymotrypsin, apolipoproteins, biotin, and growth supporting factors, which are 
required for optimal growth of cells. In addition to the indicated factors, 10% of 
FBS was shown to be the indicated amount of serum for an osteoblastic-induction 
medium, although some variations may be found (Tateishi et al., 2008). 
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Although human bone cell cultures have been regarded as a useful tool to study 
bone control mechanisms, it should be emphasized that the number of passages 
in an in vitro study is an important factor to be considered. Several authors have 
demonstrated that serially passaged cells keep the proliferation rate constant, but 
without a similar ALP activity. This enzyme activity decreases with the number of 
passages and the ability to form mineralized areas also decreases on serial 
subcultures (Fernandes et al., 1997). In fact, the loss of the osteoblast phenotype 
on serial passage has been reported by other authors (Coelho et al., 2000). Other 
interesting findings revealed that serial passage of osteoblast-like cells, MC3T3-
E1, alters their osteoblastic function and responsiveness to transforming growth 
factor-β1 (TGF-β1) and bone morphogenetic protein-2 (BMP-2). These authors 
showed that BMP-2 significantly enhances ALP activity and osteocalcin secretion 
in early passage cells while TGF-β1 has the opposite effect. Both BMP-2 and 
TGF-β1 effects significantly decrease on late passage cells. They also showed 
that ALP activity and osteocalcin secretion decreases after multiple cell passages 
(Chung et al., 1999). Taken all together, these evidences support the idea of a 
replicative senescence of in vitro cultures that may be a good starting point for cell 
ageing proposed in vivo. Besides this, data demonstrate that caution should be 
taken when considering serial passages of primary cultures, since cell phenotype 
and differentiation ability may be compromised. 
1.2.2. Mesenchymal stem cells: osteogenesis regulation signals and gene 
expression 
As mentioned earlier, mesenchymal stem cells (MSCs) are able to differentiate 
into multiple cell types, including osteoblasts. The latter are the bone forming cells, 
and together with osteoclasts (bone-destroying cells) and osteocytes (a type of cell 
that derives from the osteoblast lineage), compose the three major cells involved 
in bone remodelling. Bone formation, which is undertaken by osteoblasts 
(discussed further in section 1.3.2), involves a two-step process: first, mature 
osteoblasts synthesize and release type I collagen which constitutes 85-90% of 
the organic matrix and many other non-collagenous bone matrix proteins like 
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alkaline phosphatase (ALP), osteocalcin, osteonectin, osteopontin and bone 
sialoprotein. The organic matrix, known as osteoid, is subsequently mineralized by 
calcium and phosphate ions to produce calcified bone tissue, a mineral that is 
similar to hydroxyapatite, Ca10(PO4)6(OH)2 (Orriss et al., 2010). This lineage 
commitment of multipotent MSCs is driven by the selective expression of one 
master transcriptional regulator, Runx-2 (runt-related transcription factor 2), which 
is necessary for the osteoblast lineage (reviewed in Jensen et al., 2010). This 
master regulator of osteoblastogenesis acts throughout the induction, proliferation 
and maturation of osteoblasts regulating the expression of many osteoblast genes, 
including those encoding osteocalcin, type I collagen and osteopontin (for a 
revision, see Franceschi and Xiao, 2003). Some of these genes are depicted in 
Table 1. This table summarizes some of the most important osteogenic markers, 
including the RUNX-2 gene (also known as CBFA1). These are commonly chosen 
to evaluate, in vitro, the osteogenic differentiation of MSCs.  
The Runx-2 activity and importance in osteoblastogenesis has been explored 
extensively, and studies in which mutations were induced in RUNX-2 gene 
showed a number of skeletal abnormalities. One example is cleidocranial 
dysplasia syndrome, an autosomal-dominant skeletal dysplasia that is 
characterized by widely patent calvarial sutures, clavicular hypoplasia, 
supranumerary teeth and short stature. Besides this, homozygous mutation of 
RUNX-2 in mice was shown to be lethal due to a complete lack of mineralized 
bone (Komori et al., 1997; Mundlos et al., 1997; Otto et al., 1997). 
The signalling pathways regulating Runx-2 activity are still under extensive 
investigation, but there are several examples of such dynamic control. These 
include binding of extracellular matrix (ECM) to cell surface integrins, fibroblast 
growth factor 2 (FGF2), mechanical loading, parathyroid hormone (PTH) and bone 
morphogenic proteins (BMPs) (for a revision, see Franceschi and Xiao, 2003). 
Figure 3 summarizes these signalling pathways and how they interact to promote 
Runx-2 activity. 
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Table 1. Genetic and related protein markers of osteogenesis 
Coding Gene Protein name Protein Function 
c-fos c-Fos 
Belongs to the AP-1 class of transcription factors. Direct 
gene targets include those encoding osteocalcin, 
collagenase III, bone sialoprotein, alkaline phosphatase 
promoters (Jensen et al., 2010; Owen et al., 1990). 
RUNX-2 Runx-2 
Can directly stimulate transcription of osteoblast-related 
genes such as those encoding osteocalcin, type I 
collagen, osteopontin and collagenase III by binding to 
specific enhancer regions in DNA (Franceschi and Xiao, 
2003). 
ALPL 
Alkaline 
phosphatase 
Ubiquitous enzymes present in many organisms from 
bacteria to man. The most abundantly isoform expressed 
in bone is TNAP. Its major role is to hydrolyse PPi to 
maintain a proper concentration of this mineralization 
inhibitor ensuring normal bone mineralization (Yegutkin, 
2008). 
BGLAP Osteocalcin 
One of the most abundant matrix proteins in bones, 
synthetized by osteoblasts. It binds strongly to apatite and 
calcium, which is dependent on vitamin K (Gundberg et 
al., 2012). 
SPP1 Osteopontin 
One of the major phosphoproteins in bone. Osteoblast 
adhesion to bone matrix proteins such as osteopontin can 
modulate various aspects of cell behaviour, including 
growth, differentiation, and protein production (Liu et al., 
2008a). 
SP7 Osterix 
Zinc finger-containing transcriptional activator that is 
distinctly expressed in all developing bones and is 
important for osteoblast differentiation, usually 
downstream of Runx-2. Osteocalcin, ALP and bone 
sialoprotein coding-genes are some of its targets (Sinha 
and Zhou, 2013).  
COL1A1 Type I Collagen 
Main constituent of the organic matrix synthesized by 
mature osteoblasts, which is released by exocytosis. 
Together with noncollagenous bone matrix proteins, 
constitutes the osteoid, which latter mineralizes with 
calcium and phosphate deposition to produce calcified 
bone tissue. It also induces the expression of several 
osteoblast-related genes through integrin mediated signal 
transduction (Mizuno and Kuboki, 2001).  
IBSP 
Integrin-binding 
sialoprotein 
Noncollagenous glycoprotein in mineralized tissues such 
as bone. May be involved in cell attachment and 
signalling, hydroxyapatite nucleation, and binding of type I 
collagen (Malaval et al., 2008). 
SPARC Osteonectin 
Glycoprotein belonging to a group of matrix associated 
factors that mediate cell-matrix interactions but do not 
serve primarily structural roles; has been shown to be a 
Ca2+-binding glycoprotein. Seems to have a major role in 
bone remodelling or repair (Brekken and Sage, 2001). 
These protein-coding genes are commonly used as markers of osteogenesis, in vitro, since there 
are extensive studies attesting their importance in this cell differentiation mechanism. See text and 
cited references for details. 
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ECM containing type I collagen is mandatory for osteoblasts to differentiate and 
express osteoblast-related genes such as those encoding osteocalcin, bone 
sialoprotein, alkaline phosphatase among others (Table 1) and, ultimately, to 
mineralize. Usually, the ECM signals through β1 subunit-containing integrins (like 
α2β1). This will promote differentiation of pre-osteoblast into mature osteoblasts. 
This sequence may be prevented using either blocking antibodies or peptides that 
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Figure 3. Signal transduction pathways modulating Runx-2 activity. This 
transcription factor is frequently described as the master regulator of osteoblastogenesis, 
since it acts throughout the induction, proliferation and maturation of osteoblasts and 
regulates expression of many osteoblast genes. See text for details. Based on Franceschi 
and Xiao, 2003. 
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bind to the cell-binding domain of collagen, thus preventing ECM-dependent 
differentiation (Danen et al., 1998). Others have shown that ECM production by 
murine MC3T3-E1 cells increases significantly the transcription of osteocalcin 
coding gene, which is Runx-2 dependent (Xiao et al., 1997). Several authors 
suggested that the MEK/ERK branch of the mitogen activated protein kinase 
pathway, or MAPK, is a plausible linkage between integrin activation and 
subsequent stimulation of Runx-2-dependent transcription (reviewed in Franceschi 
and Xiao, 2003). A previous study showed that selective inhibition of ERK1/2 
phosphorylation by MEK with U0126 prevented ECM-dependent induction of the 
osteocalcin coding gene. The authors showed that BMP action on osteogenesis 
was also prevented with the same blocker (Xiao et al., 2002). Other studies 
showed that transfecting cells with MEK1 results in Runx-2 phosphorylation, 
knowing that MEK1 is involved in the MAPK pathway (Xiao et al., 2000). In 
conclusion, evidences demonstrate that osteoblasts differentiation requires close 
contact with collagen-containing ECM, interacting with it through specific β1-
integrins. This interaction allows the activation of the MAPK pathway, which 
transduce signals to the nucleus. Subsequently, Runx-2 is phosphorylated and 
allows the stimulation of osteogenesis by increasing transcription of osteoblast 
marker genes such as those depicted in Figure 3.  
As already mentioned, FGF2 is an important in vivo regulator of skeletal 
development and growth. Its administration can restore bone mass in the 
overiectomized female rat, which is a well-established model for postmenopausal 
bone loss (Liang et al., 1999). In transgenic mice, overexpression of FGF2 causes 
premature mineralization, achondroplasia and shortening of long bones. On the 
other hand, disruption of the FGF-2 gene leads to decreased bone formation and 
mass (Coffin et al., 1995; Montero et al., 2000). Some other interesting findings 
revealed that activating mutations in FGFR1 up-regulate Runx-2, enhancing 
differentiation of calvarial osteoblasts (Zhou et al., 2000). FGF2 was also shown to 
promote osteocalcin gene expression in MC3T3-E1 pre-osteoblast cells 
(Boudreaux and Towler, 1996). The major route of FGF receptor signalling, as 
shown in Figure 3, involves the activation of MEK/ERK branch of the MAPK 
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pathway (Nugent and Iozzo, 2000). Xiao and co-workers also showed that FGF2 
could rapidly induce ERK phosphorylation and increase osteocalcin mRNA, in both 
MC3T3-E1 and bone marrow stromal cells (Xiao et al., 2002). 
Others revealed that FGF2 leads to osteocalcin production by promoting the 
transcription of its coding gene through an AP-1-like site that is immediately 5’ to 
the RUNX-2 binding site (Boudreaux and Towler, 1996) (Figure 3). AP-1 refers to 
a class of transcription factors that is composed of heterodimers of Fos-related 
factors (c-Fos, Fra1, Fra2 and FosB) and Jun proteins (c-Jun, JunB and JunD). 
These are highly expressed in proliferating osteoprogenitors. 
The c-fos gene is usually evaluated to measure the extent of osteogenesis in 
vitro (Table 1). Accordingly, there are a number of direct gene targets of AP-1 in 
osteoblasts, namely those coding for osteocalcin, collagenase-3, bone sialoprotein 
and alkaline phosphatase (Table 1) (Owen et al., 1990).  
Returning to FGF2, it was also shown that its response is synergistically 
stimulated by a PKA pathway activator (forskolin), which was also shown to 
increase the activity of AP-1 related nuclear factors (c-Fos and c-Jun). So, it 
seems that AP-1-like factors and Runx-2 share cooperative interactions in the 
promotion of osteogenesis (Franceschi and Xiao, 2003).  
As depicted in Figure 3, mechanical stimulation is important in the regulation of 
bone homeostasis. Mechanical strained human osteoblast-like cells express 
increased levels of coding mRNA for osteopontin, osteocalcin and collagen I and 
III (Carvalho et al., 1998; Harter et al., 1995). The MAPK pathway seems to be 
largely involved in this process, and integrins seem to be associated to these 
mechanotransduction signals. These proteins connect the cytoskeleton to the 
extracellular proteins, mediating the transduction of mechanical stimuli into 
biochemical signals. One particular example of this observation are the 
experiments undertaken by Schmidt and co-workers, who showed that MAPK 
activation is related to α2β1 integrins, when an osteoblastic cell line was submitted 
to mechanical stress, using a magnetic drag force device (Schmidt et al., 1998). 
Ziros and co-workers also showed that osteoblast differentiation is promoted when 
mechanical stretching is applied, promoting the binding of Runx-2 to OSE2 DNA in 
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gel retardation mobility shift assays (depicted in Figure 3), also promoting ERK1/2 
phosphorylation (Ziros et al., 2002). Similar results were also found in bone 
marrow stromal cells from three-month-old Sprague Dawley rats, in which 
mechanical force promoted osteogenic differentiation (Wang et al., 2002).  
Another important recognized modulators of Runx-2 activation, and so of 
osteogenesis, are the parathyroid hormone (PTH) and bone morphogenic proteins 
(BMPs). PTH is an important regulator of calcium homeostasis (further described 
in section 1.3.2 below). This hormone has both anabolic and catabolic effects on 
osteoblasts activity. This hormone functions by binding to the G-protein coupled 
PTH-1 receptor, or PTH1R, activating two possible pathways: protein kinase A 
(PKA), with previous activation of Gαs protein and adenylate cyclase resulting in 
the production of cAMP; and protein kinase C, with previous activation of the Gαq 
protein, with subsequent activation of phospholipase Cβ which leads to the 
formation of both DAG (which activates some isoforms of PKC) and IP3 (1,4,5-
inositol trisphosphate), which recruits intracellular calcium from the endoplasmic 
reticulum. Both PKA and PKC pathways can regulate transcription factors such as 
cAMP response element binding proteins (CREBs), AP-1 family members, as well 
as Runx-2 (for a review see Karaplis and Goltzman, 2000). In fact, PTH seems to 
stimulate the collagenase 3 promoter by a PKA-dependent pathway that 
phosphorylates Runx-2 and up-regulates c-Fos/c-Jun (for a review see Franceschi 
and Xiao, 2003) (Figure 3).  
BMPs are one of the best studied inducers of osteoblast and chondrocyte 
differentiation. These proteins bind to type I and II BMP receptors. The signalling 
transduction is undertaken by Smad proteins (Smad 1, 5 and 8, or R-Smads and 
Smad 4) (Baker and Harland, 1997). These proteins interact with each other and 
with enhancer sequences of target genes (also known by SBEs or Smad binding 
elements). This leads to the up-regulation of transcription factors such as Runx-2 
and the zinc finger factor named Osterix (Table 1 and Figure 3) (Watanabe and 
Whitman, 1999). In fact, it has been reported that BMP treatment induces 
osteoblast-specific gene expression in MC3T3-E1 cells (Xiao et al., 2002) and that 
BMP-2 enhances ALP activity and osteocalcin production in human bone marrow-
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derived primary osteoblasts (Jorgensen et al., 2004). In fact, several studies 
suggest a cooperative interaction between BMP-2 and Runx-2 signals. By using a 
C3H10T1/2 mesenchymal cell line, Yang and co-workers showed that there is a 
synergistic effect of BMP-2 and Runx-2 on osteogenic differentiation. These 
authors used adenoviruses to transfect cells with both Runx-2 and BMP-2. They 
saw a small increase in ALP activity and osteocalcin mRNA when cells were 
transfected with Runx-2 virus or BMP-2 virus, but when both were present, a 
significant increase (by 10-fold) in osteocalcin mRNA was observed (Yang et al., 
2003). 
Other important factors influence osteogenesis, namely the Wnt signalling 
(previously mentioned) and the Notch signalling pathways. In particular, the latter 
has dimorphic effects on mesenchymal progenitor cell lineage, since it supresses 
its differentiation into osteoblasts while maintaining the mesenchymal progenitor 
cell phenotype (Hilton et al., 2008). It can command early osteoblastic 
proliferation, while inhibiting osteoblast differentiation and maturation.  
Recently, new insights came out concerning the role of micro RNAs (miRs) in 
the regulation of osteogenesis. These are short noncoding RNAs with 18-25 
nucleotides, which are able to regulate gene expression through binding to the 3’-
UTR of mRNAs for specific target genes. They are able to inhibit gene expression 
by promoting degradation of the target mRNAs or by inhibiting its translation 
(Erson and Petty, 2008). Some miRs function as inhibitors of osteoblastogenesis, 
while others promote it. For example, Li and co-workers found that a set of micro 
RNAs are reduced by BMP-2 stimulation of C2C12 mesenchymal cells. These 
twenty two identified micro RNAs were predicted to inhibit a range of pro-
osteogenic factors (Li et al., 2008). Another example is the involvement of two 
specific miRs named miR-29a and miR-29c which are expressed in response to 
canonical Wnt signalling and inhibit expression of the extracellular matrix protein 
osteonectin (Kapinas et al., 2009). On the other hand, miR-141 and miR-200a 
were shown to be involved in BMP-2-induced mouse pre-osteoblast differentiation 
by interacting with Dlx5 coding gene. This gene encodes to Dlx5 protein that plays 
a role in bone development and fracture healing. Mutation in this gene may be 
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associated with split-hand/split-foot malformation (Itoh et al., 2009). This approach 
may be of clinical relevance, since micro RNAs have uncovered new mechanisms 
for regulation of skeletal physiology. 
Many other factors induce osteogenesis which is known to be important in both 
in vitro and in vivo bone remodelling. Some of these will be further discussed in 
section 1.3.2, in the context of bone metabolism. Purinergic signalling, one of the 
main topics of this work is an important aspect when considering osteogenic 
modulation. This topic will be extensively discussed in section 1.4 below. 
1.2.3. Mesenchymal stem cells: loss of function and stem cell ageing 
Aging is characterized by a decline in organ/tissue maintenance and repair. 
Since adult stem cells are responsible, in part, for regeneration, it is conceivable 
that ageing is partly due to a decline of stem cell function. Some possible 
explanations may lie at the molecular level. Ageing is associated to an 
accumulation of damage affecting DNA, proteins, membranes and organelles (Ju 
and Rudoplh, 2008). One possible explanation for DNA damage is telomere 
shortening, which represents a cell intrinsic mechanism of ageing. DNA damage, 
in turn, leads to cell cycle arrest or cell death.  
Telomere is a nucleoprotein complex that protects each end of a chromosome. 
It consists of non-coding TTAGGG double strand repeats, a 3’ single strand 
overhang and associated telomere binding proteins (Blackburn, 1991). Telomere 
prevents DNA damage responses at chromosome ends, preventing fusion, 
degradation and instability (Blackburn, 2001). In fact, in humans, it is now clear 
that telomeres shorten with each round of cell division (Harley et al., 1990). The 
loss of sequence is due to the so-called end-replication problem of DNA 
polymerase, to the postreplication processing of telomere ends and to other 
factors such as oxygen species (Sfeir et al., 2005; Shay and Wright, 2000; von 
Zglinicki, 2002). At this stage, the cell requires an enzyme to counterbalance this 
feature, the telomerase. This ribonucleoprotein elongates telomeres by 
synthesizing six-nucleotide repeats (Tumpel and Rudolph, 2012). This enzyme 
consists of two important components: the telomerase RNA component (TERC), 
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which serves as a template for synthesis of telomeres, and the telomerase reverse 
transcriptase (TERT), which is the catalytic subunit of this enzyme (Ju and 
Rudoplh, 2008). Telomerase activity, in human cells, is repressed mostly in 
somatic tissues due to the suppression of TERT expression and most 
differentiated organ cells show a complete absence of TERT expression, with no 
telomerase activity (Wright et al., 1996). In contrast, stem cells are one of the few 
cells in adult humans that express telomerase (Chiu et al., 1996). Nevertheless, 
with aging, telomerase activity is insufficient to maintain stable telomeres in stem 
cell compartments, leading to DNA damage. One such example is telomere 
shortening in haematopoietic stem cells (HSCs) during ageing, limiting their self-
renewal (Morrison et al., 1996). Some authors showed that proliferative stress in 
mouse experiments accelerates telomere shortening in HSCs in serial 
transplantation experiments (Allsopp et al., 2001) and that in TERC knockout 
HSCs telomerase shortening is increased when compared to murine HSCs 
(Allsopp et al., 2003).  
So far, we have described the ability of mesenchymal stem cells to differentiate 
into multiple cell lineages, including osteoblasts. However, growing evidence has 
shown a decline of this ability with age, which is thought to influence therapeutic 
efficacy (Raggi and Berardi, 2012). In fact, telomere shortening due to telomerase 
deficiency leads to accelerated senescence of human skeletal mesenchymal stem 
cells in vitro, whereas overexpression of TERT leads to telomere elongation, 
ultimately resulting in enhanced bone formation (Simonsen et al., 2002; Stenderup 
et al., 2003). Such data strongly suggests that telomere shortening and 
telomerase activity are important factors in bone formation (Saeed et al., 2011). In 
fact, recently, Saeed and co-workers showed that telomerase-deficient mice 
exhibit bone loss. They showed that TERC deficient mice exhibit accelerated age-
related bone loss (3-12 months) revealed by X-ray (Saeed et al., 2011). MSCs and 
osteoprogenitors isolated from TERC deficient mice exhibit a reduced in vitro 
proliferation capability and impaired osteogenic differentiation capacity, with lower 
levels of Runx-2 and ALP mRNAs, as well as a reduced mineralization at a later 
stage of the cultures, when compared to MSCs isolated from wild-type animals 
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(Saeed et al., 2011). Another interesting finding showed that hormones seem to 
have an effect on telomere length regulation. In fact, in vivo studies revealed that 
oestrogen and telomere shortening are linked. In that study, the authors reported 
that oestrogen deficiency in mice (targeted disruption of the aromatase gene) 
results in a significant inhibition of telomerase maintenance of telomeres in mouse 
ovaries in a tissue-specific manner. They also showed that oestrogen replacement 
therapy leads to increases in TERT coding gene expression, telomerase activity, 
telomere length and ovarian tissue growth, thereby reinstating ovary development 
to normal (Bayne et al., 2011). Since oestrogens are important regulators of bone 
remodelling, their lack during menopause may compromise MSCs capability to 
differentiate into osteoblasts due to telomerase deficiency. In fact, other authors 
showed that TERC mutant mice have a low bone mass phenotype, and that age-
related osteoporosis is the result of impaired osteoblast differentiation in the 
context of intact osteoclast differentiation (Pignolo et al., 2008).  
Some reports point to age-related changes in the number of bone marrow stem 
cells (Sudo et al., 2000). This may contribute to impaired bone formation, since 
less available osteoprogenitors (MSCs) will limit the number of mature osteoblasts 
needed for new bone formation (Kassem and Marie, 2011). This observation was 
also reported for the haematopoietic system (Sudo et al., 2000), and as mentioned 
above, haematopoietic stem cells are important for the bone marrow niche. 
Besides this, some authors suggested that the life-span of osteoblasts 
decreases with age. They have reported an age-related increase in cell apoptosis, 
which may be related to an enhanced oxidative stress with age (Almeida et al., 
2007). Zhou and co-workers showed that there is an increase in apoptotic cells in 
MSC cultures (Zhou et al., 2008), but further studies are needed to explain this 
phenomenon. Regarding oxidative stress, it has been reported that both in vitro 
and in vivo free radicals lead to impaired osteoblastic function and bone formation 
during aging (Manolagas, 2010). It has been shown in both aging female and male 
C57BL/6 mice an increase in reactive oxygen species (ROS) levels, decreased 
glutathione reductase activity and a corresponding increase in the phosphorylation 
of p53 and p66shc, two key components of a signalling cascade that are activated 
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by reactive oxygen species and that influence apoptosis and lifespan (Almeida et 
al., 2007). Authors showed that these results are reverted upon treatment with 
oestrogens or androgens in vivo as well as in vitro. Age-related decrease in 
osteoblast function may also be related to the observed decrease in osteoblastic 
response to calciotropic hormones and growth factors. It is largely known that 
osteoblast cell proliferation and function depend on adequate responses to such 
factors in order to control bone formation. For instance, in mice, it has been 
reported a decrease in insulin-like growth factor (IGF-I) effects due to aging (Cao 
et al., 2007). Osteoblastic cells from aged human donors exhibit decreased 
proliferative responses to growth hormone and platelet-derived growth factor 
compared with cells from younger donors (Pfeilschifter et al., 1993). Other studies 
showed that osteoblasts from younger donors exhibit a better response to 
oestradiol and IGF-I when compared to older donors (Ankrom et al., 1998; D’Avis 
et al., 1997).  
In conclusion, expanding data in literature indicates that age-related impaired 
bone formation is the main pathogenic mechanism mediating bone-loss. There are 
still a limited number of anabolic therapeutic approaches for treating bone 
disorders such as osteoporosis (further discussed below in section 1.3.3), but 
targeting senescence-related osteoblastic dysfunction may create novel anti-aging 
therapeutic possibilities, which may prove to be useful in promoting bone formation 
and reducing bone loss with age. 
1.3. Bone: a dynamic and specialized tissue 
1.3.1. Structure of bone: an introduction 
Previously in this work, we have mentioned that the bone marrow is a key 
reservoir of stem cells which is housed in the medullary cavity of bone. In this 
topic, we will briefly describe bone as a dynamic tissue that is under continuous 
remodelling, with other functions besides a stem cell reservoir.  
Bone, as a specialized connective tissue, contains inorganic mineral salts 
deposited within an organic collagen matrix and cells, namely osteoblasts, 
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osteoclasts and osteocytes. In order to repair, to grow and adapt, the bone needs 
to undergocontinuous remodelling. Throughout life, many abnormalities in such 
balanced process may result in a huge variety of bone disorders and skeletal 
abnormalities (further discussed below) (Orriss et al., 2010). 
Together with cartilage, bone makes the skeletal system, holding three 
important functions: mechanical, protective and metabolic. Mechanical, since it 
bears a supportive role and is a site of muscle attachment; protective, since it 
shields vital organs and bone marrow; metabolic, since it is a reservoir of ions for 
the entire organism, in particular calcium and phosphate (Adler, 2000). Its main 
constituents are the cells and the extracellular matrix. The extracellular matrix is 
composed of collagen fibres and noncollagenous proteins (see below). The matrix 
of bone has the unique ability to calcify (Clarke, 2008).  
Non-collagenous proteins together with collagen and water, are the main 
constituents of bone matrix.  There are two main forms of extracellular matrix 
(ECM): the osteoid and mineralized matrix. Osteoid is an immature form of matrix 
excreted by osteoblasts and it’s found in areas of new bone formation. It is 
subsequently mineralised by calcium and phosphate ions to produce calcified 
bone tissue; the mineral approximates to hydroxyapatite, Ca10(PO4)6(OH)2 (Orriss 
et al., 2010).This mature form of matrix is largely mineral, being calcium and 
phosphate the main constituents. The turnover of bone minerals is highly 
regulated in a process known as bone remodelling. The extracellular matrix gives 
the bone its mechanical properties but is also important for regulation and 
formation of new bone (Baron, 1993). 
There are four major cell types within bone tissue itself: osteoclasts, 
osteoblasts, osteocytes, and bone lining cells. Within the cavities of the bone, 
there is also bone marrow, which has numerous cell types, including the 
progenitor cells for the haematopoietic cell lineages (Baron, 1993). The osteoblast 
is the cell responsible for construction of new osteoid (which eventually becomes 
ECM). It is also the osteocyte and the bone lining cell precursor, also involved in 
osteoclast regulation (Boyce, 2013). The osteoblast is derived from the 
mesenchymal marrow stromal cells as mentioned above. TGF-β, BMPs, PTH, and 
1.Introduction 
 
PhD thesis – José Bernardo Noronha Matos (2011-2014) 43   
vitamin D are all important in stimulating MSCs to become osteoblasts (Deng et 
al., 2008). MSCs can be found in both the bone marrow and the inner layer of the 
periosteum. Osteoblasts can be incorporated into the osteoid and become 
osteocytes, line the bone and become bone lining cells, or undergo apoptosis. 
They are stimulated by PTH, 1,25-hydroxyvitamin-D, and insulin-like growth factor 
(IGF)-I (Datta et al., 2008).  
The mature osteoblast is designed for protein synthesis: it has a large and 
efficient rough endoplasmic reticulum, Golgi apparatus, and secretory vesicles. 
Osteoblasts are polarized, with their synthetic functions at one end (near the 
cellular attachment areas) and their regulatory functions and nucleus at the other 
(Deng et al., 2008).  
Bone lining cells, which derive from osteoblasts, no longer play a role in 
synthesis. These flat thin cells have little metabolic activity, covering non-
metabolically active areas of the bone. However these play an important role in 
bone resorption: it is the peelback of the lining cells that stimulates and allows the 
attachment of osteoclasts to bone (Everts et al., 2002). Osteocytes are derived 
from the osteoblasts. During the formation of new bone, these become embedded 
in the bony matrix and differentiate into osteocytes. These cells form a connected 
cellular network that, along with the nerve fibres in bone, has a role in the 
response to mechanical loading (Kringelbach et al., 2014), since they sense 
mechanical strain and cracking, and respond by triggering bone remodelling. To 
balance this effect they can secrete sclerostin, which reduces bone formation 
(Kogawa et al., 2013). It survives in single cell-sized hole in the bone known as a 
lacuna. It still plays a vital role in bone homeostasis, although different from the 
osteoblast. 90% of all bone cells are osteocytes, and they can survive for decades. 
These are interconnected to one another through long cellular projections in 
tunnels known as canaliculi. Additionally, these tunnels serve as the source of 
nutrients and disposal of waste for these cells (Milovanovic et al., 2013).  
The osteoclast derives from the haematopoietic macrophage lineage. The 
osteoclast is a multinucleated giant cell that is responsible for bone resorption, 
usually found in contact with a calcified bone surface and within a lacuna 
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(Howship’s lacunae). The contact zone with the bone is characterized by the 
presence of a ruffled border and the attachment proteins that allow it to seal itself 
to the bone surface and pump carbonic acid (Baron, 1993). In addition to this 
acidic environment, the osteoclast synthesizes enzymes that degrade extracellular 
matrix proteins. Its function is intimately tied to the osteoblast cells (see below). 
This paired activity of bone-building and bone-absorbing cells is known as 
coupling and is crucial to the regulation of bone and calcium in the body (Ikeda 
and Takeshita, 2014) 
1.3.2. Bone remodelling and metabolism 
As mentioned earlier in this thesis, bone has multiple functions in vertebrates, 
including protection of vital organs and haematopoietic marrow, structural support 
for muscles, and storage and release of vital ions, such as calcium, and of growth 
factors which are stored in the matrix. Bone remodelling is the process in which 
bone, in the adult skeleton, is renewed continuously in response to a variety of 
stimuli. The osteoclasts are involved in the removal of trenches or tunnels of bone 
from the surfaces of trabecular and cortical bone, respectively (Boyce, 2013).   
Osteoblasts subsequently fill in these trenches by laying down new bone matrix 
in them. Bone formation matches resorption during normal bone remodelling 
(Boyce and Xing, 2008). Bone remodelling involves: (1) the activity of osteoblasts 
and osteoclasts; (2) the actions of a variety of cytokines; (3) the turnover of bone 
minerals, particularly calcium and phosphate (although other minerals, such as 
magnesium, may also be important); (3) the actions of several hormones, such as 
parathyroid hormone (PTH), the vitamin D family, oestrogens, growth hormone, 
steroids, calcitonin and various cytokines (such as interleukins). Many other 
factors affect bone remodelling, such as exercise, diet and drugs (Feng and 
McDonald, 2011). 
Bone remodelling starts with recruitment of osteoclast precursors and the 
subsequent differentiation of these to mature multinucleated osteoclasts induced 
by cytokines. Osteoclast precursors (OCPs) are attracted from the bone marrow 
(where they are held by the stroma-derived factor-1, SDF-1) to the bloodstream by 
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chemokines and circulate there until they are attracted back into bones by a 
variety of factors released at sites undergoing resorption, called bone remodelling 
units (BRUs), differentiating into osteoclasts (Boyce et al., 2012). These factors 
include the macrophage-colony-stimulating factor (M-CSF) and receptor activator 
of NF-κB ligand (RANKL) (Boyce et al., 2012). Osteoclasts adhere to an area of 
trabecular bone, developing a ruffled border at the attachment site. H+ ions are 
pumped through the ruffled border and, along with Cl-, form HCl, which 
demineralizes bone, and cathepsin K is secreted to degrade the matrix (Boyce, 
2013). This process gradually releases IGF-I and TGF-β, which were trapped in 
the osteoid. These cytokines recruit and activate osteoblasts cells, which invade 
the site, synthesising and secreting the organic matrix of bone, the osteoid, and 
secreting IGF-I and TGF-β (see e.g. Chernausek et al., 2007, and Janssens et al., 
2005) Some osteoblasts become embedded in the osteoid, differentiating into 
osteocytes; others interact with and activate osteoclast precursors, the process 
known as coupling (see above).  
Besides IGF-I and TGF-β, other cytokines belonging to the members of the 
TGF-β family, such as the bone morphogenic proteins (BMPs), a range of 
interleukins, various hormones and members of the tumour necrosis factor (TNF) 
family are involved in bone remodelling. RANK, receptor activator of nuclear factor 
kappa B (NFκB), is a central receptor involved in osteoclast differentiation, being 
NFκB the principal transcription factor involved. It is activated by RANKL, which 
exists as a homotrimeric protein and is typically membrane-bound on osteoblastic 
and activated T cells or is secreted by some cells, such as activated T cells 
(Kearns et al., 2008). Like other TNF receptor family members, RANK lacks 
intrinsic kinase activity to phosphorylate and activate downstream signalling 
molecules; it recruits TNF receptor-activating factors (TRAFs), particularly TRAFs 
1, 2, 3, 5, and 6, which are adapter proteins that recruit protein kinases (Boyce, 
2013). Briefly, this process allows the activation of NIK (NF-κB-inducing kinase), 
and signalling through this kinase and TRAF6 results in the activation of NF-κB 
and subsequent increased expression of NFATc1 (which has been called the 
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master regulator of osteoclastogenesis) to induce further osteoclast progenitor 
differentiation (Boyce, 2013). 
Osteoblasts also produce osteoprotegerin (OPG), a decoy ligand that inhibits 
osteoclast differentiation by blocking the RANK receptor. During coupling, OPG 
can bind to RANKL and inhibit RANKL's binding to the functional receptor, RANK, 
on the osteoclast precursor cell. RANKL/OPG ratio is critical in the formation and 
activity of osteoclasts and, thus, the optimal functioning of the RANK, RANKL and 
OPG system is crucial for bone remodelling (Boyce and Xing, 2008; Wright et al., 
2009). Oestrogens induce osteoprotegerin synthesis, which may be one 
mechanism by which exogenous oestrogens inhibit osteoclast function and bone 
resorption in postmenopausal women (see section 1.2.3). 
As mentioned above, bone remodelling involves daily turnover of bone 
minerals, being calcium and phosphate the most important.  Regarding calcium, 
99% of this mineral is in bone and teeth. Normal serum calcium varies from 2.1 to 
2.6 mM. Three different components may be found: ionized (approximately 50%), 
protein-bound (nearly 40%, mainly albumin) and complexed to anions such as 
phosphate and citrate (approximately 10%). It is the ionized form (approximately 
1.2 mM) that exerts the biological effects, and so it is tightly regulated. Hormones 
regulate plasma Ca2+ by controlling Ca2+ absorption from the intestine and its 
excretion by the kidney. These hormones may also recruit Ca2+ from the skeletal 
reservoir (Rang et al., 2011). 
Ca2+ enters the body through the intestine by facilitated diffusion (majority of 
total calcium uptake) throughout the small intestine and by active transport in the 
proximal duodenum (regulated by vitamin D). Glucocorticoids or phenytoin 
depress intestinal calcium transport. There is a calcium loss due to mucosal and 
biliary secretions and sloughing of intestinal cells. Calcium excretion in the kidney 
is also highly regulated. Around 9 g of Ca2+ is filtered in the glomeruli, of which 
>98% is reabsorbed in the tubules. The efficiency of tubular reabsorption is 
regulated by PTH and influenced by filtered Na+, the presence of non–reabsorbed 
anions, and diuretics. Regarding phosphate, approximately 80% of its total is 
found in bone and around 15% in soft tissues. It is present in collagen, bone, 
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plasma, extracellular fluid, cell membrane phospholipids and in the intracellular 
fluid. Phosphorus exists in both organic and inorganic forms in the body. The 
former includes phospholipids and organic esters. In the extracellular fluid, 
phosphorus exists as inorganic phosphate (Pi) in the form of NaH2PO4 and 
Na2HPO4. Pi interferes with tissue concentrations of Ca2+ and plays a major role in 
renal acid excretion. In bone, phosphate is complexed with calcium as 
hydroxyapatite and calcium phosphate (see above). Phosphate uptake in the 
intestine is passive, although an active component may be stimulated by several 
factors, including vitamin D. Its excretion in the kidney is highly regulated. More 
than 90% of plasma phosphate is filtered at the glomeruli, and more than 80% of 
which is reabsorbed in the tubules. Renal phosphate reabsorption is regulated by 
many factors, including PTH and dietary phosphate (for a review, see Moe, 2008). 
The most important hormones that regulate Ca2+ and phosphate concentrations 
are PTH and 1,25-dihydroxyvitamin D (or calcitriol), which regulate mineral 
homeostasis by effects on the kidney, intestine, and bone. Besides these, other 
hormones are involved in bone metabolism and remodelling, such as oestrogens, 
calcitonin and thyroid hormone (for a review, see Raisz, 1999). 
PTH, parathyroid hormone, consists of a single polypeptide chain of 84 amino 
acids. It acts on PTH receptors in various tissues (like bone, kidney and 
gastrointestinal tract) and its role is to maintain a constant concentration of Ca2+ in 
the extracellular fluid. Parathyroid hormone is synthesised in the cells of the 
parathyroid glands, stored in vesicles, and its release is controlled by the 
concentration of ionised calcium in the plasma. Calcium acts via the calcium-
sensing receptor (CaSR), a GPCR that couples with Gq-PLC and Gi. Occupancy of 
the CaSR by Ca2+ inhibits PTH secretion (in a case of hypercalcaemia); on the 
other hand, hypocalcemia stimulates PTH secretion (Bisello et al., 2004; Deal, 
2009).  
 In tissues, PTH binds to the PTH type 1 receptor, a class II G protein-coupled 
receptor that is abundant in kidney and bone (in osteoblasts and osteocytes), and 
triggers classic G-protein signalling pathways, including Gs-linked cAMP 
production and Gq/11-dependent activation of phospholipase C (PLC) β and 
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subsequently calcium transients and protein kinase C (PKC) activation (Sneddon 
et al., 2004). In the kidney, PTH enhances the efficiency of Ca2+ reabsorption 
(primarily in the distal nephron through the stimulation of the epithelial Ca2+ 
channel TRPV5), inhibits tubular reabsorption of phosphate, and stimulates 
conversion of 25-OH-ergocalciferol (25-OHD) to calcitriol, since it stimulates 1α-
hydroxylase, enhancing the synthesis and release of calcitriol. As a result, Ca2+ 
plasma concentration increases, whereas phosphate is excreted and its plasma 
concentration falls. Calcitriol, in turn, will interact with vitamin D receptors (VDRs) 
in the intestine to increase the efficiency of calcium absorption, and so promotes 
the increase of plasma Ca2+ concentration (see e.g. Li et al., 1998). 
 The skeletal actions of PTH are complex, since this hormone can stimulate 
both osteoblast-dependent bone formation and osteoclast-mediated bone 
resorption; PTH increases bone resorption and thereby increases Ca2+ delivery to 
the extracellular fluid. The major effects of PTH on differentiated osteoblasts are 
dependent upon binding to the transmembrane PTH/PTHrP receptor type 1 
(PTHR1) and activation of transcription factors such as the activator protein-1 
family, Runx-2 and cAMP response element binding protein (CREB); much of the 
regulation of these factors by PTH is protein kinase A (PKA)-dependent, 
(Swarthout et al., 2002), promoting osteoblastogenesis. On other hand, several 
studies suggest that continuous (but not intermittent) PTH can result in an 
increase in receptor activator of nuclear factor-kB ligand (RANKL) expression and 
consequent osteoclastogenesis in culture, with an associated inhibitory effect on 
osteoprotegerin expression (Locklin et al., 2003; Ma et al., 2001). 
Vitamin D (calciferol) consists of a group of lipophilic pre-hormones that are 
converted in the body into a number of biologically active metabolites that function 
as hormones (Reichel et al., 1989). Their main action is mediated by nuclear 
receptors of the steroid receptor superfamily (VDR), and consists in the keeping of 
plasma Ca2+ by increasing its absorption in the intestine, mobilising Ca2+ from 
bone and decreasing its renal excretion circulating in the blood. It also regulates 
the activities of various cell types, namely osteoblasts (Anderson et al., 2013). In 
humans, there are two sources of vitamin D, dietary ergocalciferol (D2), derived 
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from ergosterol in plants, and cholecalciferol (D3) generated in the skin from 7-
dehydrocholesterol by the action of ultraviolet irradiation (Norman, 2008). In this 
particular mechanism, exposure to ultraviolet light in sunlight converts 7-
dehydrocholesterol to cholecalciferol (vitamin D3) in the skin. In liver, hydroxylation 
occurs to form 25-OH-cholecalciferol or 25-OH-ergocalciferol (25-OHD). After 
production in the liver, 25-OHD enters the circulation, bound to vitamin D-binding 
protein and its final activation occurs predominantly in the kidney, where 1α-
hydroxylase in the proximal tubule converts 25-OHD to calcitriol. In the kidney, 
calcitriol stimulates Ca2+ reabsorption in the distal tubule. In the proximal 
duodenum, calcitriol stimulates TRPV6 Ca2+ channels and also induces the 
synthesis of calbindin D9K, calbindin D28K, and the serosal membrane Ca2+-
ATPase, promoting calcium uptake. In the absence of calcitriol, passive diffusion 
via the paracellular pathway is the mechanism involved (Morris and Anderson, 
2010). 
Regarding bone, vitamin D has a direct effect on bone cells. Osteoblasts, 
osteoclasts and osteocytes are capable of converting 25-OHD into calcitriol 
(Morris and Anderson, 2010). Human and rodent osteoblasts express the 
CYP27B1 enzyme (or 1α-hydroxylase) which is essential to convert 25-OHD to 
calcitriol and to increase expression of key genes associated with maturation and 
mineralization, the calcitriol responsive genes osteocalcin and osteopontin (Atkins 
et al., 2007). In the transgenic mouse model of osteoblast and osteocyte VDR 
overexpression, an increased bone volume and strength due to increased mineral 
apposition as well as decreased osteoclast formation was shown, proving the 
direct action of vitamin D on osteoblasts. However, on bone absorptive cells, the 
osteoclasts, it was found that these express cytoplasmic CYP27B1 and nuclear 
VDR proteins. In pre-osteoclasts, such as in human peripheral blood mononuclear 
cell preparations, CYP27B1 expression was necessary for 25D to optimise 
osteoclastogenesis in the presence of RANKL and M-CSF in vitro (Kogawa et al., 
2010). So, vitamin D action in bone is complex and goes beyond the Ca2+ increase 
in the plasma. However, it is well known that clinical vitamin D deficiency (see 
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below), in which the mineralisation of bone is impaired administration of vitamin D 
restores bone formation (Norman, 2008). 
Calcitonin is a peptide of 32 amino acids. It is a hormone secreted by the 
specialised C cells found in the thyroid follicles. Its actions oppose those of PTH. 
Calcitonin is able to decrease blood calcium levels by direct inhibition of mediated 
bone resorption and by enhancing calcium excretion by the kidney (Masi and 
Brandi, 2007). Calcitonin secretion increases in hypercalcaemia and decreases 
when plasma Ca2+ is low. Circulating concentrations are normally low (<15 pg/mL 
in males and 10 pg/mL in females) but can be markedly elevated with C cell 
hyperplasia or medullary thyroid cancer (Verburg et al., 2013). Calcitonin actions 
are mediated by the calcitonin receptor (CR), a GPCR that couples through 
multiple G proteins to diverse signal transduction pathways. Different isoforms of 
calcitonin receptors resulting from alternative splicing of the gene have been 
described in various animal species with differential tissue expression transcripts 
and different signalling properties (Moore et al., 1995; Nussenzveig et al., 1994). 
One of the most important pathways is coupled to the cAMP signal transduction, 
but calcitonin receptors may also couple to the phospholipase C (PLC) enzyme 
pathway. Other authors also demonstrated that calcitonin when bound to CTRs 
stimulates Shc tyrosine phosphorylation of MAPK Erk1/2 (Chen et al., 1998; 
Pondel, 2000). 
Osteoclasts are the major target for the action of calcitonin. Calcitonin is able to 
interfere with osteoclast differentiation from precursor cells and fusion of 
mononucleated precursors to form multinucleated cells in bone marrow cultures 
(Takahashi et al., 1988). Calcitonin may also inhibit several components of the 
osteoclast function, such as the release of acid phosphatase and the expression of 
carbonic anhydrase II (Zaidi et al., 1994; Zheng et al., 1994), which is an enzyme 
responsible for pH regulation, CO2 and HCO3- transport, and maintaining H2O and 
electrolyte balance (Sly and Hu, 1995). 
Sex steroids also play a key role in the maintenance of bone integrity. In fact, 
the loss of ovarian function at menopause has long been associated with bone 
loss (for a review, see Zallone, 2006). In males, although not so abrupt, the 
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decline of androgen levels has also been implicated to deleterious effects in the 
skeleton. In fact, it is widely accepted that androgens are locally transformed into 
oestrogens by aromatase on bone cells (Bilezikian, 2002).  
The classical receptors for oestrogens (the ERα and ERβ) or androgens (AR) 
are expressed in bone marrow stromal cells, osteoblasts, osteoclasts and their 
precursor cells (Bellido et al., 1995; Couse and Korach, 1999). This suggests that 
the effects of sex steroids on bone may be mediated directly on such cells 
(Zallone, 2006). Several studies have indicated that ER receptors are important in 
the regulation of cytokine production that may act in an autocrine and paracrine 
manner, regulating osteoclastogenesis and osteoblastogenesis. These may be 
produced by osteoblasts, stromal cells and lymphocytes (Manolagas and Jika, 
1992).  
Studies have shown that after menopause, there is an increase on circulating 
levels of IL-1 and IL-6 (Manolagas et al., 2002). These have been associated with 
bone loss, and several studies have reported that osteoclastogenesis is 
associated with increasing levels of these interleukins. Knockout of IL-6 gene in 
mice prevents bone loss following a decrease of sex steroids (Bellido et al., 1995). 
Other studies showed that in ovariectomized women and mice there are increases 
of circulating levels of IL-1 and TNF-α, produced by T cells and blood mononuclear 
cells (Kitazawa et al., 1994; Pacifici et al., 1991). These have been associated with 
an increased expression of RANKL by osteoblasts, stimulating the differentiation 
of osteoclast precursors (Wei et al., 2005). IL-7 levels are also associated with 
postmenopausal bone loss. In an ovariectomy-induced bone loss model in mice, 
neutralization of IL-7 completely prevents bone loss and rescues bone formation 
(Weitzmann et al., 2002). This effect seems to be dependent on T cells, since in T 
cell-deficiency nude mice, injection of IL-7 failed to induce bone loss (Toraldo et 
al., 2003).  
In addition, in mice models of osteoporosis, ovariectomy causes a dramatic 
increase in the osteoblast and osteocyte apoptosis. Addition of both oestrogens 
and androgens prevents such effects, a mechanism that was shown to be 
mediated by a Src/Shc/ERK signalling cascade (Kousteni et al., 2001). Several 
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authors have suggested that the protective action of sex steroids on bone is due to 
a change of the ratio among RANKL, cytokine-inducing osteoclastogenesis and 
OPG (Zallone, 2006). In previous works, it was shown that in human osteoblastic 
cells, application of 17β-estradiol is able to promote increases in OPG mRNA in a 
dose dependent manner (Hofbauer et al., 1999). This protein is able to prevent 
RANK-RANKL association, preventing osteoclastogenesis, as mentioned above.  
Other observation regarding sex steroid decay is the parallel increase in 
prostaglandin E2 (PGE2), which is a potent stimulator of bone resorption in organ 
culture and osteoclast formation in bone marrow and spleen cell cultures (Li et al., 
2002). PGE2 may enhance bone resorption either by increasing RANKL 
expression caused by activation of prostaglandin receptors in bone marrow cells 
(Kanematsu et al., 2000), or due to potentiation of RANK signalling caused by 
activation of prostaglandin receptors in osteoclast  progenitor cells (Ono et al., 
2005). It was shown that increasing levels of PGE2 may be inhibited with the 
application of oestrogens in ex vivo cultures of mouse calvariae from oestrogen 
deficient animals (Feyen and Raisz, 1987).  
Although most of the loss in bone mass caused by oestrogen deficiency is 
primarily due to enhanced bone resorption, there is also a decrease in bone 
formation (Chow et al., 1992; Qu et al., 1998). Authors showed that during 
oestrogen deficiency, there is a decrease of TGF-β (Oursler et al., 1991) and IGF-I 
(Ernst et al., 1989) expression in osteoblasts, leading to a lower stimulation of 
osteoblast proliferation and differentiation. Oestrogens are also known to stimulate 
the expression of type I collagen (Ernst et al., 1989). The opposite effects of 
oestrogen on osteoblast and osteoclast apoptosis have recently been attributed to 
different kinetics of ERK phosphorylation, since oestrogen causes a transient 
phosphorylation of ERK in osteoblasts/osteocytes and a sustained 
phosphorylation in osteoclasts (Chen et al., 2005). Despite of these findings, the 
effects of sex steroids on bone are still a matter of extensive debate and more 
work is needed to clarify the cellular mechanisms involved (for a review, see 
Lerner, 2006). 
1.Introduction 
 
PhD thesis – José Bernardo Noronha Matos (2011-2014) 53   
There are other key regulating factors on bone remodelling, which will be 
quoted briefly. Growth hormone is a pituitary polypeptide that does not have direct 
effects on bone resorption, and its direct actions on bone formation are still 
controversial. It causes a slight stimulation of IGF-I by skeletal cells and through 
this local factor, growth hormone may regulate bone formation (see above). In fact, 
this direct effect on bone cells is of minor importance since these express only a 
low level of growth hormone receptors. However, growth hormone is known to play 
an important role in stimulating bone formation in vivo, and in particular, during 
growth, appearing to be necessary for the maintenance of normal bone mass 
(Canalis, 1993).  
Thyroid hormones are known to play a role in normal growth and development, 
acting primarily on cartilage formation in conjunction with IGF-I. These are able to 
stimulate bone resorption, with clinical implications. For example, hyperthyroid 
patients may have hypercalcaemia, and postmenopausal patients on chronic 
thyroid suppression may be prone to develop osteopenia (Baran and Braverman, 
1991). 
1.3.3. Bone disorders and therapeutic approaches 
On this topic, focus will be given to diseases that affect bone remodelling and 
some of the respective therapeutic approaches. Special focus will be given to 
osteoporosis, since it is the most common form of bone disease, afflicting a 
growing number of people every year. Other less prevalent diseases will be 
referred briefly, such as renal osteodystrophy, Paget’s disease, osteopetrosis, 
rickets and osteogenesis imperfecta (Table 2).  
Osteoporosis, previously mentioned in this work, is a chronic metabolic disease 
of the bone which is characterized by low bone mass and its structural 
deterioration. It is the result of factors that negatively affect bone mass and 
density. Is the most common disease in humans which affects both sexes and all 
races (Feng and McDonald, 2011; Schuiling et al., 2011). Osteopenia is a 
condition of lower than normal density and is considered to be a precursor to 
osteoporosis by some authors, although not everyone with osteopenia develops 
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osteoporosis (Schuiling et al., 2011). Osteoporosis is traditionally classified into 
primary and secondary types: the first is further divided into type I and type II 
osteoporosis (Aaseth et al., 2012). Type I osteoporosis is commonly known as 
postmenopausal osteoporosis and is a common bone disorder in postmenopausal 
women which is caused primarily by oestrogen deficiency resulting from 
menopause (see previous section for details and cell mechanisms of disease). 
Type II osteoporosis is commonly known as age-related osteoporosis or senile 
osteoporosis, and it is associated with aging in both women and men (see section 
1.2.3 for details).  
Secondary osteoporosis is more 
widely, resulting from secondary 
complications of various other medical 
conditions, consequences of deviations 
in physical activity, diet or therapeutic 
interventions for certain disorders (Feng 
and McDonald, 2011). Glucocorticoid-
induced osteoporosis was mentioned 
previously (section 1.2.1) and is a very 
common cause of bone loss. As already 
stated, drugs that are commonly used 
to treat a variety of inflammatory 
conditions and autoimmune disorders, 
such as rheumatoid arthritis, asthma, 
and multiple sclerosis, promote an 
unbalance between bone formation and 
resorption. In fact, bone loss begins within the first several months of initiating 
glucocorticoid treatment, and extended glucocorticoid-based therapy leads to a 
significant increase in bone fracture (van Staa et al., 2000). Immobilization-
induced osteoporosis is also common, and results from a basic principal regarding 
bone: one of the major functions of bone remodelling is to adapt bone material and 
its structural properties to the mechanical demands that are placed on the 
 
Table 2. Examples of bone disorders 
Osteoporosis 
Primary 
 Menopause associated 
 Age related 
Secondary 
 Glucocorticoid induced 
 Immobilization induced 
Renal osteodystrophy 
Paget’s disease 
Osteopetrosis 
Rickets 
Osteogenesis imperfecta 
Of all of these diseases, osteoporosis is the 
most common. There are other secondary 
causes of osteoporosis that were omitted 
here, focusing on the primary forms of the 
disease. See text for details. 
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skeleton, which includes both mechanical loading and weight bearing (Feng and 
McDonald, 2011). Prolonged bed rest or immobilization resulting, for example, 
from paralysis or casting a limb reflects a decrease in mechanical requirements, 
resulting in this form of osteoporosis (Takata and Yasui, 2001). Osteocytes, the 
mechanical sensors of bone, are often associated to this regulated process of 
bone adjustments to changes in mechanical loading or weight bearing. Mechanical 
loading of the skeleton leads to deformation of bones, shear forces and streaming 
potentials within osteocyte lacunae and canalicular network, which are detected 
primarily by osteocytes (You et al., 2000). In fact, genetically modified mice lacking 
osteocytes develop osteoporosis due to defective mechanotransduction (Tatsumi 
et al., 2007). Osteoblasts and osteoprogenitors are also important 
mechanosensing cells. They release ATP and other molecules due to shear 
stress, resulting in increased osteogenesis (Riddle et al., 2007). This topic will be 
extensively discussed in the following sections. All bone cells should respond 
somehow to loaded mechanical stress and should have its share in pathogenesis 
of immobilization-induced bone loss.   
Since osteoporosis is a growing problem in developed nations, it is of impaired 
importance to develop new strategies to overcome this public health issue. 
Prevention through nutrition and exercise is still the best way to avoid 
osteoporosis. Regarding the first, calcium and vitamin D are recommended both 
for the prevention of osteoporotic fractures (for details, see previous section) 
(Schuiling et al., 2011). Exercise has a deep impact preventing osteoporosis, 
depending on the type, timing, frequency and duration. It builds bone mass density 
and changes the size and shape of bone (Hamilton et al., 2010). Although the 
optimal paybacks of exercise and its effects on peak bone mass density occur 
prior to menopause, women who are postmenopausal can prevent approximately 
2% of bone mass density loss with aerobics, weight-bearing and resistance 
exercises (Hamilton et al., 2010). Pharmacological treatment, however, is initiated 
when there is a history of an osteoporotic vertebral or hip fracture, T scores equal 
or worse than -2.5 at the lumbar spine, femoral neck, or total hip region, or T 
scores from -1.0 to -2.5, with a risk for a major osteoporotic fracture of at least 
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20% or a hip fracture of at least 3% within 10 years (given by the FRAX score) 
(Hamdy et al., 2010). Regarding the pharmacological available treatments for 
osteoporosis, there are drugs existing that decrease the rate of bone resorption 
and thereby, slow the rate of bone loss (antiresorptive therapy); other drugs 
promote bone formation (anabolic therapy). Regarding the antiresorptive agents, 
the most common are bisphosphonates, calcium supplements, vitamin D and its 
analogues, selective oestrogen receptor modulators (SERM) and calcitonin (for a 
review, see Tella and Gallagher, 2014). Bisphosphonates are enzyme-resistant 
analogues of pyrophosphate, which has a role in regulating bone resorption. 
Bisphosphonates form tight complexes with calcium in the bone matrix, and are 
released slowly as bone is resorbed by the osteoclasts, which are thus exposed to 
high concentrations of the drugs (Rang et al., 2011; Watts and Diab, 2010). 
Bisphosphonates inhibit bone resorption by an action mainly on the osteoclasts. 
There are two forms of bisphosphonates: non-nitrogen-containing 
bisphosphonates and nitrogen containing bisphosphonates. The first group inhibits 
osteoclastic activity by producing toxic analogues of ATP that cause cell death 
(Frith et al., 1997). It includes etidronate, clodronate and tiludronate. Their binding 
affinity and antiresorptive potency differs, since they have different side chains 
(Watts and Diab, 2010). Nitrogen containing bisphosphonates inhibit an enzyme 
called farnesyl pyrophosphate synthase, involved in the 3-hydroxi-3-methylglutaryl 
coenzyme A reductase pathway. Inhibition of this enzyme interferes with 
prenylation, preventing the addition of 15- and 20-carbon side chains that anchor 
GTP-binding proteins to osteoclast cell membrane, leading to less resorptive 
osteoclasts that will enter in apoptosis. These include alendronate, risedronate, 
ibandronate and zoledronate. Bisphosphonates are usually well tolerated (given 
weekly and monthly). When given orally, in some cases, they may cause severe 
oesophageal distress. In some instances, they can be given intravenously for 
skeletal protection. Possible side effects have been described, mainly related to 
long-term intake of bisphosphonates, like osteonecrosis of the jaw, 
musculoskeletal pain, atrial fibrillation, atypical fractures and oesophageal cancer. 
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For most patients with osteoporosis, however, the benefits of treatment outweigh 
the risks (for a review, see Watts and Diab, 2010).  
Calcium gluconate and calcium lactate are calcium salts used therapeutically, 
given orally. Studies suggest that supplemental calcium in elderly individuals, 
usually combined with vitamin D, improves bone mineral density. Dosing varies in 
the range of 1000 mg/day in adolescents and young adults and 1500 mg/day in 
the elderly (Varenna et al., 2013). Calcium salts, however, can cause 
gastrointestinal disturbance among other secondary effects. Calcimimetics are 
compounds that mimic the action of calcium via CaSR (calcium sensing receptors) 
to inhibit PTH secretion by parathyroid glands. Subsequent decrease in PTH 
levels leads to a decreased bone resorption. Cinacalcet is a calcimimetic used for 
the treatment of secondary hyperthyroidism due to chronic renal disease and for 
patients with hypercalcaemia associated with parathyroid carcinoma. 
Hypocalcaemia may be an adverse effect of cinacalcet, so it should not be used in 
situations where initial plasmatic calcium is less than 8.4 mg/dl (Filopanti et al., 
2013). 
Calcitonin is a powerful inhibitor of osteoclast activity that acts through specific 
receptors, preventing the release of acid phosphatase and the expression of 
carbonic anhydrase II (Zaidi et al., 1994; Zheng et al., 1994) (see previous 
section).  Salmon calcitonin (salcatonin) is the form most often used in human 
therapy at doses that markedly exceed the endogenous production rate of human 
calcitonin. It is 50 to 100 times more powerful than human calcitonin (for a review, 
see Body, 2002). Side effects may include nausea, vomiting, and facial flushing, 
among others (Rang et al., 2011). 
As mentioned in the previous section, during menopause, the decrease in 
oestrogens has a deep impact on bone formation. One way to ameliorate this 
condition is to carry out a hormone replacement therapy. Since hormones may act 
on different tissues, a group of new non-hormonal agents have been developed 
termed selective oestrogen receptor modulators (SERM). These may exhibit 
agonist actions on some tissues and antagonist actions on others. An important 
SERM is raloxifene. This SERM is used clinically in postmenopausal women to 
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slow bone loss, decreasing bone fracture risk. It supresses osteoclast activity and 
bone remodelling similarly to oestrogen through high affinity interactions with ERα 
(Aref et al., 2013; Ettinger et al., 1999). In fact, oestrogens prevented bone loss in 
ovariectomized rats (Turner et al., 1993). Some authors have also hypothesized 
that raloxifene may also act directly on the bone matrix to improve material 
properties, namely affecting tissue-level biochemical properties through non-cell 
mediated effects on hydration (Gallant et al., 2014). As in other pharmacological 
approaches, raloxifene may have adverse effects, namely the increased incidence 
of deep venous thrombosis (Grady et al., 2004). 
Regarding the anabolic therapy, PTH and PTH fragments are a new line of 
compounds that may be used to promote bone formation. The peptide fragment 
(1-34) is currently in clinical use, the teriparatide. The binding of the ligand to the 
receptor activates adenylate cyclase and a number of phospholipases (A, C, and 
D) and increases intracellular levels of cAMP and calcium (Whitfield et al., 1997). 
Possible cellular mechanisms include the expression of skeletal IGF-I and bone-
forming genes. Evidence has shown that teriparatide increases osteoblast growing 
rate and prevents osteoblastic apoptosis. These processes increase the number of 
osteoblasts and the rate of new bone formation, and prolong osteoblast survival 
(for a review, see Misiorowski, 2011). Teriparatide is given subcutaneously once a 
day. Despite of well tolerated, there has been reported nausea, dizziness, 
headache and arthralgia. Mild hypercalcaemia, transient orthostatic hypotension 
and leg cramps have also been reported (Rang et al., 2011). 
Some agents have both anabolic and anti-resorptive actions. Such an example 
is strontium ranelate.  This dual mode of action was demonstrated in experimental 
studies on bone cells and pharmacological studies in animals (for a review, see 
Neuprez et al., 2008). It seems that strontium decreases differentiation and 
resorbing activity of osteoclasts and increases osteoclast apoptosis (Marie et al., 
2001). In contrast, strontium ranelate seems to enhance pre-osteoblastic cell 
replication and collagen synthesis in culture (for a review, see Saidak and Marie, 
2012). In addition, it modulates the osteoprotegerin/receptor activator of nuclear 
factor kappa B ligand (OPG/RANKL) system in favour of OPG, and so preventing 
1.Introduction 
 
PhD thesis – José Bernardo Noronha Matos (2011-2014) 59   
osteoclast maturation (Atkins et al., 2009). Finally, strontium ranelate 
administration decreases bone resorption and maintains bone formation in adult 
ovariectomized rats, which results in the prevention of bone loss and an increase 
in bone strength (Morohashi et al., 1995). In addition, clinical studies have shown 
that strontium ranelate reduces vertebral, nonvertebral and hip fractures over 1-5 
years. Its spectrum of activity covers osteopenia and osteoporosis. In elderly 
subjects, strontium ranelate also promotes a reduction in vertebral and 
nonvertebral fractures (Neuprez et al., 2008).  
Renal osteodystrophy refers to a varied group of metabolic bone diseases that 
accompany chronic kidney diseases (Feng and McDonald, 2011). Its 
pathophysiology is complex and reflects PTH and vitamin D importance on bone 
turnover and related pathological abnormalities. High-turnover renal 
osteodystrophy can best be categorized as a secondary hyperparathyroidism state 
and low-turnover disease is characterized by a relative hypoparathyroidism state. 
Sustained PTH levels increases bone turnover with increased osteoblasts, 
osteoclasts and osteocytes and a consequent disorder on remodelling leads to 
abnormal bone formation, increased osteoid and fibrosis. Hypocalcaemia, vitamin 
D deficiency, hyperphosphataemia are primary factors contributing to secondary 
hyperparathyroidism (Malluche et al., 2010; Moe et al., 2006). Quantitative 
histomorphometry in conjunction with appropriate laboratory analyses is often 
used to make the diagnosis (Moe et al., 2006). Abnormal mineralization reflects 
the process of calcification of collagen in bone, reflected histologically as abnormal 
osteoid. This impaired mineralization is still poorly understood, but it’s believed to 
be caused by vitamin D and/or mineral deficiencies, aluminium toxicity, and 
possibly to a prolonged acidotic state (Feng and McDonald, 2011).  
The most common form of osteodystrophy is characterized by an absolute or 
relative PTH deficiency accompanied by an extremely low rate of bone formation. 
Factors implicated in this disorder include increased plasma calcium, vitamin D 
toxicity, and altered growth factors and cytokines such as BMPs, TGF- β, IGF-I 
and IL-6 (Hruska et al., 2008; Malluche et al., 2010). 
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For high-turnover disease, the therapeutic approach is focused on phosphorous 
restriction or use of phosphate binders, correcting vitamin D deficiency and, 
occasionally, the use of calcium supplements. Calcimimetic agents are recently 
being used to inhibit PTH secretion. For low-turnover disease, primary methods 
are designed to increase PTH levels, usually reducing calcium and vitamin D as 
well (Feng and McDonald, 2011). 
Paget’s disease is a bone disorder characterized by a high bone turnover. 
Paget’s disease is an osteoclastic-mediated disorder of bone that results in 
abnormal bone resorption associated with inadequate remodelling that leads to 
mechanically weakened bone. It’s a disease that is more prevalent with increasing 
age. Most patients are asymptomatic, but many present bone pain, bone 
deformities, secondary arthritis, and in some instances, secondary to bone 
deformities, neurological problems. Although the pathogenesis of the disease is 
largely unknown, it is believed to be a primary disorder of increased osteoclast 
bone resorption with a resulting secondary increase in osteoblast activity and new 
bone formation. Resulting trabecular bone is abnormal with a disorganized 
appearance (Feng and McDonald, 2011; Singer, 2009). It seems to be a genetic 
cause, since it follows a familial pattern (Beauregard et al., 2013; Gruener and 
Camacho, 2014). One such mutation is a gene that encodes an ubiquitin-binding 
protein that plays a role in NF-kB signalling (Wright et al., 2013). Associated to this 
disease is chronic viral infection, namely with paramyxoviral and the canine 
distemper virus (Bianco et al., 1992; Gordon et al., 1991). The therapeutic 
approach is directed at inhibiting osteoclasts, usually using bisphosphonates; in 
alternative, calcitonin is used to both prevent osteoclast activity and as analgesic, 
since it helps to treat patients with substantial bone pain; additionally, therapy may 
include surgery in order to correct bone deformities (Siris, 1995).  
Osteopetrosis are that family of congenital diseases which is characterized by a 
strikingly radiopaque skeleton, with loss of distinction between cortex and marrow 
space. The hallmark of the disease is the persistence of “cartilaginous bars” deep 
within metaphyseal and diaphyseal bone. Such islands of devitalized cartilage 
surrounded by bone represent the residue of nonresorbed primary spongiosa, a 
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component of endochondral ossification (Teitelbaum, 1993). The forms of disease 
are as follows: severe and intermediate autosomal recessive types and a milder 
autosomal dominant subtype. There have been identified several gene mutations 
all which encode proteins that involve osteoclast-mediated bone resorption. The 
three most important mutations are related to carbonic anhydrase II, proton pump 
and chloride channel. The proton pump is abundantly expressed in the ruffled 
membrane and transports protons into the resorption lacuna to create and 
maintain a low pH (~4.5); this situation provides a high concentration of acid onto a 
strongly basic mineral to dissolve the inorganic component of bone hydroxyapatite; 
these protons are generated from carbon dioxide and water by carbonic 
anhydrase II; in the other hand, the chloride channel, also present in the ruffled 
membrane, transports Cl- into the resorption lacuna to maintain electron neutrality. 
Mutations in these indicated proteins will compromise bone resorption, leading to 
different forms of osteopetrosis (Feng and McDonald, 2011). This disease is 
diagnosed through the use of a combination of clinical and radiological 
parameters; increased serum concentrations of creatine kinase BB isozyme and 
tartrate-resistance acid phosphatase (which derive from osteoclasts) are often 
observed (Bollerslev et al., 2000; Waguespack et al., 2002). In terms of therapy, 
which is only supportive, haematopoietic stem cell transplantation is usually a 
choice (Driessen et al., 2003); treatment regimens with interferon-γ, calcium 
restriction, vitamin D, steroids and PTH have all been tried, with no apparent 
success (Feng and McDonald, 2011).  
Rickets is a pathological situation in which there is a reduction of mineralisation 
of newly-formed bone, that is, osteoid is unmineralised (osteomalacia) and 
endochondral calciﬁcation at the growth plate is absent or reduced, with 
associated growth-plate deformity (Elder and Bishop, 2014). Vitamin D deﬁciency 
is the most common cause in most cases. It remains unclear whether an absolute 
threshold for vitamin D exists, below which rickets is inevitable; rickets can also 
occur when vitamin D is within the range associated with maximum calcium 
absorption, but calcium intake is low (DeLucia et al., 2003). In some cases, 
abnormalities that mainly affect phosphate metabolism or bone-tissue 
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mineralisation might be the cause. The consequences of vitamin D deficiency in 
bone are the direct inhibition of osteoblast progenitors and an increase in RANKL 
expression, with a parallel decrease in OPG, decreasing bone formation and 
enhancing bone turnover. Treatment is focused on fixing the vitamin D deficiency, 
increasing sunshine exposure and through dietary supplements (such as 
ergocalciferol). Some uncommon forms of rickets have been reported that could 
not be corrected with vitamin D therapy, which seems to be an inheritable form of 
the disease, eventually related to vitamin D receptor abnormalities and to vitamin 
D metabolism anomalies (Elder and Bishop, 2014). 
Osteogenesis imperfecta is an inherited connective tissue disorder of 
remarkable clinical variability, caused by a quantitative or qualitative defect in 
collagen synthesis and is characterised by bone fragility (Antoniazzi et al., 2000). It 
is often fatal in utero but those who survive fall into a spectrum of skeletal 
dysfunction ranging from little or no deformity to relentless crippling associated 
with hundreds of fractures. Cardinal manifestations are low-bone mass and 
reduced bone mineral strength, leading to bone fragility and deformity. Cortical 
bone is more diminished than is trabecular bone, and remodelling is typically brisk 
in this disease (Teitelbaum, 1993). In about 90% of individuals with the clinical 
diagnosis of osteogenesis imperfecta, mutations in the COL1A1 and COL1A2 
genes are responsible for the disorder, which code for the α1(I) and α2(I) side 
chains of type I collagen (Rohrbach and Giunta, 2012). Three types of treatment 
are available: nonsurgical management (physical therapy, rehabilitation, bracing 
and splinting), surgery, and drugs to increase the strength of bone and decrease 
the number of fractures. These include bisphosphonates administered to children 
with osteogenesis imperfecta, with the rationale that bones with increased volume 
of osteogenesis imperfecta-quality matrix will be more fracture resistant (Rauch et 
al., 2006). Other approaches are being considered, as antibodies directed against 
RANKL, in order to shift the RANKL/OPG ratio, and decrease osteoblast signalling 
that normally stimulates osteoclast development (Forlino et al., 2011; Hussar and 
Stevenson, 2010). 
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In general, the development of new therapeutic approaches is of major 
importance since these bone disorders, like osteoporosis, are highly prevalent and 
in increasing incidence on an ageing population. In the next chapter, purinergic 
signalling, in the context of bone remodelling, will be explored, reinforcing the huge 
and growing potential of such area in the development of new therapeutic 
strategies to overcome bone deterioration in common bone-related disorders. 
1.4. Purinergic signalling and bone remodelling 
1.4.1. Purinergic receptors 
As mentioned previously, bone turnover is a complex and finely tuned process. 
The importance of systemic and local factors has already been stated, and to 
these we must include the significant role of nucleotides, such as adenosine 5’-
triphosphate (ATP) and its derivatives (like adenosine). It is known that nucleotides 
play fundamental roles in energy metabolism, nucleic acid synthesis and enzyme 
regulation (Burnstock and Knight, 2004). Nucleotides, predominantly ATP, are 
present in intracellular concentrations between 2-5 mM, and extracellular 
concentrations are low, mainly due to the presence of ubiquitous ecto-
nucleotidases and other ecto-phosphatases that rapidly hydrolyse extracellular 
nucleotides to their respective nucleoside 5’-di- and monophosphates, nucleosides 
and free phosphates or pyrophosphates (see below). Nucleotides may be released 
from cells via three major mechanisms: 1) cytosolic ATP release from sites of 
tissue and cell damage (including sites of bone injury), 2) exocytic release, and 3) 
via intrinsic plasma membrane channels or pores in the absence of cytolysis, 
which includes controlled release through hemichannels (for a review, see Novak, 
2003; for further details, see below). Once released, nucleotides and their 
derivatives may act on purinergic receptors, which are important (yet largely 
unknown) bone turnover regulators (Orriss et al., 2010).  
The receptors for purines and pyrimidines are classified into two groups: P1 
receptors (A1, A2A, A2B, A3), which are primarily activated by adenosine, and P2 
receptors, which respond to ATP, adenosine diphosphate (ADP), uridine 
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triphosphate (UTP), uridine diphosphate (UDP) and nucleotide polyphosphates. 
The P2 receptors may be further subdivided into P2X ligand-gated ion channels 
and P2Y G-protein-coupled receptors (Abbracchio and Burnstock, 1994; 
Burnstock and Kennedy, 1985). To date, seven P2X receptors (P2X1-7) and eight 
P2Y receptors (P2Y1,2,4,6,11-14) have been identified, cloned and characterized, 
displaying different tissue distribution and pharmacological properties (Burnstock, 
2007; Orriss et al., 2010). The P2X channels are assembled (in a homo- or 
heteromeric manner) from seven subunits. Based on agonist efficacy, 
elctrophysiological properties and desensitization characteristics, P2X receptors 
have been grouped into three distinct classes (Dubyak, 2007): 1) includes 
P2X1 and P2X3 receptors exhibiting high affinity for ATP (EC50 = 1 μM), which are 
rapidly activated and desensitized; 2) includes P2X2, P2X4, P2X5, and P2X6 
receptors, which have lower affinity for ATP (EC50 = 10 μM) and show slow 
desensitization rate and sustained depolarizing currents; 3) is represented by the 
homomeric P2X7 receptor, which has very low affinity for ATP (EC50 = 300–400 
μM). This receptor shows little or no desensitization and acts as a nonselective ion 
pore (Di Virgilio, 1995), like other P2X receptors (Williams and Jarvis, 2000). 
Besides acting as an ATP-gated ion channel, prolonged activation of the P2X7 
receptor favour permeation of plasma membrane to high-molecular weight (up to 
900 Da) hydrophilic molecules, such as ATP and glutamate. P2Y and P1 receptors 
are classical seven-transmembrane domain receptors couped to G-proteins and 
numerous intracellular second messengers, including cAMP and inositol (1,4,5)-
triphosphate (IP3) cascades (Burnstock and Verkhratsky, 2010). 
1.4.2. P2 receptor expression by osteoblasts 
Previous studies confirmed that osteoblasts and osteoblast-like cells (from 
human and rodent species) express P2 receptors and that extracellular 
nucleotides could transiently increase [Ca2+]i and induce IP3 formation (Orriss et 
al., 2010). Table 3 illustrates the growing body of work around P2 receptors in 
these cells. Data so far obtained strenghten the role of these receptors in 
osteoblast function. After the pioneering work of Kumagai and coworkers showing 
1.Introduction 
 
PhD thesis – José Bernardo Noronha Matos (2011-2014) 65   
that ATP plays a central role in bone physiology (Kumagai et al., 1991), numerous 
studies demonstrated that nucleotides influence osteoblast and osteoclast function 
through the activation of both P2X and P2Y receptors. There are, however, 
conflicting results in the literature regarding the predominant role of P2 receptors 
on bone remodelling that derive mostly from heterogeneity of P2 receptors 
expression among osteoprogenitors vs differentiated cell populations, cell lines vs 
primary cell cultures (see e.g., Wesselius et al., 2011), and the existence of 
striking differences on the molecular composition and activity of these receptors 
between human and rodent species (see e.g. Roger et al., 2010). Another 
confounding factor that authors often disregard, which must be considered of 
clinical relevance, is the influence of systemic factors, such as the hormonal 
condition at bone microenvironment at the time of isolation of the cells. Another 
constrain is on what concerns the predominant use of animal models and 
immortalized cell lines, and less on non-modified human cells (Table 3). To 
obscure the pharmacological characterization and the investigation of the relative 
importance of P2 purinoceptors in bone biology, most studies had to deal with a 
lack of commercially-available selective agonists and/or antagonists. 
Nevertheless, data show that P2 receptors have some role on osteoblast cells 
function.  
 For instance, P2X1 and P2X3 receptors were shown to be involved in the 
prevention of bone nodule mineralization of osteoblast cultures from neonatal 
Sprague–Dawley rats, since P2X1 and P2X3 receptor agonists, α,β-meATP and 
β,γ-meATP, inhibited bone mineralisation without affecting collagen production 
(Orriss et al., 2012).  
The activity of the P2X2 receptor seems to be more relevant in osteoclasts, 
where it increased bone resorption. Resorption increased 5.6-fold when 
osteoclasts from neonatal rats were cultured for 26 h on ivory discs in the 
presence of ATP, with a maximum effect occurring at relatively low concentrations  
(0.2-2 µM) (Morrison et al., 1998). The osteoclast promoting action of ATP was 
greatly amplified when these cells were cultured in acidified media (pH 6.9-7.0) 
(King et al., 1997).  
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Table 3. P2 receptor expression by osteoblasts 
Receptor Species Cell type 
Transduction 
mechanisms 
Proposed function and 
signalling 
References 
P2X1 Rat Primary 
Cation channel 
(Ca2+ and Na+)  
Involved in bone 
mineralization inhibition (rat 
osteoblasts) 
Orriss et al., 
2012; Orriss et 
al., 2013 
P2X2 
Rat Primary 
Cation channel 
(Ca2+) 
Unknown. Also expressed in 
osteoclasts, involved in bone 
resorption (rodent 
osteoclasts) 
Alqallaf et al., 
2009; Hoebertz 
et al., 2000; 
Morrison et 
al.,1998; 
Nakamura et al., 
2000 
Human 
MC3T3-E1, 
SaOS-2 
P2X3 Rat Primary Cation channel 
Involved in bone 
mineralization inhibition (rat 
osteoblasts) 
Orriss et al., 
2012 
P2X4 
Rat Primary 
Cation channel 
(Ca2+) 
Involved in pore formation 
(human osteoblast-like cells) 
Alqallaf et al., 
2009; Ihara et 
al., 2005  
Human 
SAM-1, MG-63, 
SaOS-2 
P2X5 
Rat Primary 
Cation channel 
Involved in human osteoblast 
like cell’s differentiation – 
stimulation of the MAP 
kinase pathway 
Hoebertz et al., 
2000; Ihara et 
al., 2005; 
Nakamura et al., 
2000; Orriss et 
al., 2006  Human 
MC3T3-E1, 
SAM-1 
P2X6 
Rat Primary 
Cation channel 
Largely unknown; regulator 
of MSC commitment 
Ihara et al., 
2005; Zippel et 
al., 2012 
Human SAM-1 
P2X7 
Rat Primary 
Cation channel, 
large pore after 
prolonged 
activation 
Controversial: Apoptosis 
(human cells); induction of 
membrane cell blebbing and 
increased bone formation - 
LPA and PGE2 synthesis 
(newborn rat osteoblasts); 
skeletal 
mechanotransduction 
(mouse osteoblasts); also 
expressed in human 
osteoclasts, involved in 
cellular apoptosis and 
cytoskeleton rearrangements 
Alqallaf et al., 
2009; Gartland 
et al., 2001; 
Jorgensen et al., 
2002; Ke et al., 
2003; Li et al., 
2005; Nakamura 
et al., 2000; 
Orriss et al., 
2006; Orriss et 
al., 2010 ; 
Panupinthu et 
al., 2007; 
Panupinthu et 
al., 2008  
Human 
MG-63, SaOS-2, 
Primary 
Mouse Primary 
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Table 3. (Continued) P2 receptor expression by osteoblasts 
P2Y1 
Rat Primary 
Gq/G11 PLCβ 
activation 
Modulate osteoblast 
responses to PTH – 
increased c-fos expression 
(human and rat osteoblasts) 
Bowler et al., 
1999; Buckley et 
al., 2001; 
Hoebertz et al., 
2000; Maier et 
al., 1997; Orriss 
et al., 2006 
Human MG-63 
P2Y2 
Rat Primary 
Gq/G11, possibly 
Gi/G0, PLCβ 
activation 
Propagation of intracellular 
Ca2+ waves (human 
osteoblasts); inhibition of 
bone mineralization – 
inhibition of ALP (rat 
osteoblasts); stimulation of 
Erg1 and Runx-2 expression 
– activation of PKC and ERK 
pathways (osteoblast-like 
HOBIT cell line); sensitises 
mechanical stress-activated 
Ca2+ channels – activation of 
ERK, p38 MAPK and JNK1 
pathways (ROS-A 17/2.8 
osteoblastic cells) 
Bowler et al., 
1995; Costessi 
et al., 2005; 
Hoebertz et al., 
2000; Hoebertz 
et al., 2002; 
Jorgensen et al., 
2000; Katz et al., 
2006; Katz et al., 
2008; Maier et 
al., 1997; Orriss 
et al., 2006; 
Orriss et al., 
2007; Pines et 
al., 2003 
Human 
MG-63, Primary, 
SaOS-2, Te85 
P2Y4 
Rat Primary 
Gq/G11, possibly 
Gi, PLCβ 
activation 
Possibly involved in the 
inhibition of cell 
mineralization (rat 
osteoblasts) 
Hoebertz et al., 
2002; Maier et 
al., 1997; Orriss 
et al., 2006 
Human MG-63 
P2Y6 
Rat Primary 
Gq/G11 PLCβ 
activation 
Largely unknown; also 
expressed in osteoclasts, 
involved in their survival (rat 
osteoclasts) 
Korcok et al., 
2005; Maier et 
al., 1997; Orriss 
et al., 2006 
Human MG-63 
P2Y11 Human 
osteosarcoma 
HOS cells 
Gq/G11, Gs Largely unknown 
Liu and Chen, 
2010 
P2Y12 Rat Primary 
Gi, inhibition of 
adenylate cyclase 
Involved in bone nodule 
mineralization 
Orriss et al., 
2010; Syberg et 
al., 2012 
P2Y13 Rat Primary Gi/G0 
Increased ALP activity and 
osteogenic differentiation 
(mouse bone marrow 
stromal cells) 
Biver et al., 
2013; Orriss et 
al., 2011  
P2Y14 Rat Primary Gq/G11 
Unknown, although suggest 
to play a role in early 
osteogenic differentiation of 
human MSCs 
Maier et al., 
1997; Orriss et 
al., 2006; Zippel 
et al., 2012 
Growing number of studies indicate that extracellular nucleotides play a role in modulating 
osteoblast function, via P2 receptors. Alkaline phosphatase, ALP; c-jun NH2-terminal protein 
kinase 1, JNK1; extracellular related kinase, ERK; lysophosphatidic acid, LPA; Mesenchymal 
stem cells, MSCs; p38 mitogen-activated kinase, p38 MAPK; phospholipase A2, PLA2; 
phospholipase D, PLD; prostaglandin E2, PGE2; protein kinase C, PKC (based on indicated 
references; see text for details). 
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The P2X4 receptor is also expressed in osteoblasts, where it is involved in 
membrane pore formation. In human osteoblast-like cells, the prototypic P2X7 
receptor agonist, BzATP, caused the incorporation of YO-PRO 1 fluorescent dye 
(a strong indicator of pore formation), but selective P2X7 receptor antagonists 
were unable to completely block pore formation, thus suggesting that coexpressed 
P2X4 may also contribute to this mechanism (Alqallaf et al., 2009).  
ATP, acting on P2X5 receptors (among others), has been reported to stimulate 
osteoblast proliferation (Nakamura et al., 2000). In human osteoblast-like MG-63 
cells, Nakamura and co-workers showed that extracellular ATP increased 
[3H]thymidine incorporation and cell proliferation, a mechanism that seemed to be 
MAP kinase-dependent (Nakamura et al., 2000).  
The P2X6 receptor’s role is osteoblast-like cells is largely unknown, yet it has 
been shown to be expressed in primary cultures of humans and rats (Ihara et al., 
2005).  
Regarding the P2X7 receptor, a huge number of studies suggested that this 
receptor plays important roles in distinct cellular mechanisms, but not all of them 
agree on the pathways involved. Gain of function polymorphisms of the P2X7 
receptor have been associated with increased bone mass (Jorgensen et al., 
2012), whilst loss of function polymorphisms have been associated with increased 
fracture risk, reduced bone mineral density and osteoporosis in postmenopausal 
women (Gartland et al. 2012; Husted et al., 2013; Ohlendorff et al., 2007). It was 
also suggested that the increased vertebral fracture incidence could be due to an 
increased number of osteoclasts. However, heterogeneity of the P2X7 receptor 
expression among osteoprogenitors and differentiated osteoblast-like cell 
populations has also been a matter of concern (Burnstock et al., 2013). The P2X7 
receptor has been implicated in reversible morphological changes (e.g. blebbing) 
(Li et al., 2005; Panupinthu et al., 2007) and/or in the promotion of apoptosis in 
osteoclasts (Burnstock, 2002; North, 2002). However, controversy still exists about 
its significance in humans that are undermined by striking species differences 
shown for the P2X7 receptor (see e.g. Roger et al., 2010). 
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Regarding the P2Y metabotropic receptors, some authors have suggested 
some of their particular roles in osteoblast cells. The P2Y1 receptor was shown to 
modulate human osteoblast responses to systemic factors such as PTH. These 
authors have shown that nucleotide agonists such as ADP and ATP increased 
[Ca2+]i and moderately induced the expression of the c-fos proto-oncogene. They 
also observed that there is a synergistic effect on c-fos induction with the 
combination of ATP and PTH, previously referred as a key bone cell regulator. 
 They concluded that extracellular ATP, via P2Y receptors, can potentiate strong 
responses to ubiquitous growth and differentiating factors (Bowler et al., 1999). 
Regarding the P2Y2 and P2Y4 receptors, Hoebertz and co-workers showed that 
ATP and UTP at ≥ 1 µM are strong inhibitors of mineralization in cultured primary 
rat calvarial osteoblasts (Hoebertz et al., 2002). The potent inhibitory actions of 
ATP and UTP were consistent pharmacologically with mediation via the P2Y2 and 
P2Y4 receptor subtypes, although reactive blue 2, a P2Y4 receptor antagonist, 
failed to prevent the nucleotide-induced blockade of mineralization. This suggests 
that the P2Y2 receptor is mainly involved in this mechanism, an idea that was also 
supported by other authors (Orriss et al., 2007). In fact, it was shown that P2Y2 
knockout mice presents huge increases in trabecular and cortical bone in both 
femora and tibiae, through skeletal analysis by dual energy X-ray absorbtiometry 
and micro-CT (Orriss et al., 2007). Other interesting reports have shown that the 
P2Y2 receptor activation is coupled to intracellular pathways, such as PKC, with 
subsequent stimulation of Runx-2 protein expression (Costessi et al., 2005). The 
p38 mitogen-activated protein kinase and c-Jun NH2-terminal protein kinase (JNK) 
were also shown to function downstream the P2Y2 receptor activation; such 
intracellular pathways were associated with mechanical-stress activated Ca2+ 
channels (Katz et al., 2006; Katz et al., 2008). 
UDP-sensitive P2Y6 receptors have been poorly explored. In fact, uracil 
nucleotides seem to be released in parallel to ATP by different cell types as 
soluble factors in response to mechanical stimulation (see for a review, e.g., 
Hoebertz et al., 2003). Previous works have shown that UDP-sugars, like UDP-
glucose (P2Y14 receptor activator) may be released together with ATP under 
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resting and stimulating conditions (Kreda et al., 2007, 2008; Lazarowski et al., 
2003). UDP itself is an end product during glycogen synthesis, which may be 
released to the extracellular fluid. In fact, using an enzymatic assay, others 
detected UTP release from several cell types with a proportion of approximately 
10-30% of released nucleotides (Lazarowski and Harden, 1999). UTP can also act 
through P2Y receptors to upregulate ATP release from human osteoblasts, 
providing a possible feedback mechanism (Bowler et al., 1998). Human 
osteosarcoma cell lines also express mRNAs for P2Y4 and P2Y6 receptors (Maier 
et al., 1997), which are preferentially or selectively activated by UTP and UDP, 
respectively. Curiously, rat osteoclasts also express P2Y6 receptors which seem to 
be involved in their survival, a cell mechanism dependent on NF-kB activation 
(Korcok et al., 2005). Decreased bone resorption was observed in P2Y6 knockout 
mice, thus suggesting that this receptor may play an important role in bone 
remodelling (Orriss et al., 2011). 
 The P2Y11 receptor expression was detected by RT-PCR in a human 
osteosarcoma cell line, the HOS cells, but its function remains elusive. It is usually 
coupled to Gq/11 and Gs, increasing IP3 levels and adenylate cyclase function, 
respectively (Liu and Chen, 2010).  
P2Y12 receptors are usually associated to bone nodule formation. This 
association came with the use of clopidogrel (Plavix), a selective P2Y12 receptor 
antagonist that is widely prescribed to reduce the risk of heart attack and stroke 
and acts via the inhibition of platelet aggregation. Using rat osteoblasts, 
researchers found that clopidogrel was able to inhibit in vitro mineralization in a 
concentration-dependent manner, slowing osteoblast proliferation and cell viability, 
together with a reduction in ALP activity and collagen formation. In vivo, 
clopidogrel-treated mice showed a decreased trabecular bone volume in the tibia 
and femur (Syberg et al., 2012) when compared to control mice, reinforcing this 
receptor’s role in bone formation. More studies are required to investigate the role 
of the P2Y12 receptor in human bone remodelling before one can assume that its 
antagonists, like clopidogrel, are deleterious to the maintenance of bone mass. 
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Regarding P2Y13 receptors, recent studies demonstrated a decreased bone 
formation and bone resorption in a knockout mice, suggesting a role of these 
receptors in bone remodelling (Orriss et al., 2011). In fact, recent studies 
demonstrated that in mice, ADP stimulation of P2Y13+/+ (but not P2Y13-/-) adherent 
bone marrow stromal cells (BMSCs) increased the formation of alkaline 
phosphatase-colony-forming units (CFU-ALP), as well as the expression of 
osteoblastic markers, namely osterix, alkaline phosphatase, and type I collagen 
(Biver et al., 2013). In the knockout model, BMSCs were shown to preferentially 
differentiate into adipocytes, with a higher expression of PPARγ2 and adipsin 
(Biver et al., 2013).  
Concerning the P2Y14 receptor, although its role in bone remodelling remains 
elusive, some authors suggested that, together with P2X6 and P2Y4, it seems an 
important regulator in MSC commitment to both adipogenic and osteogenic 
differentiation of human adipose tissue-derived stem cells. They found that P2Y14 
receptor’s expression decreased from undifferentiated to osteoblast-differentiated 
cells and suggested that its role in bone cells should be important at an early stage 
of differentiation (Zippel et al., 2012). 
1.4.3. Release of nucleotides from osteoblast and osteoblast-progenitor 
cells 
Extracellular adenine nucleotides, like ATP, play important roles in the 
differentiation and function of osteoblasts. Both BMSCs and differentiated 
osteoblasts constitutively release ATP; the amount of released ATP increases 
dramatically when these cells are submitted to mechanical stress or in pathological 
conditions, such as during hypoxia and inflammation (Brandao-Burch et al., 2012; 
Orriss et al., 2009). Their specific targets include several subtypes of P2Y (G-
protein coupled) and P2X (ligand-gated ion channels) purinoceptors (Romanello et 
al., 2005). Romanello first described controlled ATP release with mechanical 
stimulation (Romanello et al., 2001). Several studies point towards exocytosis 
being the primary mechanism by which ATP is released from osteoblasts 
(Genetos et al., 2005; Orriss et al., 2009; Romanello et al., 2005). However, 
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several other studies suggest that maxi-anion channels (Sabirov and Okada, 
2009), connexins, namely connexin 43 (Thi et al., 2012), and the P2X7 receptor 
(Brandao-Burch et al., 2012), are also important in the release of ATP from 
osteoblasts. Pannexins have also been implicated in nucleotide release, namely 
pannexin 1 and 3 (Ishikawa et al., 2014; Thi et al., 2012). In this respect, pannexin 
1, in concert with P2X7 receptors, have been suggested to form a complex that 
underlies the hemichannel function in osteoblasts mechanosignalling involving the 
release of ATP. Connexin 43-null osteoblasts have unaltered mechanically-
induced PGE₂ release and ATP-induced YoPro dye uptake. In parallel, the same 
authors found that PGE₂ release in response to fluid shear stress was abolished in 
P2X7 receptor-null osteoblasts; likewise, ATP-induced fluorescent dye uptake was 
attenuated following treatment of wild-type cells with a P2X7 receptor antagonist 
or a pannexin 1 channel blocker (Thi et al., 2012). Regarding pannexin 3, this 
hemichannel is the most abundant in bone (as well as in skin and cartilage) 
(Shestopalov and Panchin, 2008). Authors have suggested that it plays a key role 
in the transition from cell proliferation to cell differentiation. Using rat primary 
calvarial cells and explants it was found that the pannexin 3 hemichannel inhibits 
cell growth by promoting β-catenin degradation through GSK3β activation and 
inhibit cyclin D1 transcription and Rb phosphorylation through reduced 
cAMP/PKA/CREB signalling. Furthermore, the pannexin 3 may be located in the 
endoplasmic reticulum, where it induces the transcription and phosphorylation of 
p21 through the calmodulin/Smad pathway, resulting in the cell cycle exit 
(Ishikawa et al., 2014). 
The mechanisms responsible by the release of ATP and, therefore, the 
concentration of the nucleotide in the extracellular milieu depend on the 
differentiation status of the cell, with mature bone-forming cells releasing up to 
sevenfold more ATP than immature proliferating cells (Orriss et al., 2009). In this 
regard, Riddle and co-workers have shown that BMSCs release ATP through 
exocytosis. They also showed that ATP was a prerequisite for fluid flow–induced 
increases in intracellular calcium concentration, activation of calcineurin, nuclear 
translocation of NFATc1, and proliferation (Riddle et al., 2007). Other authors have 
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shown that the expression of connexin 43, the most predominant connexin 
expressed by bone cells, increases with osteoblastic differentiation, possibly 
allowing gap junction hemichannels to augment in prevalence and increasing their 
functional importance in bone cell mechanotransduction (Donahue, 2000).  
Many studies have shown increased extracellular levels of ATP in response to 
external stimuli, namely hypoxia (Orriss et al., 2009), mechanical stress (Hecht et 
al., 2013) and fluid flow (Genetos et al., 2005; Romanello et al., 2001; Rumney et 
al., 2012). In the case of hypoxia, this stimulus resulted in an increased ATP 
release from osteoblasts up to 2.5-fold without affecting cell viability, a mechanism 
that was found to be mainly driven by exocytosis (Orriss et al., 2009). Hecht and 
co-workers mechanically induced ATP release from osteoblast cells (MC3T3-E1) 
using a stretching device integrated into scanning electrochemical microscopy. 
They showed that stretching MC3T3-E1 cells up to 21% results in a concentration 
of ~30 μM of extracellular ATP, which was almost abolished in the presence of 
nifedipine, an L-type voltage sensitive calcium channel (L-VSCC) inhibitor (Hecht 
et al., 2013). Fluid flow was shown to involve extracellular-signal regulated kinase 
(ERK1/2) activation, a mechanism that is Ca2+-, PKC and ATP-dependent in 
MC3T3-E1 osteoblasts (Liu et al., 2008b). Additionally, this ATP-dependent 
ERK1/2 phosphorylation was shown to be mediated through P2X7 receptors (Liu 
et al., 2008b).  
Ultrasound stimulation (US) was also found to promote ATP release from 
osteoblasts, providing a basis to interpret the beneficial effect of US to accelerate 
fracture healing. Authors found increased concentrations of ATP in culture medium 
of US-treated cells and both ATP and US stimulation caused increased receptor 
activator of nuclear factor-kappa B ligand (RANKL), decreased osteoprotegerin 
expression and increased cell proliferation by SaOS-2 cells (Hayton et al., 2005). 
Furthermore, low-intensity pulsed ultrasound stimulation (LIPUS) treatment was 
shown to induce ATP release from osteoblasts. This resulted in an increased 
P2Y1-dependent proliferation (Alvarenga et al., 2010). 
Calcitropic hormones were found recently to promote ATP release from 
osteoblast-like cells. Vitamin D3, in the absence of mechanical stimulation, 
1.Introduction 
 
PhD thesis – José Bernardo Noronha Matos (2011-2014) 74   
increased ATP release from SAOS-2 and ROS 17/2.8 osteoblasts when compared 
to the control stiuation (Biswas and Zanello, 2009).  These authors found that ATP 
secretion was abolished when cells are preincubated with inhibitors of vesicular 
exocytosis. Similarly, siRNA VDR (vitamin D receptors) silencing prevented 
vitamin D3 stimulation of ATP exocytosis (Biswas and Zanello, 2009). 
Furthermore, bisphosphonates, which are used for the treatment of osteoporosis 
(see section 1.3.3), have been reported to induce ATP release, favouring P2Y 
receptors activation. Authors showed that risedronate promotes non-lytic ATP 
release leading to activation of ERKs through the involvement of P2Y receptors, 
namely P2Y1 and P2Y2. In fact, bisphosphonates were previously shown to exert 
part of their effects by using a sort of membrane-receptor triggering by means of 
connexin 43 direct binding, due to their charged nature (Plotkin et al., 2002). 
These and other studies suggest that the local ATP release in response to 
different stimuli may represent a local trigger in bone that may influence 
osteogenesis (Burnstock et al., 2013). 
1.4.4. ATP hydrolysis: ecto-nucleotidases and osteoblasts 
Once released, nucleotides may be rapidly broken down enzymatically by a 
cascade of a number of ecto-nucleotidases (Burnstock et al., 2013) (Figure 4). 
Consequently, ectonucleotidases may command a series of physiological 
responses by regulating P2 receptor activation (Kukulski et al., 2005). There are 
four families of ecto-nucleotidases: the NTPDases (ecto-nucleoside triphosphate 
diphosphohydrolase), the NPPs (ecto-nucleotide pyrophosphatase/ 
phosphodiesterase), alkaline phosphatases and ecto-5’-nucleotidase 
(Zimmermann et al., 2012).  Ecto-nucleotidases may have overlapping 
specificities. For instance, NTPDases catalyse the reactions NTP → NDP + 
phosphate (Pi) and NDP → NMP + (Pi), whereas NPPs hydrolyse NTP → NMP + 
1.Introduction 
 
PhD thesis – José Bernardo Noronha Matos (2011-2014) 75   
pyrophosphate (PPi) or NDP → NMP + Pi (Burnstock et al., 2013). Regarding the 
NTPDase family, these are dominantly ectonucleotidases (Zimmermann et al., 
2012). Four of the eight members of this family, namely NTPDase1, NTPDase2, 
NTPDase3 and NTPDase8 appear to be relevant to the control of P2 receptor 
signalling since they are located at the outer surface of the plasma membrane and 
hydrolyse nucleotides in the range of concentration that activates P2 receptors 
(Bigonnesse et al., 2004; Lavoie et al., 2004; Mateo et al., 1999; Picher et al., 
1996; Smith and Kirley, 1999). These enzymes have two plasma membrane 
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Figure 4. Schematic overview of functional effects of ATP on bone cells. ATP release 
from osteoblasts, osteocytes and osteoclasts can influence their function in an autocrine or 
paracrine manner, influencing both bone resorption and formation. Black arrows represent P1 
or P2 activation, dashed arrows represent ATP breakdown and red texts/arrows represent 
multiple ATP effects on bone cells. NTPDase1, N1; NTPDase2, N2; NTPDase3, N3; ecto 5’-
nucleotidase, Ecto 5’; nucleotide pyrophosphatase/phosphodiesterase, NPP; largely unknown 
or controversial effect, ?. Figure adapted from Burnstock et al., 2013. 
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spanning domains with an active site facing the extracellular milieu (Zimmermann 
et al., 2012). In contrast, the other NTPDases, namely 4-7, are anchored to the 
membrane of intracellular organelles by one (NTPDases5 and -6) or two 
(NTPDases4 and -7) transmembrane domains and their catalytic site faces the 
lumen of intracellular compartments, namely the Golgi apparatus and the 
endoplasmatic reticulum (Kukulski et al., 2005; Trombetta and Helenius, 1999; 
Wang et al., 1998). Since NTPDases have different biochemical properties, they 
are able to regulate P2 receptor activation differently, since they have different 
abilities in dephosphorylating nucleoside triphosphates and diphosphates 
(exclusively in the presence of divalent cations, Ca2+ or Mg2+, and usually all active 
within a pH of 7.0-8.5) (Kukulski et al., 2005). Among the four plasma membrane 
bound NTPDases, NTPDase1 (also known as CD39) hydrolyses ATP and ADP 
with the same affinity, NTPDase2 is a preferential triphosphonucleosidase 
whereas NTPDase3 and 8 are functional intermediates between NTPDase1 and -
2 (Kukulski et al., 2005).   NTPDase1, -2, -3 and -8 efficiently hydrolyse ATP and 
UTP with Km values in the micromolar range, indicating that they should terminate 
the effects exerted by nucleotide agonists at P2X1-7 and P2Y2,4,11. In fact, 
Kukulski and co-workers, using COS-7 transfected cells, showed that NTPDase1 
does not allow the accumulation of ADP, suggesting that it should terminate the 
activation of P2Y1,12,13 receptors. In contrast, they showed that NTPDases2, -3 and 
-8 are expected to promote the activation of ADP receptors, because in the 
presence of ATP, they produce a sustained (NTPDase2) or transient (NTPDases3 
and -8) accumulation of ADP (Kukulski et al., 2005). Additionally, they found that 
all plasma membrane NTPDases dephosphorylate UTP with a significant 
accumulation of UDP, favouring P2Y6 receptor activation. Furthermore, comparing 
Km and Vmax values obtained from combined ATP and UTP hydrolyses 
experiments, authors revealed that adenine nucleotides are better substrates than 
uracil nucleotides for human NTPDase1 and -2. Furthermore, they found that 
human NTPDase3 dephosphorylated ADP to AMP much faster than UDP to UMP, 
leading to a sustained UDP accumulation (Kukulski et al., 2005). So, differential 
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expression and function of these NTPDases will dictate which P2 receptors will be 
preferentially activated within a cell population (Figure 4). 
Previous studies have revealed the coexistence of both ATP consuming and 
ATP-generating activities (nucleoside diphosphokinase or ecto-NDPK) on the cell 
surface, namely in human SaOS-2 osteoblast-like cells (Buckley et al., 2003). In 
addition, the expression of multiple NTPDases and NPPs has been previously 
reported (Orriss et al., 2007; Orriss et al., 2010). Regarding NPPs, NPP1 has been 
found to be important in bone biology. PPi, mostly generated from ATP hydrolysis 
by NPP1, is a strong inhibitor of bone mineralization (for a review, see Mackenzie 
et al., 2012). In fact, several studies suggest that ATP is a primary source of PPi in 
bone, pointing to a dual inhibitory action on bone mineralization via both P2 
receptors mediated signalling and direct hydrolysis to PPi (Figure 4). It is believed 
that PPi is important to prevent ectopic mineralization (for example in soft tissues) 
(see e.g. Nitschke et al., 2012). At the same time, PPi is a source of Pi which is 
important in hydroxyapatite formation, a conversion that is undertaken by ALP. So, 
the concerted action of these two enzymes, NPP1 and ALP, is an important aspect 
of bone mineralization process.  
In this regard, it was found that, in a mouse model lacking NPP1, the trabecular 
number, trabecular bone volume, structure model index, trabecular and cortical 
thickness are all significantly reduced in tibiae and femurs from NPP1 (-/-) mice 
when compared to control animals, showing that NPP1 (-/-) mice are characterized 
by severe disruption to the architecture and mineralization of long-bones, 
dysregulation of calcium/phosphate homeostasis, all suggesting an important role 
for this enzyme in bone remodelling (Mackenzie et al., 2012). Other studies 
suggested that generalised arterial calcification in infants and severe 
hypophosphataemia is associated with recessive inactivating mutations in the 
ENPP1 gene (see e.g. Rutsch et al., 2003). One should be aware that NPPs may 
be inhibited by AMP, which is one of the end products of ATP hydrolysis. 
Intriguingly, it binds with more affinity when compared to ATP (Landt and Butler, 
1978; Stefan et al., 2005). This aspect raises the question if NPP’s action has a 
sustained impact on bone remodelling in vivo, particular in a circumstance in which 
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ecto-5’-nucleotidase activity is compromised. In such case, AMP accumulation 
would lead to NPP1 inhibition, reducing ATP catalysis by this enzyme.  
ATP breakdown throughout the enzymatic cascade leads, eventually, to 
adenosine production by ecto-5’-nucleotidase. Adenosine has been shown to be 
produced by human osteoblast cells via ATP breakdown, modulating the secretion 
of IL-6 and osteoblastogenesis (Costa et al., 2011; Evans et al., 2006). In fact, 
human bone marrow derived MSCs were shown to express ecto-5’-nucleotidase 
(CD73) and to express all four P1 receptors (Costa et al., 2011). Agonists for all 
four receptors concentration-dependently increase MSCs proliferation. In 
particular, authors showed that A2B activation with 5’- (N-
ethylcarboxamide)adenosine (NECA) facilitates osteogenic differentiation 
measured by increases in ALP activity; the effect of NECA was prevented with the 
selective A2B antagonists, PSB 603 (Costa et al., 2011). These results were 
strenghten by the use of A2B knockout mice, thus revealing the importance of this 
receptor subtype in osteogenic differentiation of mesenchymal stem cells and 
bone formation in vivo (Carroll et al., 2012). Regarding ecto-5’-nucleotidase 
(CD73) as an important enzyme on adenosine formation by osteoblasts, a recent 
study demonstrated that CD73 knockout mice show osteopenia, with significant 
decreases of osteoblast-cell markers. In the same study, in vitro experiments 
revealed that CD73 deficiency results in impaired osteoblast differentiation, but not 
in the number of osteoblast progenitors. In addition, authors demonstrated the 
enhanced expression of osteocalcin and bone sialoprotein in MC3T3-E1 cells 
overexpressing CD73 (Takedachi et al., 2012). These and other studies reinforce 
the role of P1 receptors on bone remodelling.  
1.4.5. P2 receptor expression by osteocytes and osteoclasts 
So far, focus has been given to purinergic signalling in osteoblast progenitor 
cells, osteoblasts and, only briefly, to osteoclasts. Besides their role in bone 
formation, P2 receptors have been previously pointed as important modulators of 
bone resorption. Briefly, it was found that ATP was able to stimulate resorption by 
cells from human osteoclastoma (Bowler et al., 1998) and from rodent osteoclasts 
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(Morrison et al., 1998). It was later suggested that these pro-resorptive effects 
were mediated by the P2X2 receptors. ADP, via P2Y1 receptors, was also pointed 
as an important receptor involved in osteoclast formation and activity, since ADP 
and 2-methylthioADP at nanomolar to submicromolar levels caused up to four to 
six-fold increases in osteoclastic bone resorption (Hoebertz et al., 2001). 
Interestingly, P2Y1 receptor knockout animals showed reduced trabecular bone in 
long bones, which pointed this receptor as an important modulator of bone 
remodelling (Orriss et al., 2011). However, another receptor was subsequently 
shown to mediate ADP effects on osteoclasts. P2Y12 receptor is expressed in 
osteoclasts (Orriss et al., 2011), and KO of this receptor impaires ADP elicited 
responses by these cells (Su et al., 2012).  
The P2Y6 receptor seems also to be important in osteoclast survival. Its 
activation on cultured osteoclasts prevents TNF-α-induced apoptosis, also 
promoting NF-kB translocation and activation (Korcok et al., 2005). 
Regarding P2X7 receptor, its activity appears to be complex in osteoclasts. It 
was demonstrated that ATP release from osteoclasts is P2X7 mediated (Brandao-
Burch et al., 2012), and that blockade of the pore-forming P2X7 receptor inhibits 
formation of multinucleated human osteoclasts in vitro (Gartland et al., 2003). It 
was further demonstrated that P2X7 activation may lead to NF-kB (Korcok et al., 
2004) and PKC translocation (Armstrong et al., 2009), cytoskeletal reorganization 
and secretion of lytic granules into the resorption lacunae (Hazama et al., 2009). 
However, others have shown that ATP release in response to mechanical stimuli 
may act on P2X7 receptors to inhibit osteoclast resorption (Naemsch et al., 2001). 
Regarding P1 receptors, it was suggested that adenosine resulting from 
released ATP may act on P1 receptors from osteoprogenitor cells, inducing IL-6 
secretion and inhibition of osteoprotegerin release, promoting osteoclastogenesis 
(Evans et al., 2006). The A1 receptor was pointed as a promoter of osteoclast 
differentiation,  since blockade of this receptor resulted in disruption of the 
association of tumor necrosis factor receptor-associated factor 6 (TRAF6) and 
transforming growth factor-β-activated kinase 1 (TAK1), a signalling event that is 
important for NF-κB activation (He and Cronstein, 2012). A2A receptors seem to be 
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equally involved in osteoclast function. Studies point for a compromised osteoclast 
differentiation upon A2A activation (Mediero et al., 2012). Others have shown that 
P2X7-mediated ATP release and subsequent adenosine formation may increase 
osteoclast fusion, an effect that seems to be A2A mediated (Pellegatti et al., 2011).  
Within the osteoblast lineage, osteocytes are also important cells within the 
bone, since they represent 90% of all bone cells (see section 1.3.1). However, little 
is known about the role of purinergic signalling in their survival or function (Figure 
4). Part of the difficulty to study these cells is that 3D-cultures are needed to allow 
the maintenance of their phenotype. As previously mentioned, they form an 
interconnected cell network located in the fluid-filled lacunocanaliculi system, 
allowing them to translate mechanical signals into biochemical signals to effector 
cells, facilitating bone remodelling (Burnstock et al., 2013). Using cell cultures, it 
was possible to realize that mechanical stimulated osteocytes could present [Ca2+]i 
transients that are reduced by both suramin and thapsigargin, suggesting that this 
is due to ATP acting via P2Y receptors (Huo et al., 2008). Osteocytes were also 
found to express T-type voltage-sensitive calcium channels, and its α2δ1 subunit 
was shown to regulate mechanical-induced release of ATP (Thompson et al., 
2011). Some authors suggest that ATP release from osteocytes (Kringelbach et 
al., 2014) may act in vivo to reduce progressive, age-related mineral 
encroachment from the surrounding bone, thus preventing cell death and cell 
“fossilization” (Burnstock et al., 2013) (Figure 4). In fact, in MLO-Y4 osteocytes, 
P2X7 and P2Y2 receptors were found to be functionally expressed (Kringelbach et 
al., 2008).  
 
Current evidence shows that purinergic signalling exerts complex local effects 
on the function of bone cells (e.g. osteoblasts). The effects of this signalling 
system are influenced by multiple factors including the receptor subtype, the 
extracellular nucleotides present locally and the expression of ecto-nucleotidases 
which will, in turn, regulate nucleotides accumulation and activity. However, there 
is still a huge controversy around the importance of each of the purinergic 
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receptors and enzymes on bone cells and how they may interact to promote bone 
remodelling 
Since purinergic signalling has now been implicated in many bone disorders (for 
a review, report to Burnstock et al., 2013), it is of great importance to explore 
these potential targets for future therapies, clarifying the molecular mechanisms 
operating upstream and downstream of these receptors in both health and 
disease. These unexplored cell targets will certainly prove useful in the therapeutic 
management of bone diseases in the future.  
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2. GOALS 
The specific aims of the project were to investigate: 
(1) The expression and function of uracil nucleotide-sensitive receptors (P2Y2, 
P2Y4, and P2Y6) in human MSCs, since their role in osteogenic differentiation was 
largely unknown;  
(2) The expression and function of P2X7 receptors on osteogenic differentiation 
of human MSCs in culture, exploring the underlying molecular mechanisms 
involved; this was done due to the controversy of the P2X7 receptor role on bone 
remodelling in human cells; 
(3) The relevance of NTPDases in the management of osteogenic differentiation 
and/or cell proliferation in younger females versus postmenopausal women; this 
topic is, so far, largely unknown, particularly in non-modified human cells. 
 
Hopefully, this will provide new insights for development of novel therapeutic 
strategies for bone disorders such as osteoporosis, in which targeting both 
receptors and ecto-nucleotidases may prove beneficial. 
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ABSTRACT 
This study aimed at investigating the expression and function of uracil nucleotide-
sensitive receptors (P2Y2, P2Y4, and P2Y6) on osteogenic differentiation of human 
bone marrow-derived mesenchymal stem cells (MSCs) in culture. Bone marrow 
specimens were obtained from postmenopausal female patients (68±5 years old, 
n=18) undergoing total hip arthroplasty. UTP and UDP (100 µM) facilitated 
osteogenic differentiation of the cells measured as increases in alkaline 
phosphatase (ALP) activity, without affecting cell proliferation. Uracil nucleotides 
concentration-dependently increased [Ca2+]i in MSCs; their effects became less 
evident with time (7>21 days) of the cells in culture. Selective activation of P2Y6 
receptors with the stable UDP analogue, PSB 0474, mimicked the effects of both 
UTP and UDP, whereas UTPγS was devoid of effect. Selective blockade of P2Y6 
receptors with MRS 2578 prevented [Ca2+]i rises and osteogenic differentiation 
caused by UDP at all culture time points. MSCs are immunoreactive against P2Y2, 
P2Y4, and P2Y6 receptors. While the expression of P2Y6 receptors remained fairly 
constant (7~21 days), P2Y2 and P2Y4 became evident only in less proliferative 
and more differentiated cultures (7<21 days). The rate of extracellular UTP and 
UDP inactivation was higher in less proliferative and more differentiated cell 
populations. Immunoreactivity against NTPDase1, -2, and -3 rises as cells 
differentiate (7<21 days). Data show that uracil nucleotides are important 
regulators of osteogenic cells differentiation predominantly through the activation 
of UDP-sensitive P2Y6 receptors coupled to increases in [Ca2+]i. Endogenous 
actions of uracil nucleotides may be balanced through specific NTPDases 
determining whether osteoblast progenitors are driven into proliferation or 
differentiation. 
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INTRODUCTION 
Dynamic mechanical loading increases bone density and strength by promoting 
osteoblast proliferation, differentiation, and matrix production. The molecular 
mechanisms through which mechanical forces are converted into biochemical 
signalling in bone are still poorly understood. There is increasing evidence pointing 
to extracellular nucleotides, such as ATP and UTP, as soluble factors released in 
response to mechanical stimulation in different cell systems (see for a review, e.g., 
Hoebertz et al., 2003). Nucleotides are also released from cells as a consequence 
of pathological insults, like hypoxia and inflammation. Mechanisms of nucleotides 
release including vesicle exocytosis, ATP-binding cassette transporters, connexin 
hemichannels, and voltage-dependent anion channels, have been considered 
(Burnstock, 2006). Once released, the action of nucleotides may be rapidly 
terminated by cell-surface-located ectonucleotidases (Yegutkin, 2008; 
Zimmermann, 2000). Therefore, nucleotides released to the bone 
microenvironment form concentration gradients enabling differential targeting of 
receptors to produce selective special effects. For instance, rapid breakdown of 
ATP into adenosine restricts its action to that of a localized signal and shifts 
purinergic transmission mediated by nucleotide-sensitive P2 receptors to long-
lasting modulatory signals mediated by metabotropic P1 adenosine receptors. 
Adenine nucleotides working through several subtypes of P2 purinoceptors 
regulate all aspects of bone biology including development, growth, turnover, and 
repair (for a revision, see Orriss et al., 2010). Recently, we provided evidence that 
adenosine is also an important regulator of osteogenic differentiation of human 
bone marrow-derived mesenchymal stem cells (MSCs) through the activation of 
subtype-specific (A1, A2A, and A2B) receptors depending on the proliferation status 
of the cells (Costa et al., 2011).  
Besides the well-recognized role of ATP in bone remodelling, few reports have 
questioned the action of uracil nucleotides as autocrine/paracrine signalling 
molecules in the human bone. So far, constitutive release of UTP has been 
reported for several cell types, but not yet for osteoblasts. Nevertheless, UTP can 
easily be generated extracellularly from other nucleotides through the action of 
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ecto-enzymes (Lazarowski et al., 2000; Zimmermann, 2000). UTP can also act 
through P2Y receptors to upregulate ATP release from human osteoblasts, 
providing a possible feedback mechanism (Bowler et al., 1998). Localization of 
metabotropic P2Y2 receptors that recognize both ATP and UTP as the most potent 
agonists was evidenced by in situ hybridization in human osteoblasts (Bowler et 
al., 1995). Human osteosarcoma cell lines also express mRNAs for P2Y4 and 
P2Y6 receptors (Maier et al., 1997), which are preferentially or selectively activated 
by UTP and UDP, respectively. Interestingly, this receptor profile varies between 
primary cells and established osteoblastic cell lines (reviewed by Bowler et al., 
2001). To add further complexity, there is a clear heterogeneity of P2 receptors 
expression within single populations of both primary and clonal osteoblasts (see 
e.g., Dixon et al., 1997). In rat BMSCs, intracellular Ca2+ mobilization via UTP-
sensitive P2Y2 receptors was stronger at high cell density, indicating that cell 
density closely regulates cell cycle progression through increased P2Y2 receptors 
expression as cells proliferate (Ichikawa and Gemba, 2009). Likewise, Orriss et al. 
(2006) showed that ATP and UTP induced Ca2+ transients in primary rat 
osteoblasts increase during differentiation with time in culture; these changes were 
notably accompanied by an increase in the expression of P2Y receptors, 
particularly the UTP-sensitive P2Y2 receptor and to a lesser extent the P2Y4 and 
P2Y6 receptors. Follow-up studies demonstrated that both ATP- and UTP-treated 
rat osteoblasts deposited abundant collagenous matrix with the characteristic 
morphology of bone nodules (Orriss et al., 2010). Elevated Ca2+ levels can 
activate a variety of intracellular signalling systems in different cell types. The 
question is which ones are activated in human osteoprogenitor cells upon P2Y 
receptors stimulation by uracil nucleotides and, most importantly, whether receptor 
expression and coupling to specific signalling pathways also change due to 
postmenopausal and/or pathological bone modifications?  
Although the above observations are intriguing, the relative abundance of each 
receptor subtype and their exact role regarding bone formation and remodelling 
during the osteogenic differentiation in human osteoprogenitor cells remains 
unclear. Dissection of individual receptor responses has been hampered by the 
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lack of specific P2Y receptor agonists and antagonists, along with the presence of 
ecto-nucleotidases bound to the extracellular side of osteoblast membranes that 
rapidly interconvert or degrade nucleotides. Four plasma membrane-bound 
members of the ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase) 
family have been cloned, namely NTPDase1, -2, -3, and -8 (Robson et al., 2006; 
Zimmermann, 2000). These enzymes have distinct biochemical properties. 
NTPDase1 hydrolyzes ATP/UTP and ADP/UDP equally well, NTPDase2 
preferentially hydrolyzes triphosphonucleosides, and NTPDase3 and -8 have 
intermediate hydrolysis profiles (Kukulski et al., 2005; Stefan et al., 2005; 
Zimmermann, 2000). The hydrolysis of tri- and diphosphonucleosides by 
NTPDases yields AMP/UMP as final products that can be fully dephosphorylated 
to adenosine/uridine by ecto-5’-nucleotidase (Colgan et al., 2006). This enzyme 
(also known as CD73 membrane-cell marker), together with CD105 and CD90 
antigens, has been widely used to identify osteoblast progenitors derived from 
human BMSCs (Dominici et al., 2006).  
Comprehensive studies on the kinetics of the metabolism of uracil nucleotides 
via ecto-nucleotidases in human osteoprogenitor cells are still lacking. In spite of 
this, the coexistence of various metabolic pathways represents an opportunity for 
regulating cell-specific responses mediated by the P2-receptor family to locally 
produced nucleotides (see for a review, Kukulski et al., 2011). In this work, we 
characterized the extracellular enzymatic pathways responsible for the catabolism 
of uracil nucleotides along osteogenic differentiation of human primary bone 
marrow-derived MSCs in culture using HPLC analysis. In addition, we investigated 
the time course of expression of NTPDase subtypes (1, 2, and 3) and uracil-
sensitive P2 purinoceptors (P2Y2, P2Y4, and P2Y6) by confocal microscopy. First 
passage human MSCs obtained from postmenopausal female patients (68±5 
years old) undergoing total hip arthroplasty were used. Cell cultures were 
characterized for proliferation (MTT assay) and osteogenic differentiation 
(measured as increases in alkaline phosphatase activity); to this end, cells where 
cultured for 28 days in the absence and in the presence of UTP, UDP, and several 
subtype-selective receptor agonists and antagonists. The ability of uracil 
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nucleotides to trigger intracellular [Ca2+]i transients via P2Y2, P2Y4, and P2Y6 with 
respect to the growth state of primary MSCs (7 vs. 21 days in culture) was 
evaluated by confocal microscopy using the fluorescent Ca2+ indicator, Fluo-4NW. 
Hopefully, our findings will contribute to elucidate the role of extracellular uracil 
nucleotides (UTP and UDP) as important targets for local regulation of osteoblast 
cell proliferation and differentiation in the postmenopausal bone, prompting for 
new strategies to control disorders where bone destruction exceeds bone 
formation (e.g., osteoporosis, rheumatoid arthritis, fracture mal-union). 
MATERIALS AND METHODS 
Cell Cultures 
Human bone marrow specimens were obtained from the neck of the femur of 
selected adult female patients (68±5 years old, n=18) undergoing total hip 
arthroplasty as a result of primary osteoarthrosis. For comparison purposes we 
also used bone marrow specimens from younger adult female patients of 14–40 
years old (n=4) (Figure 6). Informed consent to use the biological material, that 
would be otherwise discarded, was obtained. The procedures were all approved 
by the Ethics Committees of Centro Hospitalar de Vila Nova de Gaia—Espinho 
(University Hospital) and of Instituto de Ciências Biomédicas de Abel Salazar 
(Medical School) of the University of Porto. The investigation conforms to the 
principles outlined in the Declaration of Helsinki. Bone marrow samples were 
placed immediately in fresh-frozen α-minimal essential medium (α-MEM) 
supplemented with 10% foetal bovine serum (FBS), 100 U/ml penicillin, 100 µg/ml 
streptomycin, and 2.5 µg/ml amphotericin B (standard culture medium) and 
transported to the laboratory on the day or following day of surgery. Bone marrow 
cells were dispersed on plastic dishes by repeated gently pipetting, cultured in 
standard culture medium, and incubated at 370C in a humidified atmosphere of 
95% air and 5% CO2. Non-adherent cells were removed after 5 days and after that 
the culture medium of the adherent cells was changed twice a week. Primary 
cultures were maintained for 10–15 days until near confluence when adherent 
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cells were enzymatically released with 0.04% trypsin–EDTA solution and 0.025% 
type I collagenase in phosphate-buffered saline (PBS), at pH 7.4 during 15–20 
min. The resultant cell suspension was cultured (104 cells/cm2) (day 0) in 
conditions known to favour osteogenic differentiation. To this end, the standard 
culture medium was supplemented with 50 µg/ml ascorbic acid, 10 mM β-
glycerophosphate, and 10 nM dexamethasone. MSC cultures were established for 
28 days in the absence (control) or in the presence of purinoceptor agonists/ 
antagonists that were added to the culture medium at day 1 (see e.g., Costa et al., 
2011). Drugs were renewed in the culture at each medium change, i.e., twice a 
week. All the experiments were performed in the first subculture, since previous 
results showed that serial passage of bone marrow-derived MSCs result in the 
progressive loss of the osteoblast phenotype (Coelho et al., 2000; Fernandes et 
al., 1997). Cell cultures were routinely monitored by phase contrast microscopy 
and characterized at days 1, 4, 7, 14, 21, and 28 for cell viability/proliferation (MTT 
assay), alkaline phosphatase (ALP) activity, and total protein content. 
Cell viability/proliferation 
MTT assay and total protein content. Proliferation studies included MTT 
assay and total protein content. MTT assay consisted of the reduction of 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) to a purple formazan 
reaction product by viable cells. In the last 4 h of each test period, cells were 
incubated with 0.5 mg/ml of MTT in the conditions referred above. The medium 
was carefully removed, decanted, and the stained product dissolved with DMSO 
before absorbance (A) determination at 600 nm using a microplate reader 
spectrometer. Results were expressed as A/cm2 (Figure 6A). Total protein content 
was determined by Lowry’s method, after treatment of the cell layer with 0.1 M 
NaOH for 1 h. Bovine serum albumin (BSA) was used as a standard, and 
absorbance evaluated at 750 nm. Results are expressed as µg/cm2 (Amaral et al., 
2002; Costa et al., 2011). 
Fluorimetric DNA determination. The total cell DNA content was determined 
as previously described (West et al., 1985). At the end of the culture period, cells 
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were washed twice with PBS 1X and incubated for 20 min with EDTA (10 mM, 
pH=12.3) at 370C. Cell plates were then kept on ice and pH adjusted to 7.0 with 
addition of KH2PO4 (1 M). To each sample, a solution of Hoescht 33258 (200 
ng/ml in NaCl 100 mM plus Tris 10 mM buffer, pH=7.0) was added. Fluorescence 
was measured (Perkin Elmer, Luminescence Spectrometer LS 30, Waltham, MA) 
and DNA concentration determined using a DNA calibration curve (0–100 µg 
DNA/ml). DNA standards were prepared using salmon DNA at 1 mg/ml in Tris (10 
mM) plus EDTA (1 mM) buffer (pH=8.0). Results were expressed as µg of 
DNA/cm2. 
Alkaline phosphatase (ALP) activity 
ALP activity was determined in cell lysates (obtained by treatment of the cell 
layers with 0.1% Triton X in water) and assayed for the hydrolysis (30 min at 370C) 
of p-nitrophenyl phosphate (25 nM) in an alkaline buffer solution (pH=10.3), 
followed by colorimetric determination of p-nitrophenol at 405 nm. Results were 
expressed in nanomoles of p-nitrophenol produced per µg of protein (nmol min-1 
µg protein-1) (Amaral et al., 2002; Costa et al., 2011) (Figure 6B). ALP activity is a 
good indicator for osteoblast cell differentiation as previously shown (Costa et al., 
2011; Hoemann et al., 2009).  
Histochemical staining for ALP 
Fixed cultures (1.5% glutaraldehyde in 0.14 M sodium cacodylate buffer, 10 
min) were stained for ALP. Fixed cells were incubated for 1 h in the dark with a 
mixture prepared in Tris buffer (pH=10) containing 2 mg/ml of fast blue RR salt; 
the incubation was stopped by rinsing the samples with water. The presence of 
ALP was identified by a brown to black staining, according to the enzyme content 
(see e.g., Figure 6D). Stained culture wells were photographed using an inverted 
microscope (Olympus IX8, Tokyo, Japan) coupled to a high-sensitivity digital 
colour camera (ColorView II, Olympus, Tokyo, Japan) and analysed with the 
software Cell F (Olympus, Tokyo, Japan). 
Kinetic experiments and HPLC analysis 
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The kinetics of inactivation of UTP and UDP in human primary MSC cultures 
was studied at days 7 and 21, at 370C (three replicas were performed in each 
individual experiment). The kinetics of extracellular ATP catabolism was also 
studied for comparison purposes (see e.g., Magalhães-Cardoso et al., 2003). After 
a 30-min equilibration period, cells were incubated with 100 µM of ATP, UTP, or 
UDP added to the culture medium in the conditions referred above (zero time). 
Samples (75 µl) were collected from each well at different times up to 30 min for 
high-performance liquid chromatography (HPLC, LaChrom Elite, Merck, Frankfurt, 
Germany) analysis of the variation of substrate disappearance and product 
formation. Aliquots of 20 µl of collected samples were used for nucleotide analysis. 
The rate of ATP disappearance and subsequent formation of ADP, AMP, and 
adenosine was analysed as previously described (Costa et al., 2011). Separation 
of UTP, UDP, UMP, and uridine was achieved by ion-pair reverse-phase HPLC, at 
room temperature, on a Merck Lichrospher® 100 RP-18 (5 µm) column. The 
composition of the mobile phase was 60 mM KH2PO4 and 5 mM 
tetrabutylammonium (pH=6) in methanol. Each run consisted of a linear gradient 
from 5 to 35% methanol (v/v) performed at 1.5 ml/min flow rate during 8 min; re-
equilibration of the column required an additional 7-min period. Nucleotides and 
nucleosides were detected by UV absorption at 262 nm. Under these experimental 
conditions, the retention times for uracil nucleotides and nucleosides were as 
follows: UTP (6.41 min), UDP (4.67 min), UMP (2.18 min), and uridine (1.49 min). 
The actual concentrations of UTP, UDP, UMP, and uridine were expressed in 
micromolar.  
Concentrations of the substrate and products were plotted as a function of time 
(progress curves). The following parameters were analysed for each progress 
curve: half-degradation time of the initial substrate, time of appearance of the 
different concentrations of the products, concentration of the substrate or any 
product remaining at the end of the experiment. Because enzymatic activity is 
usually represented as a function of the total protein content, yet in osteoblast 
differentiating cultures type I collagen accounts to 85–90% of the organic matrix, 
here we also decided to normalize the ecto-nucleotidase activity by the amount of 
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viable cells given by the MTT assay. The spontaneous degradation of uracil 
nucleotides at 370C in the absence of the cells was negligible over 30 min. At the 
end of the experiments, the remaining incubation medium was collected and used 
to quantify the lactate dehydrogenase (LDH, EC 1.1.1.27) activity. The negligible 
activity of LDH in the samples collected at the end of the experiments is an 
indication of the integrity of the cells during the experimental period.  
Single-cell [Ca2+]i transients by confocal microscopy  
Human primary MSCs were seeded into 35 mm dishes at a density of 2x104 
cells/ml and allowed to grow for 7 or 21 days in supplemented α-MEM medium. On 
the day of the experiment, cells were washed twice with PBS and incubated at 
370C for 45 min with the cell-permeant fluorescent Ca2+ indicator, Fluo-4NW (2.5 
µM), in PBS containing 2.5% pluronic acid in 100 µM DMSO. After removal of the 
fluorophore loading solution, cells were washed twice more and 150 µl of PBS was 
added per culture dish. Culture dishes were then mounted on a thermostatized 
perfusion chamber at the stage of an inverted laser-scanning confocal microscope 
(Olympus FV1000, Tokyo, Japan) equipped with a 20x magnification objective 
lens (LUCPLFL 20x PH; N.A. 0.45). From this time onwards, the chamber was 
perfused continuously (1 ml/min) with gassed (95% O2 plus 5% CO2) Tyrode’s 
solution (pH=7.4) containing (mM): NaCl 137, KCl 2.7, CaCl2 1.8, MgCl2 1, 
NaH2PO4 0.4, NaHCO3 11.9, and glucose 11.2, at 370C. Test drugs were delivered 
using a multichannel perfusion system (ValveLink 8.2, Digitimer, San Francisco, 
CA). Changes in fluorescence of the Fluo-4NW dye were detected in the time-
lapse mode with the FluoView Advanced Software (Olympus, Tokyo, Japan). Fluo-
4NW was excited with the 488 nm line a Multi-line Ar laser. The emitted 
fluorescence was detected at 510–560 nm using the scanner of the confocal 
microscope (Olympus FV1000, Tokyo, Japan). The fluorescence images were 
collected at 20 sec intervals. Intracellular Ca2+ transients induced by uracil 
nucleotides were calibrated to the maximal calcium load produced by ionomycin (5 
µM, 100% response) (Henriksen et al., 2006; Panupinthu et al., 2007). 
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Antibody production 
The development and specificity of anti-human nucleotidase antibodies has 
been reported previously (e.g., Dranoff et al., 2004; Munkonda et al., 2009). 
Hartley guinea pigs and New Zealand rabbits were obtained from Charles River 
Laboratories (Quebec City, Canada). Genetic immunization protocol was carried 
out with plasmids (pcDNA3 for human NTPDase1 and pcDNA3.1 for human ecto-
5’-nucleotidase) encoding each protein using New Zealand rabbits for antibodies 
against human NTPDase1 and Hartley guinea pigs for human ecto-5’-nucleotidase 
antibodies.  
Immunofluorescence confocal microscopy 
MSCs were allowed to grow in chamber slides for 7 or 21 days. At the end of 
each test period, cultured cells were fixed in 4% paraformaldehyde (PFA) in PBS 
for 10 min, washed three times in PBS (10 min each) and, subsequently, 
incubated with blocking buffer I (10% FBS, 1% BSA, 0.1% Triton X, 0.05% NaN3) 
for 1.5 h. Primary antibodies, diluted in blocking buffer II (5% FBS, 1% BSA, 0.1% 
Triton X, 0.05% NaN3), were applied [NTPDase1 1:150 (hN1-9LI4, rabbit), 
NTPDase2 1:200 (hN2-Kw3I4, rabbit), NTPDase3 1:200 (hN3-B3S, mouse), ecto-
5’-nucleotidase 1:300 (h5’NT-2CI4, guinea-pig), P2Y1 1:50 (goat), P2Y2 1:150 
(rabbit), P2Y4 1:75 (rabbit), P2Y6 1:75 (rabbit), P2X7 1:75 (rabbit), osteocalcin 1:75 
(rabbit), collagen type I 1:50 (rabbit)] and the slides incubated in the dark for 2 h. 
After incubation, cells were washed three times in PBS 1x (10 min each); Alexa 
Fluor 488 (anti-rabbit), Alexa Fluor 568 (anti-mouse), and Alexa Fluor 653 (anti-
goat) secondary antibodies in blocking buffer II (5% FBS, 1% BSA, 0.1% Triton X) 
were applied for 1 h. A last wash was performed with PBS 1x and glass slides 
mounted with VectaShield medium and stored at 40C. Observations were 
performed and analysed with a laser scanning confocal microscope (Olympus 
FV1000, Tokyo, Japan) (Alqallaf et al., 2009). 
Flow cytometry analysis 
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Plastic-adherent human bone marrow-derived MSCs (first subculture) were 
allowed to grow for 7 days in conditions known to favour osteogenic differentiation. 
At the end of this period, the cells were enzymatically released as mentioned 
before. The resultant cell suspension was centrifuged at 2000 rpm (5 min); the 
supernatant was discarded and cells were re-suspended in 2ml of PBS 1x 
containing 0.2% BSA. This procedure was repeated twice. Samples (100 µl) 
containing 250–500x103 cells were incubated for 15 min at room temperature with 
10 µl of antigen-specific anti-human (mouse) fluorochrome-conjugated monoclonal 
antibodies (mAb). The antibodies employed were the following: Anti-CD14 labelled 
with fluorescein isothiocyanate (FITC) (clone MφP9), anti-CD29 labelled with 
fluorescein isothiocyanate (FITC) (clone TS2/I6), anti-CD34 labelled with 
allophycocyanin (APC) (clone 8GI2), anti-CD45 labelled with peridinin-chlorophyll 
protein (PerCP) (clone 2DI), anti-CD105 labelled with phycoerythrin (PE) (clone 
IG2), anti-CD117 labelled with phycoerythrin (PE) (clone 95C3); in some 
experiments, anti-ecto-5’-nucleotidase (h5’NT-2cI4, guinea-pig) was used, 
combined with the secondary antibody Alexa Fluor 649 (anti-guinea-pig). Cells 
were first identified based on their flow cytometric characteristics—high sideward 
(SSC) and forward (FSC) light scatter profile. Cells were then gated on the basis 
of sideward scatter distribution. Once identified, cells were analysed for the 
expression of the surface antigens recognized by the mAb referred above. 
Controls were performed by incubating the cells with the conjugates or secondary 
antibodies alone, in order to measure unspecific fluorescence (negative controls). 
All experiments were done in triplicate on a FACSCalibur cytometer (BD 
Biosciences, San Jose, CA), using the CellQuest software version 3.1 (BD 
Biosciences, San Jose, CA) for sample acquisition and the Paint-a-gate Pro 
software (BD Biosciences, San Jose, CA) for data analysis.  
Reagents and antibodies 
Cell culture reagents were purchased from Sigma-Aldrich (St. Louis, MO). 
Adenosine (ADO), adenosine 5’-diphosphate sodium salt (ADP), adenosine 5’-
triphosphate disodium salt (ATP), 4-[[4-formyl- 5-hydroxyl-6-methyl-3-
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[(phosphonooxy)methyl]-2-pyridinyl]azo]- 1,3-benzenedisulfonic acid tetrasodium 
salt (PPADS), uridine, uridine 5’-diphosphate trisodium salt (UDP), and uridine 5’- 
triphosphate trisodium salt (UTP) were purchased from Sigma-Aldrich (St. Louis, 
MO). 3-[[5-(2,3-Dichlorophenyl)- 1H-tetrazol-1-yl]methyl]pyridine hydrochloride 
(A438079), 2’-deoxy-N6-methyladenosine 3’,5’-bisphosphate tetrasodium salt 
(MRS 2179), N,N’’-1,4-butanediyl-bis-[N’-(3-isothiocyanatophenyl) thiourea (MRS 
2578), 3-(2-oxo-2-phenylethyl)-uridine-5’-diphosphate disodium salt (PSB 0474), 
and uridine-5’-(γ-thio)-triphosphate trisodium salt (UTPγS) were obtained from 
Tocris Cookson Inc. (Bristol, UK). All primary antibodies used in this study have 
previously been validated: Anti-P2Y1 was from Santa Cruz (Santa Cruz, CA); anti-
P2Y2 and anti-P2Y4 were from AbCam (Cambridge, UK); anti-P2Y6 and anti-P2X7 
were purchased from Alomone (Jerusalem, Israel); anti-osteocalcin and anti-Type 
I collagen were from AbD Serotec (Kidlington, Oxford, UK); anti-CD29-FITC (clone 
TS2/I6) was supplied by eBioscience (San Diego, CA); anti-CD117-PE (clone 
95C3) and anti-CD105-PE (clone IG2) were supplied by Immunotech (Marseille, 
France); anti-CD14-FITC (clone MφP9), anti-CD45-PerCP (clone 2DI), and anti-
CD34-APC (clone 8GI2) were supplied by BD Biosciences, San Jose, CA. Primary 
antibodies anti-NTPDase1, anti-NTPDase2, anti-NTPDase3, and anti-ecto-5’-
nucleotidase were developed in the Centre de Recherche en Rhumatologie et 
Immunologie, University Laval, Québec, Canada. Alexa Fluor 488-labeled anti-
rabbit, Alexa Fluor 568-labeled anti-mouse, Alexa Fluor 653-labeled anti-goat and 
the fluorescent calcium indicator Fluo-4NW were supplied by Molecular Probes 
(Invitrogen, Carlsbad, CA). Dimethylsulphoxide (DMSO) was obtained from Merck 
(Frankfurt, Germany). Tissue culture plates: 96-well plates were purchased from 
Corning, Lowell, MA; FluoroDish plates for confocal microscopy were from World 
Precision Instruments (Hitchin, Hertfordshire, UK); chamber slides were from Nunc 
(Rochester, NY).  
Presentation of data and statistical analysis 
Results presented in this study are from bone marrow specimens obtained from 
eighteen individual female patients (68±5 years old, n=18). For each experiment 
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and assay, 6–8 replicas were accomplished. The data are expressed as mean ± 
S.E.M. from an n number of patients. Data from different individuals were 
evaluated using one-way analysis of variance (ANOVA) and no significant 
differences in the pattern of cell behaviour were found. Statistical differences found 
between control and drug-treated cultures were determined by Bonferroni’s 
method. P-values <0.05 were considered to represent significant differences. 
RESULTS 
Phenotypic cells characterization by flow cytometry 
Primary cultures were maintained for 10–15 days until near confluence when 
adherent cells were enzymatically released. The resultant cell suspension was 
cultured in conditions that favour osteogenic differentiation. Plastic-adherent MSCs 
(first subculture) were allowed to grow for 7 days. All the experiments were 
performed in the first subculture, since previous results from our collaborators and 
independent groups showed that serial passage of bone marrow-MSCs result in 
the progressive loss of the osteoblast phenotype detected as decreases in ALP 
activity and mineralization potential from the 1st to the 2nd subculture (Coelho et 
al., 2000; Fernandes et al., 1997; Schmidt and Kulbe, 1993). 
MSCs are thought to be multipotent cells. These cells, which are present in the 
adult bone marrow, can replicate as undifferentiated cells and have the potential to 
differentiate to lineages of mesenchymal tissues, including bone. First passage 
MSCs prepared in the present experimental conditions were used for 
immunophenotypic analysis by flow cytometry. These cells exhibited positive 
immunoreactivity against several surface molecules, including CD105 (SH2), 
CD29 (integrin β1), and CD117 (tyrosine protein kinase Kit) (Figure 5), which have 
been identified as markers of bone marrow-derived mesenchymal stromal cells 
(Baddoo et al., 2003; Boiret et al., 2005; Cognet and Minguell, 1999; Dennis et al., 
2002; Gronthos et al., 2003; Pittenger et al., 1999). Conversely, cells isolated from 
the human bone marrow and cultured under the experimental conditions were 
negative for haematopoietic surface markers, like 
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CD14 and CD45, which has been extensively used as a good argument to 
distinguish bone marrow haematopoietic cells from MSCs (Baddoo et al., 2003; 
Pittenger et al., 1999). Flow cytometry analysis showed that a subpopulation of 
human bone marrow cells were moderately positive for CD34, an endothelial and 
haematopoietic cell marker. Overall, we consider that under the present 
experimental conditions first passage plastic-adherent human bone marrow cells 
are highly enriched in multipotent mesenchymal stromal cells.  
IgG PerCP 
CD45-PerCP 
IgG APC 
CD34-APC 
IgG FITC 
CD14-FITC 
IgG FITC 
CD29-FITC 
IgG PE 
CD105-PE 
IgG PE 
CD117-PE 
Mesenchymal  
stem cell 
markers 
Haematopoietic 
and endothelial 
cell markers 
Figure 5. Flow cytometric analysis of surface markers of mesenchymal stem cells (MSCs) 
(CD29, CD105, and CD117) and haematopoietic and endothelial cells (CD45, CD14, and 
CD34) in plastic-adherent MSCs (first subculture) allowed to grow for 7 days in culture. Black 
histograms indicate isotype controls (fluorochrome-conjugates or secondary conjugated 
antibodies alone), white histograms show surface antigen expression level. Staining and stem 
cell markers have been chosen in accordance with the minimal criteria for defining multipotent 
mesenchymal stromal cells by the International Society for Cellular Therapy (Dominici et al., 
2006). Cells were first identified based on their flow cytometric characteristics—high sideward 
(SSC) and forward (FSC) light scatter profile (total cell suspension). These cells were then 
gated on the basis of sideward scatter distribution, and they were analyzed for the expression 
of certain surface antigens recognized by the antibodies employed, namely anti-CD29 labelled 
with fluorescein isothiocyanate (FITC) (clone TS2/I6), anti-CD105 (mouse) labeled with 
phycoerythrin (PE) (clone IG2), anti-CD117 (mouse) labelled with phycoerythrin (PE) (clone 
95C3), anti-CD45 (mouse) labelled with peridinin-chlorophyllprotein (PerCP) (clone 2D1), anti-
CD34 (mouse) labelled with allophycocyanin (APC) (clone 8G12), and anti-CD14 (mouse) 
labelled with fluorescein isothiocyanate (FITC) (clone MwP9). Results are in mean 
fluorescence intensities, expressed in arbitrary relative linear units. 
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Osteoprogenitor cells from postmenopausal women exhibit low ALP activity 
Human MSCs (first subculture) were allowed to grow for 28 days in an 
osteoblast-inducing medium. Meanwhile, cell cultures were characterized for 
proliferation and osteogenic differentiation events at days 1, 4, 7, 14, 21, and 28. 
Results regarding cell viability/proliferation were measured by the MTT assay. 
Cultures grown in control conditions showed a gradual increase in cell proliferation 
until day 28 (Figure 6A). We found no significant ( P>0.05) differences regarding 
the proliferation profile (MTT assay) of the cells from both age groups, i.e., 
reduction of the tetrazolium salt (MTT) was similar between cells obtained from 
bone marrow specimens of female patients whose ages were 58–83 years 
(postmenopausal group, n=18) and 14–40 years (control group, n=4), respectively 
(Figure 6A). Results concerning total protein content reflected similar information 
as that obtained from the MTT assay (data not shown). The enzymatic MTT assay 
is often considered inappropriate to compare viability/proliferation of cells that can 
exhibit differences in their metabolic activity, such as cells from younger versus 
postmenopausal groups of patients. We, therefore, decided to compare the results 
from the MTT assay with those where cellularity and proliferation throughout the 
culture period was evaluated by quantifying total DNA content per culture well. 
Doing this, we also found no significant differences (P>0.05) in cell growth profiles 
of distinct age groups (Figure 6C). As expected, significant (P<0.05) differences 
were observed regarding the osteogenic differentiation profile (given by ALP 
activity) between the two groups of patients. Cell cultures from the younger group 
(patients of 14–40 years old, n=4) exhibit higher ALP activity than the 
postmenopausal group (patients of 58–83 years old, n=18). The ALP activity in the 
younger group of patients reached a maximum between days 7 and 21, 
decreasing significantly thereafter (Figure 6B), whereas in the postmenopausal 
group of patients the ALP activity increased slowly, yet progressively, with the 
incubation time until day 28. The biochemical results were confirmed by data from 
histochemical ALP staining, where the activity of ALP was identified by a 
progressive increase in the brownish staining of the cultures from day 7 to day 21 
(Figure 6D). The differences in ALP activity found between the two age groups do 
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not reflect differences in cell proliferation since cell growth rate profiles of patients 
Figure 6. Proliferation and differentiation of mesenchymal stem cells (MSCs, first subculture) 
grown in an osteoblast inducing medium during 28 days. Bone marrow specimens were 
obtained from female patients with 58–83 years (postmenopausal group, n=18, black bars) and 
14–40 years (control group, n=4, white bars) (see Materials and Methods section). Panel (A) 
represents cell viability/proliferation measured by the MTT assay; results are expressed as 
absorbance determination at 600nm per cm2 at certain time points. Panel (B) represents the 
activity of alkaline phosphatase (ALP) in cell lysates; results are expressed in nanomoles of p-
nitrophenol produced per min per µg of total protein at certain time points. Panel (C) shows that 
data from the MTT assay correlates positively with the results from DNA quantification 
measuring cell proliferation in two groups of female patients ageing 20–27 years old (control 
group, n=4) and 50–63 years old (postmenopausal group, n=3); DNA quantification is 
expressed as µg of DNA per cm2
 
at certain time points. No significant (P > 0.05) differences 
were found between the two age groups. Six to eight replicas were performed for each 
individual experiment. The vertical and horizontal bars represent S.E.M. *P < 0.05 represent 
significant differences between the two age groups for certain time points. Panel (D) represents 
the presence of ALP at culture days 7 and 21 by cytochemistry (brown to black staining, 
according to the enzyme content). Images are representative of three independent experiments. 
Zoom 100X. 
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with different ages were virtually similar (see Figure 6C). While we do not know the 
contribution of the smaller CD34 positive haematopoietic cell subpopulation to 
quantitative ALP measurements as compared to the expanded multipotent 
mesenchymal stromal cell population undergoing osteogenic progression in our 
cultures, it is interesting to note that haematopoietic cells rarely express ALP 
activity (Borgen et al., 1998). 
Effect of uracil nucleotides and their stable analogues in the proliferation 
and osteogenic differentiation of human primary MSCs  
First passage human primary MSCs were cultured for 21 days in conditions that 
favour osteogenic differentiation. We tested UTP (100 µM), UDP (100 µM), and 
their enzymatically stable derivatives, UTPγS (100 µM) and PSB 0474 (10 µM), 
respectively (Figures 7 and 8). UTP is one of the most potent P2Y2 receptor 
agonists, but the nucleotide is also very active at P2Y4 receptors. UTP derivatives 
containing the sulphur group, like UTPγS, are relatively potent P2Y2 receptor 
agonists, but are only moderately selective or non-selective versus P2Y4 receptors 
(see e.g., El-Tayeb et al., 2006). In contrast, UDP analogues containing large 
phenacyl substituents at N3, like PSB 0474, are potent and selective P2Y6 
receptor agonists with no affinity for other uracil-sensitive P2Y receptors in the low 
micromolar concentration range. Continuous application of the agonists to the 
culture medium was devoid of effect on the proliferation of human primary MSCs 
measured by the MTT assay (data not shown).  
The results concerning ALP activity are shown in Figures 7A and 8. Continuous 
treatment of the cells with UTP (100 µM) and UDP (100 µM) significantly (P<0.05) 
increased ALP activity during the first week as compared to controls tested in the 
absence of uracil nucleotides (Figure 7A). The effect of both UTP (100 µM) and 
UDP (100 µM) decreased progressively thereafter; at day 21, the activity of ALP 
was about the same in the presence of UTP (100 µM) and UDP (100 µM), as 
compared to control cultures (Figure 7A). The stable UTP analogue, 
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Figure 7. Panel (A), represented is the variation of alkaline phosphatase (ALP) activity of 
human primary bone marrow-derived mesenchymal stem cells (MSCs, first subculture) 
exposed continuously (during 21 days) to UTP (100 µM) and UDP (100 µM) in the absence 
and in the presence of PPADS (100 µM) and MRS 2578 (100 nM), respectively. For 
comparison purposes PPADS (100 µM) and MRS 2578 (100 nM) were also tested alone. The 
ordinates represent changes in the activity of ALP as compared to control cultures grown in the 
absence of test drugs at the same time points (see Figure 6). Zero represents identity between 
the two values (drug vs. control); positive and negative values represent facilitation or inhibition 
of osteogenic cell differentiation relative to control data obtained at the same time points. Each 
column represents pooled data from an n number of individuals; 6–8 replicas were performed 
for each individual experiment. The vertical bars represent S.E.M. *P < 0.05 represent 
significant differences from control values obtained in the absence of tested drugs; **P < 0.05 
represent significant differences compared with the effect of the agonist in the presence of its 
corresponding antagonist (PPADS or MRS 2578). Panel (B), represented is the fluorescence 
intracellular Ca2+
 
oscillations in human primary MSCs at culture days 7 and 21 caused by UTP 
(100 µM) and UDP (100 µM) in the absence and in the presence of PPADS (100 µM) and MRS 
2578 (100 nM), respectively. Cells were pre-incubated with the fluorescent calcium indicator, 
Fluo4-NW (2.5 µM, in PBS plus 2.5% pluronic acid), for 45 min at 370C.  
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UTPγS (100 µM), was devoid of effect on osteoblast cell differentiation measured 
by the increase of ALP activity in the cultures (Figure 8), suggesting that UTP has 
to be catabolised into UDP in order to facilitate differentiation of human 
osteoprogenitor cells. The selective P2Y6 receptor agonist, PSB 0474, applied in 
the low micromolar (10 µM) concentration range, progressively increased ALP 
activity from the first week onwards reaching a maximum on culture day 21 (Figure 
8). In order to know whether the effects of uracil nucleotides in ALP activity in 
human primary MSC cultures were mediated by subtype specific P2Y receptors, 
we tested their effects in the presence of PPADS (100 µM, a non-selective P2Y 
receptor antagonist) and MRS 2578 (100 nM), a selective P2Y6 receptor 
antagonist displaying no activity at UTP-sensitive P2Y2 and P2Y4 receptors nor at 
ADP-activated P2Y1 responses (Mamedova et al., 2004). PPADS (100 µM) 
attenuated the increase in ALP activity caused by UTP (100 µM) (Figure 7A). 
Blockade of P2Y6 receptors with MRS 2578 (100 nM), significantly (P<0.05) 
attenuated the increases in ALP activity caused by both UDP (100 µM) (Figure 7A) 
and PSB 0474 (10 µM) (data not shown). When used alone, neither PPADS (100 
µM, n=7) nor MRS 2578 (100 nM, n=6) changed cell proliferation and osteogenic 
differentiation as compared to controls (Figure 7A). These results indicate (1) that, 
on their own, PPADS (100 µM) and MRS 2578 (100 nM) are unable to change 
ALP activity in human primary MSCs cultures, and (2) that extracellular 
accumulation of uracil nucleotides in non-stressed cell cultures is probably not 
enough to activate selectively any of its receptors. 
Figure 7. (Continued) Changes in fluorescence were detected by laser-scanning confocal 
microscopy (Olympus FV1000, Tokyo, Japan) in the time-lapse mode. Intracellular Ca2+ 
transients were calibrated to the maximal calcium load produced by ionomycin (5 µM, 100% 
response). The black bars at the bottom of each graph indicate the period of drug exposure. 
Each point represents pooled data from: 64 cells (UTP 100 µM, four different individuals, day 
7), 55 cells (UTP 100 µM, three different individuals, day 21), 37 cells (UTP 100 µM plus 
PPADS 100 µM, three different individuals, day 7), 82 cells (UDP 100 µM, four different 
individuals, day 7; UDP 100 µM, three different individuals, day 21) and 72 cells (UDP 100 µM 
plus MRS 2578 100 nM, four different individuals, day 7). The vertical bars represent S.E.M. 
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Figure 8. Variation of alkaline phosphatase (ALP) activity of human primary bone marrow-
derived mesenchymal stem cells (MSCs, first subculture) exposed continuously during 7 or 21 
days to UTP (100 µM), UDP (100 µM), and their stable analogues, respectively UTPγS (100 
µM) and PSB 0474 (10 µM). The ordinates represent changes in the activity of ALP as 
compared to control cultures grown in the absence of test drugs at the same time points (see 
Figure 6). Zero represents identity between the two values (drug vs. control); positive and 
negative values represent facilitation or inhibition of osteogenic cell differentiation relative to 
control data obtained at the same time points. Each column represents pooled data from an n 
number of individuals; 4–6 replicas were performed for each individual experiment. The vertical 
bars represent S.E.M. *P < 0.05 represent significant differences from control values obtained 
in the absence of tested drugs.  
Uracil nucleotides promote increases in intracellular Ca2+ in human primary 
MSCs 
Human primary MSCs cultured for 7 or 21 days in supplemented α-MEM 
medium were challenged with 100 µM UTP and UDP applied in the absence and 
in the presence of PPADS and MRS 2578, respectively. Both UTP and UDP 
triggered increases in intracellular Ca2+ ([Ca2+]i), measured with the intracellular 
fluorophore, Fluo-4NW, using a laser-scanning confocal microscope (Figure 7B). 
At   culture day 7, we observed sustained responses that typically peaked 2 min 
after application of uracil nucleotides and decayed back to the baseline after 
washout of the drug. UDP was more potent than UTP, i.e., when the cells were 
challenged with UTP (100 µM) and UDP (100 µM) single-cell fluorescence [Ca2+]i 
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signals increased on average 21±8% (n=64 cells from four patients) and 40±3% 
(n=82 cells from four patients) of the maximal response produced by the calcium 
ionophore, ionomycin (5 µM), under the same experimental conditions (Figure 7B). 
Pre-incubation with PPADS (100 µM) significantly (P<0.05) attenuated [Ca2+]i rises 
caused by UTP (100 µM, n=37 cells from three patients) (Figure 7B). Selective 
blockade of P2Y6 receptors with MRS 2578 (100 nM) prevented the [Ca2+]i 
responses triggered by UDP (100 µM, n=72 cells from four patients) (Figure 7B). 
Intracellular Ca2+ responses strikingly decreased with time in culture. For instance, 
ionomycin (5 µM)-calibrated single-cell [Ca2+]i rises caused by UTP (100 µM) and 
UDP (100 µM) were about 3–4-fold greater in 7-day cultures than in 21-day 
cultures (Figure 7B). This contrast with the twofold increase in viable cells 
observed between days 7 and 21, as estimated by the MTT assay (see Figure 6). 
Consistently, more differentiated cells were less responsive to stimulation by uracil 
nucleotides, with only small increases in fluorescence [Ca2+]i signals and ALP 
activity (Figure 7) being noted in 21-day cultures. In contrast to the pattern of 
fluorescence [Ca2+]i signals observed in 7-day cultures, perfusion of the cells with 
uracil nucleotides caused a slow, yet progressive, rise in intracellular Ca2+ 
fluorescence which did not reach a peak until drug washout (Figure 7B). 
Detection of P2Y2, P2Y4, and P2Y6 receptor subtypes in postmenopausal 
primary MSCs by immunofluorescence 
For immunocytochemistry, human primary MSCs were allowed to grow in 
chamber slides for 7 and 21 days in supplemented α-MEM. Under the present 
experimental conditions, osteogenic differentiation of human primary MSCs was 
also inferred by the increase in the immunoreactivity against type I collagen (85–
90% of organic matrix) and the noncollagenous bone matrix protein, osteocalcin, 
comparing cells at culture days 7 and 21 (Figure 9).  
Although the presence of the three subtypes of uracil sensitive P2Y receptors 
(P2Y2, P2Y4, and P2Y6) was confirmed in human primary MSCs by 
immunocytochemistry, staining changed significantly in intensity with time in 
culture (Figure 9). Immunoreactivity for P2Y2 and P2Y4 receptor proteins increased 
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significantly with time, whereas the P2Y6 receptor protein expression remained 
fairly constant as cultures progressed. The immunostaining pattern for uracil-
7 days 21 days 
P2Y2 
P2Y4 
P2Y6 
150µm 
Type I 
Collagen 
Osteo 
calcin 
Figure 9. Immunocytochemical detection of uracil-sensitive P2Y receptors (P2Y2, P2Y4, and 
P2Y6), type I collagen and osteocalcin on human primary bone marrow-derived mesenchymal 
stem cells (MSCs). Shown is the time-related immunoreactivity fluorescence detection by 
confocal microscopy of human MSCs (first subculture) allowed to grow for 7 and 21 days in 
an osteoblast-inducing medium. Cells grown in eight-well chamber slides were processed for 
immunocytochemistry in parallel and were visualized keeping unaltered the settings of the 
confocal microscope throughout the procedure. For further details on immunofluorescence 
labelling see Materials and Methods section. 
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sensitive P2Y receptors with time in postmenopausal primary MSCs was slightly 
different from that predicted in rat primary osteoblasts (Orriss et al., 2006). These 
authors showed that mature rat osteoblasts preferentially express the ATP- and 
UTP-sensitive P2Y2 receptor and to a lesser extent P2Y4 (also ATP/UTP selective) 
and P2Y6 (UDP-sensitive) receptors. 
ATP increases intracellular Ca2+ but decreases osteogenic differentiation of 
postmenopausal primary MSCs 
For comparison, we also tested the effect of ATP (100 µM) on intracellular Ca2+ 
accumulation and osteogenic differentiation (measured by ALP activity) throughout 
MSC cultures life span in similar experimental conditions as those used for uracil 
nucleotides (Figure 10). Contrasting with the effect of uracil nucleotides on 
osteogenic differentiation (see above), continuous ATP (100 µM) application 
progressively decreased ALP activity from the first week onwards reaching a 
maximum on culture day 21 (Figure 10A). Acute superfusion of 7-day MSC 
cultures with ATP (100 µM) elicited a fast [Ca2+]i rise, which typically peaked 40 
sec after nucleotide addition and decayed back almost to baseline within 1–2 min; 
a second progressive, but of much lower amplitude, ATP-induced rise in 
intracellular Ca2+ was observed following the initial high-magnitude [Ca2+]i transient 
(Figure 10B). Intracellular Ca2+ responses induced by ATP (100 µM) decreased 
with time in culture; for example, the late response to ATP almost disappeared at 
culture day 21 as compared to that observed in 7-day cultures (Figure 10B). 
Likewise, fast [Ca2+]i transients calibrated by ionomycin (5 µM) were of smaller 
magnitude in 21-day cultures than in 7-day cultures. It is worth noting that ATP-
induced fast [Ca2+]i rises undergo rapid desensitization, i.e., application of a 
second ATP (100 µM) pulse following a washout period of at least 6 min elicited a 
significantly (P<0.05) smaller intracellular Ca2+ response than that observed with 
the first pulse (Figure 10B, inserts). Consecutive UTP applications induced [Ca2+]i 
transients which were both of a similar magnitude, thus indicating that uracil 
nucleotide-sensitive P2 purinoceptors are not prone to desensitization.  
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Recent studies have demonstrated that P2 receptor expression in osteoblasts is 
strongly differentiation-dependent (Orriss et al., 2006). Besides uracil activated 
receptors (P2Y2, P2Y4, and P2Y6) (see above), human osteoblast-like cells 
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Figure 10. Effects of ATP (100 µM) on intracellular Ca2+ accumulation and osteogenic 
differentiation (measured by ALP activity) of human primary bone marrow-derived 
mesenchymal stem cells (MSCs) kept in culture during 21 days. Panel (A), represented is the 
variation of alkaline phosphatase (ALP) activity of human MSCs (first subculture) exposed 
continuously to ATP (100 µM) during 21 days as compared to control cultures grown in its 
absence at the same time points (see Figure 6). Zero represents identity between the two 
values (drug vs. control); positive and negative values represent facilitation or inhibition of 
osteogenic cell differentiation relative to control data obtained at the same time points. Each 
column represents pooled data from an n number of individuals; 6–8 replicas were performed 
for each individual experiment. The vertical bars represent S.E.M. *P < 0.05 represent 
significant differences from control values obtained in the absence of ATP (100 µM). Panel 
(B), represented is the fluorescence intracellular Ca2+ oscillations in human MSCs at culture 
days 7 and 21 caused by ATP (100 µM) in the absence and in the presence of selective P2Y1 
and P2X7 receptor antagonists, respectively MRS 2179 (0.3 µM) and A438079 (3 µM). Cells 
were pre-incubated with the fluorescent calcium indicator, Fluo4-NW (2.5 µM, in PBS plus 
2.5% pluronic acid), for 45 min at 370C. Changes in fluorescence were detected in the time-
lapse mode by laser-scanning confocal microscopy (Olympus FV1000, Tokyo, Japan). 
Intracellular Ca2+ transients were calibrated to the maximal calcium load produced by 
ionomycin (5 µM, 100% response). Each point represents pooled data from: 78 cells (ATP 100 
µM, three different individuals, day 7), 58 cells (ATP 100 µM, three different individuals, day 
21), 64 cells (ATP 100 µM plus MRS 2179 0.3 µM, three different individuals, day 7) and 47 
cells (ATP 100 µM plus A438079 3 µM, three different individuals, day 7). The vertical bars 
represent S.E.M. [Ca2+]i transients resulting from two consecutive ATP (100 µM, for 1 min) 
applications 6 min apart from each other to human MSCs cultures (7 and 21 days), are also 
shown for comparison purposes (figure inserts). The black bars at the bottom of each graph 
indicate the period of drugs exposure. Human MSCs exhibit immunoreactivity against P2Y1 
and P2X7 receptors at culture day 7. Images obtained under the confocal microscope are 
representative of three independent experiments. Scale bar is 150 µm. 
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express P2Y1 receptors as indicated by RT-PCR (Maier et al., 1997) and 
immunolabeling (see Figure 10B) studies. Activation of P2Y1 receptor is thought to 
modulate osteoblast responses to systemic factors such as parathyroid hormone 
via intracellular Ca2+ mobilization (Bowler et al., 1999; Buckley et al., 2001). 
Controversy however exists on the role of ATP activated P2X receptors, namely 
the P2X7 receptor, on human osteoblasts (Orriss et al., 2010; see also for a 
detailed review on the P2X7 receptor, Grol et al., 2009). Early reports suggested 
that P2X7 receptor activation caused enhanced osteoblast apoptosis (Gartland et 
al., 2001). The P2X7 receptor is also thought to mediate the ERK1/2 activation 
caused by fluid shear stress in osteoblast-like cells, via increased [Ca2+]i and 
protein kinase C activation (Liu et al., 2008b). These findings prompted us to 
investigate the expression of P2Y1 and P2X7 receptors on postmenopausal 
osteoprogenitor cells in culture by immunofluorescence confocal microscopy to 
see whether they could be implicated in ATP-induced intracellular Ca2+ responses 
and decreased osteogenic cells differentiation.  
Figure 10B shows that postmenopausal MSCs in culture exhibit 
immunoreactivity against P2Y1 and P2X7 receptors. As previously demonstrated 
by RT-PCR analysis in rat primary osteoblasts (Orriss et al., 2006), P2Y1 and 
P2X7 receptors immunoreactivity was detected at early time points (culture day 7), 
but it declined thereafter (data not shown). These findings are in keeping with our 
results showing that ATP-induced intracellular Ca2+ responses decreased 
significantly at culture day 21 as compared to those observed in 7-day cultures 
(Figure 10B). Pre-incubation of 7-day cultures with the subtype selective P2Y1 
receptor antagonist, MRS 2179 (0.3 µM), totally abolished the fast [Ca2+]i transient 
induced by ATP (100 µM), while keeping the late component of [Ca2+]i rise. 
Conversely, the selective P2X7 receptor antagonist, A438079 (3 µM), significantly 
attenuated the late [Ca2+]i response induced by ATP (100 µM) without much 
affecting the fast component. These results suggest that, in contrast to uracil 
nucleotides,  ATP (100 µM) or its metabolite ADP operate biphasic [Ca2+]i 
responses in postmenopausal MSCs in culture, which are respectively mediated 
by fast desensitizing P2Y1 receptors and by slow activating (non-desensitizing) 
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P2X7 receptors. More recent studies from Dixon’s group suggested that P2X7 
stimulation leads to increased membrane blebbing and bone formation 
(Panupinthu et al., 2007, 2008). Thus, the potential role of the P2X7 receptor in 
osteoblasts deserves further clarification and so does the involvement of other 
P2X receptor subtypes which may be also expressed in human osteoblast-like 
cells.  
Pattern of the extracellular catabolism of ATP and uracil nucleotides (UTP 
and UDP) in postmenopausal primary MSC cultures by HPLC 
Figure 11 illustrates the time course of the extracellular catabolism of ATP and 
uracil nucleotides (UTP and UDP) in intact postmenopausal primary MSCs in 
culture. ATP (100 µM) was catabolised with a half-degradation time of 24±2 min 
(n=9 observations from three individuals) and 12±1 min (n=9 observations from 
three individuals) at culture days 7 and 21, respectively (Figure 11A, B, see also 
Table 4). Because enzymatic activity is usually represented as a function of the 
total protein content, yet in osteoblast differentiating cultures type I collagen 
accounts to 85–90% of the organic matrix, we decided to normalize the ecto-
nucleotidase activity by the amount of viable cells given by the MTT assay (Table 
4). Normalization of the activity of the enzyme hydrolysing ATP to the total protein 
content or to the amount of viable cells demonstrates that speed up of ATP 
catabolism as cultures progressed is due predominantly to the concomitant 
increase in the number of cells, since the net enzymatic activity decreased by 25–
50%.  
Postmenopausal primary MSCs allowed to grow for 7 days hydrolysed ATP to 
adenosine with a very modest appearance of ADP and AMP (Figure 11A). In 
contrast with the majority of tissue systems, MSCs exhibit low level of ecto-
adenosine deaminase activity (Costa et al., 2011), so that adenosine progressively 
accumulates in 7-day cultures to a maximum of 38.3±3.2 µM 30 min after ATP 
(100 µM) application with only negligible (<1 µM) inosine and hypoxanthine 
formation. At 21-day cell cultures, ADP accumulation in the medium transiently 
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Figure 11. Time course of extracellular ATP (A and B), UTP (C and D), and UDP (E and F) 
metabolism in human primary bone marrow-derived mesenchymal stem cells (MSCs) in 
culture at days 7 (A, C, and E) and 21 (B, D, and F). Nucleotides (100 µM) were added to the 
culture medium at time zero. Samples (75 µl) were collected from each well at indicated times 
in the abscissa. Each collected sample was analysed by HPLC to separate and quantify ATP 
or UTP (filled circles), ADP or UDP (open circles), AMP or UMP (filled squares), and 
adenosine (ADO) or uridine (open squares). Each point represents pooled data from three 
individuals; three replicas were performed in each individual experiment. The vertical bars 
represent S.E.M. and are shown when they exceed the symbols in size. 
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increased to a maximum of 16.0±0.5 µM 10 min after ATP (100 µM) application 
(Figure 11B). Formation of adenosine from dephosphorylation of AMP by ecto-5’-
nucleotidase (CD73 membrane-cell maker, EC 3.1.3.5) was moderately delayed 
as compared to 7-day cultures; adenosine reached a maximal concentration of 
36.0±5.6 µM 30 min after ATP (100 µM) application to human MSCs cultured for 
21 days. Given the linearity of the semi-logarithmic progress curves obtained by 
polynomial fitting of the catabolism of ATP and AMP, the analysis of the 
corresponding half-degradation time values suggests that the extracellular 
catabolism of ATP into AMP through ecto-nucleotidases is the rate-limiting step to 
generate adenosine from exogenously added adenine nucleotides in MSC cultures 
(cf. Costa et al., 2011).  
Extracellular UTP (100 µM) was catabolised with a half degradation time of 
143±29 min (n=9 observations from three individuals) and 12±1 min (n=9 
observations from three individuals) at culture days 7 and 21, respectively (Figure 
11C, D). The UTP metabolites detected in the bath were UDP, UMP, and uridine, 
whose concentrations increased with time in human MSC cultures (Figure 11C, 
D). UDP transiently accumulated to maximal concentrations of 14.7±1.3 µM and 
11.1±1.2 µM 5 min after UTP (100 µM) application to 7- and 21-day cultures, 
respectively. Uridine progressively accumulated in human MSC cultures to 
maximal concentrations of 21.1±2.3 µM and 62.2±2.8 µM 30 min after UTP (100 
µM) application at days 7 and 21, respectively. The net enzymatic inactivation of 
UTP normalized to the total protein content or to the amount of viable cells 
increased by 6–10-fold as cultures progressed from day 7 to 21, respectively 
(Table 4). Given that the number of viable cells increased only by about twofold in 
the same period of time in culture, the results suggest that more differentiated 
human MSCs exhibit higher ecto-nucleotidase activity implicated in the inactivation 
of extracellular UTP. In these circumstances, the kinetics of inactivation of UTP 
and ATP become comparable yet differences may be noted in the profile of 
products formation (Figure 11).  
The progress curves of UDP (100 µM) disappearance in postmenopausal 
primary MSC cultures at days 7 and 21 are represented in Figure 11 E, F, 
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respectively. The results show that extracellular UDP (100 µM) is slowly 
inactivated in less differentiated cultures; the rate UDP catabolism speeds up (2–
3-fold) significantly as cultures progressed to more differentiate status. That is, 
UDP (100 µM) was catabolised with a half-degradation time of 69±16 min (n=9 
observations from three individuals) and 6±1 min (n=9 observations from three 
individuals) at culture days 7 and 21, respectively (Figure 11E, F). The UDP 
metabolites detected in the bath were UMP and uridine. Thirty minutes after UDP 
(100 µM) application, the concentration of uridine in the culture medium was about 
25.8±6.0 µM and 85.5±3.2 µM in samples collected from cell cultures at days 7 
and 21, respectively. At culture day 21, the enzymatic inactivation rate of UDP 
normalized to the total protein content or to the amount of viable cells was the 
strongest of all nucleotides tested, whereas it had only intermediate values in 7-
day cultures (Table 4). This might explain why UDP does not easily accumulate in 
Table 1: Ectonucleotidase activity and half-degradation time values of ATP, UTP and 
UDP on human primary bone marrow stromal cells during osteogenic differentiation. 
 Day 7 Day 21 
 t½ (min) 
pmol/µg prot. 
/15 min 
pmol/MTT abs.  
/15 min 
t½ (min) 
pmol/µg prot. 
/15 min 
pmol/MTT abs.  
/15 min 
ATP 24±2     173±32 6488±1203      12±1* 82±15*  4871±899 
UTP 143±29 16±14 576±492 12±1**  85±5** 5042±254** 
UDP  69±16 60±14   2255±492   6±1**     114±2** 6783±122** 
  
ATP and ADP (100 µM) were added to culture media of human primary osteoblast cells 
at days 7 and 21. Samples (75 µl) were collected from each well at times 1, 5, 10, 15 
and 30 min after application of the substrate. Each collected sample was analyzed by 
HPLC to separate and quantify ATP and/or UTP, ADP and/or UDP, AMP and/or UMP, 
and adenosine and/or uridine (see Figure 5). Enzymatic activity is usually presented as a 
function of the total protein content (day 7: 17.5±2.6 µg/cm
2
 vs day 21: 52.5±10.6 
µg/cm
2
, n=14). Yet, in osteoblast differentiating cultures type I collagen accounts to 85-
90% of the organic matrix, thus normalization of the ectonucleotidase activity was also 
done by the amount of viable cells given by the MTT assay (day 7: 0.480±0.024 A/cm
2
 
vs day 21: 0.892±0.049 A/cm
2
, n=20). Values are means ± SEM from 3 individuals; 3 
replicas were performed in each individual experiment. *P<0.05 and **P<0.01 
represent significant differences when compared with day 7. 
ATP, UTP and UDP (100 µM) were added to culture media of human primary MSCs at days 7 
and 21. Samples (75 µl) were collected from each well at times 1, 5, 10, 15, and 30 min after 
application of the substrate. Each collected sample was analysed by HPLC to separate and 
quantify ATP and/or UTP, ADP and/or UDP, AMP and/or UMP, and adenosine and/or uridine 
(see Figure 11). Enzymatic activity is usually presented as a function of the tot  protein 
content (day 7: 17.5±2.6 µg/cm2 vs. day 21: 52.5±10.6 µg/cm2, n=14). Yet, in osteoblast 
differentiating cultures type I collagen accounts to 85–90% of the organic matrix, thus 
normalization of the ectonucleotidase activity was also done by the amount of viable cells 
given by the MTT assay (day 7: 0.480±0.024 A/cm2 vs. day 21: 0.892±0.049 A/cm2, n=20). 
Values are means SEM from three individuals; three replicas were performed in each 
individual experiment.  
*P<0.05 represents significant differences when compared with day 7. 
**P<0.01 represents significant differences when compared with day 7. 
Table 4. Ectonucleotidase activity and half-degradation time values of ATP, UTP and UDP 
on human primary bone marrow-derived mesenchymal stem cells (MSCs) during osteogenic 
differentiation. 
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more mature MSC cultures when UTP (100 µM) was used as a substrate (Figure 
11D).  
The presence of a saturating concentration (10 mM) of β-glycerophosphate in 
the culture medium did not alter the degradation kinetics of ATP and uracil 
nucleotides (UTP and UDP), suggesting that the contribution of non-specific 
phosphatases (e.g., ALP, EC 3.1.3.1) to the extracellular catabolism of nucleotides 
applied in a 100-µM concentration is negligible (data not shown). 
Detection of NTPDase1, -2, -3, and ecto-5’-nucleotidase in postmenopausal 
primary MSCs by immunofluorescence 
Comparing the kinetics of adenine and uracil nucleotides hydrolysis suggests 
that the former are much better substrates than uracil nucleotides for enzymes of 
the ecto-nucleotidase family putatively expressed in less differentiated (7-day) 
human MSC cultures. Reversion of this enzymatic pattern that plays a major role 
in tri- and diphosphonucleoside hydrolysis may be a hallmark of osteogenic 
differentiation of human MSCs in culture and has the potential to fine-tuning 
regulate P2 receptors signalling in the human bone.  
Human primary MSCs were allowed to grow in chamber slides for 7 and 21 
days in supplemented α-MEM before immunolabeling with specific primary 
antibodies directed against human NTPDase1, -2 and -3, and ecto-5´-
nucleotidase. Fluorescence immunoreactivity against ecto-NTPDase1, -2 and -3, 
and ecto-5’-nucleotidase in human primary MSCs shows a 
cytoplasmic/membrane-staining pattern typical for ectoenzymes, which increased 
in intensity with time (7<21 days) in culture (Figure 12). This is particularly evident 
for NTPDase1 and -3 (Figure 12A, C). Interestingly, immunoreactivity against 
NTPDase2 was almost unapparent at 7-day cultures (Figure 12Bi) and became 
stronger in more differentiated (21-day) cell cultures (Figure 12Bii). Human primary 
MSCs also exhibited positive immunoreactivity against CD73 (ecto-5’-
nucleotidase) that is found to be expressed exclusively (>95%) in osteoprogenitors 
(see e.g., Liu et al., 2009). Immunolabeling of CD73 molecules in postmenopausal 
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primary MSCs was demonstrated by both immunocytochemistry (Figure 12) and 
flow cytometry (data not shown). 
DISCUSSION 
The actions of extracellular adenine nucleotides on the basic functions of bone 
cells appear to be relatively clear-cut. ATP and ADP exert striking in vitro actions 
at concentrations in the low micromolar range to stimulate the formation and 
resorptive activity of osteoclasts, whereas ATP decrease ALP activity (see e.g., 
Figure 10A) and inhibit mineralized bone formation by osteoblasts (Hoebertz et al., 
2003). Identification of uracil nucleotides-sensitive P2Y2, P2Y4, and P2Y6 
receptors suggests that extracellular UTP/UDP have also important roles in 
regulating cellular function in a variety of tissues and organs. Few reports have, 
however, questioned the action of these compounds as autocrine/paracrine 
mediators in human bone physiology. In this study, we show that uracil 
7 days 
21 days 
NTPDase 1 NTPDase 2 NTPDase 3 5’-NTase 
Ai 
Aii 
Bi 
Bii 
Ci 
Cii 
Di 
Dii 
Figure 12. Immunocytochemical detection of NTPDase1, -2, and -3 and ecto-5’-nucleotidase 
on human primary bone marrow-derived mesenchymal stem cells (MSCs). Shown is the time-
related immunoreactivity fluorescence detection by confocal microscopy of human MSCs 
(first subculture) allowed to grow for 7 (Ai–Di) and 21 (Aii–Dii) days in an osteoblast-inducing 
medium. Cells grown in eight-well chamber slides were processed for immunocytochemistry 
in parallel and were visualized keeping unaltered the settings of the confocal microscope 
throughout the procedure. For further details on immunofluorescence labelling see Materials 
and Methods section. Scale bar is 150 µm. 
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nucleotides, both UTP and UDP, are important enhancers of intracellular [Ca2+] 
and osteogenic differentiation of human primary bone marrow-derived MSCs 
isolated from postmenopausal women, but their effects decrease in magnitude 
with time of the cells in culture. Paradoxically, these changes were notably 
accompanied by an increase in the expression of UTP-sensitive P2Y2 and P2Y4 
receptors in differentiated osteoblasts (Figure 9; see also Orriss et al., 2006), 
whereas the expression of UDP-sensitive P2Y6 receptor remained fairly constant 
along cells differentiation. Given that (1) UDP was more potent than UTP and that 
(2) the enzymatically stable UDP analogue, PSB 0474, enhanced ALP activity at 
all stages of MSC cultures whereas UTPγS was devoid of effect, it is reasonable 
to admit that the P2Y6 receptor exerts a predominant role on osteogenic 
differentiation of bone marrow-derived MSCs from postmenopausal women. 
Another interesting finding from this study suggests that stimulation of P2Y6 
receptors by UDP originated from the catabolism of UTP in bone 
microenvironment may be balanced through the activity of type-specific 
membrane-bound NTPDases whose expression varies along MSCs maturation 
(see e.g., Figure 12).  
To our knowledge, this is the first study to investigate the role of uracil 
nucleotide-sensitive receptors (P2Y2, P2Y4, and P2Y6) on intracellular [Ca2+] levels 
and osteogenic differentiation (measured as increases in ALP activity) of primary 
bone marrow-derived MSCs from postmenopausal female patients maintained in 
long-term cultures. Promotion of osteogenic differentiation of human MSCs by 
uracil nucleotides contrasts with the inhibitory action of ATP regarding ALP activity 
under similar experimental conditions (see Figure 10). The fact that UDP was 
more potent than UTP fits with the P2Y6 being a dominant receptor type involved 
in osteogenic differentiation of human primary MSCs. Indeed, UDP was reported 
to be 100-fold more potent than UTP at the human recombinant P2Y6 receptor 
(Communi et al., 1996). Selective activation of P2Y6 receptors with PSB 0474 (El-
Tayeb et al., 2006) mimicked the effects of both UTP and UDP, whereas the 
stable UTP analogue, UTPγS, was devoid of effect. Blockade of UDP-sensitive 
P2Y6 receptors with MRS 2578 (Mamedova et al., 2004) prevented [Ca2+]i rises 
3. Original Research Papers 
 
PhD thesis – José Bernardo Noronha Matos (2011-2014) 117  
and osteogenic differentiation caused by UDP at all culture time points. 
Surprisingly, the effects of both UTP and UDP on intracellular [Ca2+] and 
osteogenic differentiation became less evident as cultures progressed towards a 
more differentiated status. Immunofluorescence analysis revealed a strong 
differentiation dependence of P2 receptor expression in long-term human MSC 
cultures which was characterized by a striking increase in the levels of UTP-
sensitive P2Y2 and P2Y4 receptors during the third week of culture, while the 
expression of the P2Y6 receptor remained fairly constant along culture time. This 
receptor profile is compatible with that found by Orriss et al. (2006) in primary rat 
osteoblasts. As changes in subtype-specific P2 receptors expression could not 
afford for the decrease in the effects of uracil nucleotides on intracellular [Ca2+] 
and osteogenic differentiation of human MSCs, we drew our attention towards the 
possibility that uracil nucleotides were increasingly broken down by membrane 
bound ecto-enzymes upon cells differentiation. The rate of extracellular UTP and 
UDP hydrolysis was 3 to 10-fold higher in more differentiated cell populations, 
which is consistent with the increase of NTPDase1, -2, and -3 immunolabeling on 
human MSCs with time in culture (Figure 12). Together, these data provide good 
evidence for significant up regulation of uracil nucleotides break down enzymes as 
osteogenic differentiation proceeds, which may rapidly terminate activation of the 
predominant (P2Y6) receptor subtype.  
The P2Y6 receptor was cloned from a human cDNA library and was found to be 
expressed in transformed human osteoblast-like cells (Maier et al., 1997). In most 
instances, P2Y6 receptors signal through pertussis toxin-insensitive Gq to activate 
PLCβ, leading to formation of IP3 and subsequent release of Ca2+ from 
intracellular stores (Ralevic & Burnstock, 1998). In agreement with those early 
findings (see also Orriss et al., 2006), we found strong pharmacological and 
immunocytochemical evidences for the expression of the P2Y6 receptor on primary 
bone marrow-derived MSCs isolated from postmenopausal female patients, 
together with significant intracellular [Ca2+] responses to UDP (the natural ligand 
selective for this receptor). Our data also show that stimulation of the P2Y6 
receptor promotes ALP activity at early culture stages, indicating the progression 
3. Original Research Papers 
 
PhD thesis – José Bernardo Noronha Matos (2011-2014) 118  
of MSCs towards osteogenic differentiation. Unlike adenine nucleotides (e.g., 
ATP), which downregulate ALP activity in human MSCs (see Figure 10), little else 
is known about the P2Y6 receptor or the role that it might play in bone cell 
metabolism. Activation of P2Y6 receptors may transiently activate NF-kB 
increasing survival of rabbit osteoclasts (Korcok et al., 2005), through the 
sequential activation of conventional protein kinase C (PKC) isoforms and IkB 
kinase leading to IkB degradation by the proteasome (Ye, 2001). Activation of 
P2Y1, P2Y2, and P2Y6 receptors induces transient rises in intracellular [Ca2+], 
while only the P2Y6 receptor couples to NF-kB activation, indicating that the rise in 
intracellular [Ca2+] alone is not sufficient to activate NF-kB (Korcok et al., 2005). It 
remains to be explored whether this pathway also operates in human osteoblast 
progenitors.  
Besides the P2Y6 receptor, UTP-sensitive P2Y2 and P2Y4 receptors have also 
been identified in osteoblast-like cell lines from both humans and rodents, but 
previous attempts failed to detect their expression in normal human osteoblasts 
(Maier et al., 1997; Orriss et al., 2006). Here, we demonstrate that the 
immunoreactivity against P2Y2 and P2Y4 receptors increased strongly between 
day 7 and 21 in human primary MSCs in culture. Immunohistochemical and 
quantitative real-time PCR studies revealed that P2Y2 receptor expression 
increased as rat BMSC density increased (Ichikawa and Gemba, 2009). 
Paradoxically, responsiveness of these cells to UTP, which is the most potent 
agonist of P2Y2 and P2Y4 receptor subtypes, decreased in differentiated 
osteoblasts. Moreover, the hydrolysis-resistant UTP analogue, UTPγS, was 
without effect, suggesting that UTP has to be catabolised into UDP in order to 
facilitate differentiation of human osteoprogenitors predominantly through the 
activation of P2Y6 receptors.  
In agreement with early findings (reviewed by Hoebertz et al., 2003), we 
provided evidences confirming that ATP acts as a negative regulator of osteogenic 
differentiation of human postmenopausal bone marrow-derived MSCs in culture, 
whereas uracil nucleotides did the opposite. We also demonstrated that ATP 
operates biphasic [Ca2+]i responses in osteoprogenitor cells, which are 
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respectively mediated by fast desensitizing P2Y1 receptors and by slow activating 
(non-desensitizing) P2X7 receptors. Human osteoblast-like cells express P2Y1 
receptors as indicated by RT-PCR (Maier et al., 1997) and by immunolabeling 
(see Figure 10B) studies. Activation of P2Y1 (and P2Y2) receptors by extracellular 
ATP sensitizes osteoblast cells to [Ca2+] responses caused by parathyroid 
hormone (Bowler et al., 1999; Buckley et al., 2001). Synergism between ATP and 
parathyroid hormone activate bone remodelling at discrete sites of cell skeletal 
damage (Bowler et al., 2001). Conflicting results have been published on the 
expression and the potential role of the P2X7 receptor in osteoblasts. The P2X7 
receptor was thought originally to be predominantly expressed in cells of the 
haematopoietic cell lineage, including macrophages and osteoclasts, which 
consist of a small percentage of the cells in our cultures (see Figure 5). However, 
recent studies have shown the expression of P2X7 receptors in a subpopulation of 
osteoblasts, both from human bone explants (see also Figure 10B), in the human 
osteosarcoma cell line SaOS-2, and in primary osteoblasts obtained from mouse 
calvarial cultures (reviewed by Hoebertz et al., 2003). Further, prolonged ATP 
stimulation induced pore formation in subpopulations of these osteoblast cultures 
as measured by ethidium bromide uptake. In the SaOS-2 cells, stimulation with the 
selective P2X7 receptor agonist BzATP not only induced pore formation, but also 
increased LDH release and initiated apoptotic processes in the cells, indicating 
that P2X7 receptors might be involved in the regulation of cell survival in 
osteoblasts. Interestingly, single nucleotide polymorphisms in the P2X7 receptor 
gene are associated with loss of lumbar spine bone mineral density and 
postmenopausal fracture risk in female patients (Ohlendorff et al., 2007).  
The study of nucleotide receptors and their functions is complicated by the 
presence at the cell surface ectonucleotidases, which rapidly break down 
nucleotides into nucleosides (for a review, see Zimmermann, 2000). The broad 
functional diversity of the extracellular nucleotide-hydrolysing enzymes is not 
matched by a selective tissue distribution that might be expected if there were 
tissue-specific requirements in the extracellular nucleotide hydrolysis pathways. It 
is likely that enzymes belonging to different enzyme families are co-localized on 
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individual cell or tissue surfaces. Among the nucleotidases, NTPDase1, 
NTPDase2, NTPDase3, and NTPDase8, and two members of the ecto-nucleotide 
pyrophosphatases/ phosphodiesterases (E-NPP) family, NPP1 and NPP3, are 
located at the plasma membrane and hydrolyse extracellular nucleotides (Kukulski 
et al., 2005; Stefan et al., 2005; Zimmermann, 2000). Detailed studies using 
antibodies can differentiate between closely related enzyme species. Our findings 
showed that human primary MSCs express NTPDase1 and -3 at all differentiation 
time points (7 and 21 days in culture), whereas NTPDase2 immunoreactivity 
becomes evident only in more differentiated cells. Human NTPDase1 (also called 
CD39 or apyrase, EC 3.6.1.5) acts preferentially on adenine nucleotides (Km~20 
µM) as compared with uridine nucleotides (Km~50 µM); this enzyme 
dephosphorylates ATP directly to AMP, removing one phosphate at a time with 
almost no release of intermediate ADP. The ADP hydrolysing capacity of 
NTPDase1 may even exceed the ATPase activity of the enzyme by up to 1.5–2 
times. NTPDase2 (CD39L1, EC 3.6.1.3) conversely is a preferential nucleoside 
triphosphatase; this enzyme hydrolyses diphosphates 10–15 times less efficiently 
than nucleotide triphosphates, leading to minimal monophosphates accumulation 
(Matsuoka and Ohkubo, 2004). NTPDase3 (CD39L3 or HB6) and NTPDase8 
(hepatic ATPDase) are described as functional intermediates between NTPDase1 
and -2 (Kukulski et al., 2005). With the exception of NTPDase8, the apparent Km 
constants of human NTPDases obtained for adenine nucleotides as substrates are 
in the low micromolar range; higher Km values were obtained for the hydrolysis of 
uracil nucleotides. Interestingly, UTP is a much better substrate than UDP for 
NTPDase1 and -3 (Kukulski et al., 2005), which may influence the real potency of 
UTP on human MSCs in culture. Distinctively from adenine nucleotides, all 
membrane-bound NTPDases dephosphorylate UTP with a transient formation of 
UDP, thus favouring P2Y6 receptor activation (Kukulski et al., 2005; see Figures 7 
and 11). Expression of NTPDase2 in more differentiated (21 days in culture) 
human MSCs would be expected to terminate ATP and UTP activation of P2X7 
and P2Y2,4 receptors, respectively, which might contribute to up-regulate these 
receptors during osteogenic differentiation (Figure 9; see also Orriss et al., 2006). 
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Simultaneously, increased NTPDase2 activity could provide generation of ADP 
and UDP for stimulation of P2Y1 and P2Y6 receptors. However, the concomitant 
increase in the expression of NTPDase1 and -3 (see Figure 12) may efficiently 
hydrolyse ADP (data not shown) and UDP (see Table 4), thus precluding 
activation of receptors for these two nucleotides, P2Y1 and P2Y6, regulating 
intracellular [Ca2+] accumulation. As for NPP1 and NPP3 (EC 3.6.1.9), they 
release nucleoside 5’-monophosphate plus Pi or PPi from a variety of nucleotides 
and nucleotide derivatives, but intriguingly, their phosphorylated product bind to 
NPPs with a higher affinity than their substrates do, and inhibit catalysis (Stefan et 
al., 2005). Osteoblasts express NPP1, NPP2, and NPP3 enzymes (Johnson et al., 
2000; Orriss et al., 2007). The enzyme responsible for the final hydrolysis of 
nucleoside-5’-monophosphates to their respective nucleoside, ecto-5’-
nucleotidase (CD73, EC 3.1.3.5), occurs in essentially all tissues. It is interesting 
to note that human MSCs exhibit high ecto-5’-nucleotidase activity and are 
immunoreactive against CD73, which is found to be expressed exclusively (>95%) 
in osteoprogenitors (Costa et al., 2011; Liu et al., 2009). Fast conversion of 
nucleoside-5’-monophosphates to their respective nucleosides and the kinetics of 
ATP/UTP inactivation through members of the E-NPP family in human MSC 
cultures may explain why the concentration of AMP/UMP in the extracellular milieu 
was kept at a low level while keeping high levels of PPi that contribute to inhibit 
bone mineralization (Hoebertz et al., 2003; Orriss et al., 2010). Altogether, our 
results suggest that NTPDases and NPP enzymes have the potential to exert a 
tight, distinct, and sophisticated regulation of subtype-specific P2 receptors 
signalling, and therefore affect intracellular [Ca2+] and osteogenic differentiation of 
human primary MSCs maintained in long-term cultures. This is especially relevant 
considering the poverty of uracil metabolizing enzymes apart from the 
ectonucleotidases (Robson et al., 2006).  
All cells contain high intracellular ATP concentrations (1–5 mM), as well as the 
capacity to release ATP following trauma. Given that intracellular ATP levels are 
10–50 times higher than the other purine or pyrimidine nucleoside triphosphate 
species (including UTP) it is not surprising that at sites of tissue injury, wounding, 
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or fracture, micromolar concentrations of purine or pyrimidine nucleotides will be 
present to activate P2 receptors. Nevertheless, it is obvious that nucleotides must 
exist transiently in the bone microenvironment without cell damage to be 
physiologically relevant regulators of bone remodelling. There are two distinct 
nonlytic mechanisms by which nucleotides may be constitutively released from 
cells: (a) Exocytic release specifically concentrated within secretory granules or 
vesicles; and (b) release of cytosolic nucleotides via intrinsic plasma membrane 
channels or pores, which includes ABC transporters and connexin hemichannels 
controlled release (Bodin and Burnstock, 2001; Novak, 2003). Various agonists to 
P2 receptors can also initiate nucleotides release; in a positive feedback loop, 
UTP may act through P2Y2 receptors to upregulate ATP release from primary 
human osteoblasts (Bowler et al., 1998). In addition, bone cells constitutively 
release ATP (and possibly UTP) upon mechanical stimulation, hypoxia, and 
hypo/hypertonic stress (reviewed by Bowler et al., 2001). The ability of various cell 
types (e.g., murine airway epithelial cells, human cardiomyocytes) to release UTP 
has been directly confirmed (Lazarowski et al., 1997, 2003). It is important to 
stress that the extracellular accumulation of nucleotides such as UTP, UDP, and 
ADP may not necessarily involve a requirement for their selective release from 
intracellular pools. Rather, these nucleotides may accumulate as a secondary 
consequence of extracellular metabolism (degradation or synthesis) of nucleotide 
precursors that are directly released in various physiological or pathological 
conditions (Burrell et al., 2005; Buxton et al., 2001; Joseph et al., 2004; Yegutkin 
et al., 2001, 2002). Thus, ADP or UDP may either be released directly or be 
generated via the extracellular hydrolysis of directly released ATP or UTP. It is 
also possible that extracellular UTP may be secondarily generated via an ecto-
nucleoside diphosphokinase (NDPK)-mediated transphosphorylation of directly 
released UDP by ATP that is co-released from the same cell or released 
coincidently from adjacent cells (Donaldson et al., 2000; Lazarowski et al., 1997, 
2000; Lazarowski and Harden, 1999). The human osteoblastic cell line SaOS-2 
expresses a strong ecto-NDPK activity that acts to generate additional 
extracellular ATP in the presence of a γ-phosphate donor that might be UTP or 
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GTP (Buckley et al., 2003). Unfortunately, we were unable to detect the 
coexistence of UTP-consuming and UTP-generating enzymes, like the ecto-
NDPK, in the kinetic studies performed in this study (Figure 11).  
Membrane compartmentalization of ecto-enzymes and other components of 
purinergic signalling cascade have been demonstrated (reviewed by Yegutkin, 
2008). According to that model, nucleotide-inactivating ecto-enzymes are located 
in close proximity with each other and next to nucleotides permeation sites, 
releasable stores and purinoceptors, presumably associated with lipid rafts and 
caveolae. Based on the compartmentalization model it seems reasonable to 
accept that released extracellular nucleotides and their derivatives are mainly 
concentrated on the cell surface, where they are subsequently ‘‘hand-to-hand’’ 
delivered for the succeeding phosphatase reactions. This important feature 
permits divergent cellular functions to take place at specific microdomains on the 
cell surface. Altogether, these multiple mechanisms for extracellular accumulation 
of particular P2 nucleotide agonists underscore why the characterization of 
potential nucleotide release mechanisms in a particular tissue or cell model should 
usually involve a corresponding analysis of extracellular nucleotide metabolism in 
that cell system (for a review, see Dubyak, 2007). In keeping with this model, our 
data emphasizes the value of a concerted action of UTP-consuming enzymes 
yielding to UDP generation and subsequent P2Y6 receptors activation in 
determining whether osteoblast progenitors are driven into proliferation or 
differentiation in postmenopausal human bone. These previously unrecognized 
targets for local regulation of osteogenic differentiation of bone marrow-derived 
MSCs may prompt for novel therapeutic strategies to control human diseases 
where bone destruction exceeds bone formation (e.g., osteoporosis, rheumatoid 
arthritis, osteogenesis imperfecta, fracture malunion). 
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ABSTRACT 
Polymorphisms of the P2X7 receptor have been associated with increased risk of 
fractures in postmenopausal women. Although both osteoblasts and osteoclasts 
express P2X7 receptors, their function in osteogenesis remains controversial. 
Here, we investigated the role of the P2X7 receptor on osteogenic differentiation 
and mineralization of bone marrow mesenchymal stem cell (MSC) cultures from 
postmenopausal women (age 71±3 yr, n=18). We focused on the mechanisms 
related to intracellular [Ca2+]i oscillations and plasma membrane-dynamics. ATP, 
and the P2X7 agonist BzATP (100 µM), increased [Ca2+]i in parallel to the 
formation of membrane pores permeable to TO-PRO-3 dye uptake. ATP and 
BzATP elicited reversible membrane blebs (zeiosis) in 38±1 and 70±1% of the 
cells, respectively. P2X7-induced zeiosis was Ca2+ independent, but involved 
phospholipase C, protein kinase C, and Rho-kinase activation. BzATP (100 µM) 
progressively increased the expression of Runx-2 and Osterix transcription factors 
by 452 and 226% (at day 21), respectively, alkaline phosphatase activity by 88% 
(at day 28), and mineralization by 329% (at day 43) of bone marrow MSC cultures 
in a Rho-kinase-dependent manner. In summary, reversible plasma membrane 
zeiosis involving cytoskeleton rearrangements due to activation of the P2X7-Rho-
kinase axis promotes osteogenic differentiation and mineralization of bone marrow 
MSCs, thus providing new therapeutic targets for postmenopausal bone loss. 
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INTRODUCTION 
Mesenchymal stem cells (MSCs) are a rare population of non-haematopoietic 
stromal cells present in the adult bone marrow, which exhibit extensive 
proliferative ability in uncommitted state while retaining great potential to 
differentiate into osteoblasts under appropriate conditions (Bobis et al., 2006; 
Pittenger et al., 1999). These unique properties make MSCs attractive candidates 
for bone growth and repair during aging, fracture healing, and diseases 
accompanied by excessive bone loss.  
Extracellular adenine nucleotides acting via several P2 purinoceptors play 
important roles in the regulation of bone formation as they are constitutively 
released into the bone microenvironment, the levels of which significantly increase 
during bone injury (reviewed in Burnstock et al., 2013). Adenine nucleotides 
stimulate bone formation by increasing the expression of osteoblast-related genes, 
such as RUNX-2 (Ciciarello et al., 2013). Released ATP also inhibits osteoclast-
induced bone resorption by altering cytoskeletal structure (Miyazaki et al., 2012) 
and NF-kB translocation to the nucleus (Korcok et al., 2004). Communication 
between osteoblasts and osteoclasts involves intercellular Ca2+ signalling, which 
requires ATP release and activation of P2X7 receptors in osteoclasts (Jorgensen 
et al., 2002). Expression of the P2X7 receptor was also shown in a subpopulation 
of human differentiated osteoblasts (Gartland et al., 2001; Henriksen et al., 2006), 
as well as in several human osteoblast like cell lines (e.g., MG-63, SaOS-2, Te85; 
Nakamura et al., 2000), but not in others (reviewed in Wesselius et al., 2011). 
These differences, together with heterogeneity on the molecular composition and 
activity of P2X7 receptors among human and rodent species (e.g., see Roger et 
al., 2010), may explain the controversy in the literature regarding the predominant 
role of the P2X7 receptor in bone remodelling (reviewed in Burnstock et al., 2013). 
Bone turnover is coordinated in adulthood. Yet later in life, especially in women 
after menopause, osteoclast function is increased relative to osteoblast activity, 
and this unbalanced cellular activity causes increased bone resorption. 
Epidemiological studies indicate that single nucleotide polymorphisms in the P2X7 
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receptor gene may favor the loss of bone mineral density and the risk of fracture in 
postmenopausal women (e.g., see Ohlendorff et al., 2007 but also Jorgensen et 
al., 2012). Although the high incidence of vertebral fractures may result from 
increased number of osteoclasts, we hypothesized that heterogeneity of the P2X7 
receptor expression among osteoprogenitors and differentiated osteoblast-like cell 
populations might also play a role (Burnstock et al., 2013). Therefore, this study 
was designed to investigate the mechanisms underlying participation of the P2X7 
receptor in osteogenic differentiation and mineralization of MSCs in 
postmenopausal women. 
The P2X7 receptor channel possesses unique characteristics among the P2X 
family by their much longer intracellular C-terminal tail, slow desensitization rate, 
and ability to switch between two open states depending on activation conditions. 
Basal P2X7 receptor activation leads to opening of membrane channels 
permeable to small cations (e.g., Ca2+, K+, Na+; Alloisio et al., 2010; Carrasquero 
et al., 2009; Orriss et al., 2006). During mechanical stress, tissue trauma and/or 
inflammation, prolonged exposure to high concentrations of ATP (>100 µM) leads 
to a leftward shift in agonist affinity and to opening of dilated plasma membrane 
pores permeable to molecules up to 900 Da (Panupinthu et al., 2007). This 
renders cells more prone to reversible morphological changes (e.g., 
microvesiculation and blebbing), as observed in mouse osteoblasts (Li et al., 
2005) and/or susceptible to apoptosis, as occurs in osteoclasts (North, 2002).  
Given the osteogenic potential of MSCs for bone growth and repair in 
adulthood, and the controversy regarding the participation of the P2X7 receptor in 
human bone turnover, we focused our attention on the mechanisms underlying 
P2X7-induced membrane blebbing, pore formation, osteogenic differentiation, and 
mineralization of bone marrow-derived MSCs isolated from postmenopausal 
women as compared to younger females.  
MATERIALS AND METHODS 
Reagents and antibodies 
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ATP, ADP, adenosine 5′-[β-thio]diphosphate (ADPβS), and 2’,3’-O-(benzoyl-4-
benzoyl)-adenosine 5′-triphosphate (BzATP) were from Sigma-Aldrich (St. Louis, 
MO, USA). We obtained 3-[[5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl]methyl]pyridine 
(A438079), chelerythrine (CHL), (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinolinyl) 
sulfonyl]-hexahydro-1H-1,4-diazepine (H1152), 2'-deoxy-N6-methyladenosine 3',5'-
bisphosphate (MRS 2179), phorbol 12-myristate 13-acetate (PMA), thapsigargin 
and 1-[6-[[(17β)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-
dione (U73122) from Tocris Cookson Inc. (Bristol, UK). Primary antibodies used 
were anti-P2Y1, anti-Runx-2 (M-70), anti-Osterix (M-15) (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA); and anti-P2X7 (Alomone, Jerusalem, 
Israel). Anti-β-actin and horseradish-peroxidase-conjugated secondary antibodies 
were from AbCam (Cambridge, UK); Alexa Fluor 488-labelled anti-rabbit, Alexa 
Fluor 653-labelled anti-goat, Fluo-4NW and quinolinium 4-[3-(3-methyl-2(3H)-
benzothiazolylidene)-1-propenyl]-1-[3-(trimethylammonio)propyl]-diiodide (TO-
PRO-3) were from Molecular Probes (Invitrogen, Carlsbad, USA). 
Cell cultures and phenotypic characterization 
Human bone marrow samples were obtained from the neck of the femur of 
postmenopausal women (age 71±3 yr, n=18) undergoing total hip arthroplasty as a 
result of primary osteoarthrosis. For comparison purposes, we also used bone 
marrow specimens from the sacrum of three younger female patients (age 14 yr) 
requiring bone engraftment for spinal fusion to correct scoliosis. Handling of bone 
marrow samples and culture of adherent cells was performed during 10–15 days 
(until near confluence), as described previously (Noronha-Matos et al., 2012). First 
subcultures were maintained for 43 days in standard culture medium [α-minimal 
essential medium (α-MEM) plus 10% fetal bovine serum, 100 U/ml penicillin, 100 
µg/ml streptomycin, and 2.5 µg/ml amphotericin B] supplemented with 50 µg/ml 
ascorbic acid, 10 mM β-glycerophosphate, and 10 nM dexamethasone to promote 
osteogenic differentiation. Phenotypic characterization of the cells (first subculture) 
was performed by flow cytometry (Noronha-Matos et al., 2012). These cells 
exhibited positive immunoreactivity against CD105 (SH2), CD29 (integrin β1) and 
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CD117 (tyrosine-protein kinase Kit), which have been identified as surface 
markers of bone marrow-derived MSCs (Bobis et al., 2006; Pittenger et al., 1999). 
Conversely, the cells were negative for haematopoietic surface markers, like CD14 
and CD45, which have been extensively used as a good argument to distinguish 
bone marrow haematopoietic cells from MSCs (Baddoo et al., 2003; Pittenger et 
al., 1999). Thus, first passage plastic-adherent human bone marrow cells obtained 
under the present experimental conditions are highly enriched in multipotent 
MSCs. 
Viability/proliferation and osteogenic differentiation of bone marrow MSCs 
Cell viability/proliferation was evaluated by the 3-[4,5-dimethylthiazol- 2-yl]-2,5-
diphenyltetrasodium bromide (MTT) assay (Costa et al., 2011; Noronha-Matos et 
al., 2012). Data from the MTT assay correlates positively with the results 
measuring cell proliferation from total DNA quantification per culture well (e.g., see 
Noronha-Matos et al., 2012). Osteogenic differentiation of bone marrow-derived 
MSCs was inferred from increases in alkaline phosphatase (ALP) activity and from 
the expression of osteogenic transcription factors, namely Runx-2 and Osterix. 
ALP activity was determined in cell lysates by colorimetric determination of p-
nitrophenol (PNP) hydrolysis, as described previously; obtained values were 
expressed in nanomoles of PNP per minute normalized by the MTT absorbance 
(nmol·min-1·MTT-1; Noronha-Matos et al., 2012). Levels of Runx-2 and Osterix 
proteins were determined by Western blot analysis at culture day 7 and 21. Equal 
protein amounts (10 µg) loaded into SDS-PAGE (10%) gels were transferred onto 
a polyvinyl identifluoride membrane using a Mini-Protean Tetra Cell coupled to a 
Mini-Trans-Blot module (Bio-Rad, Hercules, CA, USA). Blocked membranes were 
incubated with anti-human primary antibodies (1:200): anti-Runx-2 (M-70, rabbit), 
anti-Osterix (M-15, goat). β-Actin (rabbit) was used as control. The peroxidase 
detection system (1.25 mM luminol; 0.2 mM coumaric acid; 0.1 M Tris, pH 8.5; and 
0.032% hydrogen peroxide) was used for visualization of the immunoreactivity. 
Gels were analyzed using a gel blot imaging system (ChemiDoc MP; Bio-Rad). At 
culture day 43, calcium deposition in mineralized nodules was revealed by alizarin 
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red staining and photographed using a microscope (Zeiss Axiophot; Carl Zeiss, 
Oberkochen, Germany) equipped with a CCD camera (CoolSnap HQ; Ropers Inc., 
Tucson, AZ, USA) running MetaFluor 6.3 image acquisition software 
(Photometrics, Tuczon, AZ, USA) (23). Images were exported to ImageJ 1.37c 
(U.S. National Institutes of Health, Bethesda, MD, USA) for quantification of the 
area of bone nodules. 
Single-cell intracellular calcium ([Ca2+]i) transients and morphological 
changes by confocal microscopy 
[Ca2+]i oscillations were evaluated in cells loaded with the fluorescent Ca2+ 
indicator, Fluo-4NW (2.5 µM), as described previously (Noronha-Matos et al., 
2012). Briefly, 7-day culture dishes were mounted on the stage of a laser-scanning 
confocal microscope (Olympus FV1000; Olympus, Tokyo, Japan) and perfused 
continuously (1 ml/min) with gassed (95% O2 and 5% CO2) Tyrode’s solution (pH 
7.4) containing (mM): 137 NaCl, 2.7 KCl, 1.8 CaCl2, 1 MgCl2, 0.4 NaH2PO4, 11.9 
NaHCO3, and 11.2 glucose, at 37ºC (e.g., see Noronha-Matos et al., 2012). In 
some experiments, CaCl2 was omitted, and the extracellular Ca2+ chelator, EGTA 
(1 mM), was added. [Ca2+]i transients were calibrated to the maximal calcium load 
produced by the Ca2+ ionophore, ionomycin (5 µM, 100% response; Noronha-
Matos et al., 2012). The percentage of cells in each microscopic field (LUCPLFL 
20xPH; NA 0.45) exhibiting microvesiculation and blebbing (zeiosis) before and 
during addition of test drugs was also determined. For cell area quantification, the 
morphology of the cells was compared before and after the drug exposure (6 min). 
The area (µm2) of loaded cells with Fluo-4NW (2.5 µM) was measured using the 
FluoView Advanced software package (Olympus); images were exported to Image 
J 1.37c for mathematical analysis. 
TO-PRO-3 dye uptake and pore formation 
Membrane pore formation was monitored by measuring TO-PRO-3 dye uptake 
synchronously to Ca2+ signals in cells previously loaded with the fluorescent Ca2+ 
indicator, Fluo-4NW (2.5 µM; see above for details). After mounting culture dishes 
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on the stage of the confocal microscope, cells were continuously superfused with 
the fluorescent dye, TO-PRO-3 (1 µM), for 6 min and up to the end of the 
experiment. Changes in fluorescence emitted by Fluo-4NW and TOPRO-3 were 
detected in the time-lapse mode with the FluoView Advanced software. Fluo-4NW 
was excited with the 488 nm multiline Ar laser, and the emitted fluorescence was 
detected at 510–560 nm; TO-PRO-3 was excited with the 633 nm red He-Ne laser, 
and the emitted fluorescence was detected at 661 nm. Fluorescence images were 
collected at 20 sec intervals. 
Immunofluorescence staining 
Human bone marrow cells were allowed to grow in chamber slides for 7 or 21 
days. Paraformaldehyde-fixed cells were incubated with the following primary 
antibodies: anti-P2Y1 (1:50, goat) and anti-P2X7 (1:75, rabbit), in the dark for 2 h. 
Alexa Fluor 488 (anti-rabbit) and Alexa Fluor 653 (anti-goat) were applied as 
secondary antibodies for 1 h in the dark. Chamber slides were mounted with 
VectaShield medium and observed by confocal microscopy (Olympus FV1000; 
Noronha-Matos et al., 2012). 
Presentation of data and statistical analysis 
Results presented in this study are from bone marrow samples obtained from 
18 postmenopausal female patients (age 71±3 yr); for comparison purposes, we 
also used bone marrow cells from 3 younger female patients (age 14 yr) in some 
of the experiments. For each experiment and assay, 3–8 replicas were 
accomplished. Data are expressed as means ± S.E.M from an n number of 
individual experiments. Data from different individuals (from the same age group) 
were evaluated using 1-way analysis of variance (ANOVA), and no significant 
differences in the pattern of cell behavior were found. Statistical differences found 
between control and drug-treated cultures were determined by Bonferroni’s 
method. Values of P<0.05 were considered to represent significant differences. 
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Informed consent to use the biological material, which would be otherwise 
discarded, was obtained. All procedures were approved by the Ethics Committees 
of Centro Hospitalar de Vila Nova de Gaia (University Hospital, Espinho, Portugal), 
Gabinete Coordenador de Investigação/Departamento de Ensino e Investigação 
(DEFI)–Centro Hospitalar do Porto (CHP; Porto, Portugal), and of Instituto de 
Ciências Biomédicas Abel Salazar (Medical School) of the University of Porto 
(Porto, Portugal). The investigation conforms to the principles outlined in the 
Declaration of Helsinki.  
RESULTS 
Adenine nucleotides cause [Ca2+]i transients in MSCs from postmenopausal 
women, but only ATP and BzATP produce plasma membrane blebbing 
All adenine nucleotides, ATP, BzATP, ADP and ADPβS, increased [Ca2+]i 
above the control level (Tyrode’s solution) when applied to 7 day cultures of bone 
marrow-derived MSCs from postmenopausal women. ATP (100 µM) caused a fast 
[Ca2+]i rise, which typically peaked 40 sec after nucleotide addition and decayed 
back almost to baseline within 1–2 min; a second progressive, but of much lower 
amplitude, ATP-induced rise in intracellular Ca2+ was observed following the initial 
[Ca2+]i transient (Figure 13A); BzATP (100 µM) elicited a sustained response that 
typically peaked 3 min after application and decayed back to the baseline after 
washout of the drug (Figure 13A).  Both ATP (100 µM) and BzATP (100 µM) 
caused dramatic changes in cell morphology, including initial cellular retraction 
followed by the formation of reversible plasma microvesiculation and blebs 
(zeiosis; Figure 13B, C). Blebs enlarged and shrank in an asynchronous pattern 
with a mean lifetime of 2–3 min. When ATP and BzATP were removed, blebbing 
activity reversibly ceased within 1–2 min. ADP (100 µM) and its enzymatically 
stable analogue, ADPβS (100 µM), were also able to elicit [Ca2+]i transients, but 
these were of much lower amplitude when compared to ATP and BzATP (Figure 
13A). Nucleoside diphosphates failed to induce changes in cell membrane 
morphology (Figure 13B, C). 
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ATP and BzATP cause membrane pore formation in MSCs from 
postmenopausal women 
Activation of ATP-sensitive P2X7 receptors may trigger the formation of large, 
nonspecific pores, which are permeable to molecules up to 900 Da (Panupinthu et 
al., 2007) via the recruitment of a distinct pore-forming moiety (Pelegrin and 
Surprenant, 2006; Verhoef et al., 2003). To test whether membrane pore formation 
occurs in bone marrow-derived MSC cultures from postmenopausal women 
challenged with ATP and BzATP, we measured the uptake of the fluorescent dye, 
TO-PRO-3, a carbocyanine nucleic acid stain with a molecular mass of 671 Da, 
simultaneously with [Ca2+]i transients in cells previously loaded with Fluo-4NW. 
TO-PRO-3 (1 µM) dye uptake by the cells stabilized ~200 s after starting its 
Figure 13. Adenine nucleotides cause [Ca2+]i transients in MSCs from postmenopausal 
women, but only ATP and BzATP produce plasma membrane blebbing. Fluorescent [Ca2+]i 
oscillations in bone marrow-derived MSCs from postmenopausal woman (age 71±3 years old) 
loaded with Fluo-4NW, at culture day 7, monitored in the time-lapse mode with a laser-
scanning confocal microscope. Cells were challenged with Tyrode’s solution (control), ATP 
(100 μM), BzATP (100 μM), ADP (100 μM) and ADPβS (100 μM) for 6 min (horizontal bars at 
the bottom of each graph). (A) Intracellular Ca2+ transients were calibrated to the maximal 
calcium load produced by ionomycin (5 μM, 100% response). Each point represents pooled 
data from 3 to 5 different individuals for a total of 85 (Tyrode), 78 (ATP), 66 (BzATP), 63 (ADP) 
and 64 (ADPβS) cells. Error bars = S.E.M. (B) Representative pseudocolor micrographs of 
experiments shown in panel (A) obtained before and during drug treatment. Arrows indicate 
plasma membrane blebs formed during perfusion with ATP or BzATP. Scale bar = 100 μm. (C) 
Percentage of cells exhibiting plasma membrane blebs within each cell populations. Bars 
represent pooled data from n cells. Error bars = S.E.M. *P<0.05 vs. control. 
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perfusion. No changes in [Ca2+]i fluorescence were observed during TO-PRO-3 
superfusion.  
Figure 14 shows that the TO-PRO-3 dye uptake by postmenopausal MSCs 
occurred immediately after the initial [Ca2+]i rise elicited by both ATP (100 and 500 
µM) and BzATP (100 and 300 µM). TO-PRO-3 dye uptake was kept at high levels 
for 4–5 min beyond the initial [Ca2+]i peak caused by ATP, but followed the more 
sustained [Ca2+]i rise produced by BzATP. The magnitude of [Ca2+]i transients and 
sustained TO-PRO-3 dye uptake was dependent on the concentration of the 
nucleotides. TO-PRO-3 is a membrane-impermeant DNA intercalator that binds to 
double-strand DNA with a much lower affinity than other carbocyanine dyes, 
exhibiting a dissociation constant in the micromolar range (Sovenyhazy et al., 
2003). The dynamics of TO-PRO-3/DNA binding causes oscillations between 3 
distinct wavelength absorption modes (514, 584, and 642 nm). This, together with 
a focus on the average of TO-PRO-3 dye uptake variations in whole-cell area 
Figure 14. ATP and BzATP, but not ADP, cause membrane pore formation in MSCs from 
postmenopausal women. Shown are fluorescent [Ca2+]i oscillations and TO-PRO-3 dye 
uptake in bone marrow-derived MSCs from postmenopausal woman (age 71±3 years old) at 
culture day 7; cells were monitored in the time-lapse mode with a laser-scanning confocal 
microscope. After loading with the intracellular Ca2+ indicator, Fluo-4NW, the cells were 
superfused throughout the experiment with the nucleic acid fluorescent dye, TO-PRO-3 (1 
μM), in order to monitor dye uptake due to membrane pore formation. Cells were then 
challenged with 100 and 500 μM ATP, 100 and 300 μM BzATP and 100 and 500 μM ADP for 
6 min (horizontal bars at the bottom of each graph). Data points represent pooled data from 3 
individuals for a total of 73 (ATP), 99 (BzATP) and 70 (ADP) cells. Error bars = S.E.M.  
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rather than in nuclei, may give the impression that TO-PRO-3 uptake signals are 
transient and reversible. Nevertheless, if one considers the nucleus as the region 
of interest, we could observe that the dye progressively accumulates with time 
after the application of ATP (100 and 500 µM) and BzATP (100 and 300 µM). 
Despite elevations of [Ca2+]i triggered by ADP (100 and 500 µM), this nucleotide 
was unable to promote TO-PRO-3 dye uptake and, therefore, the formation of 
membrane pores in these cells. 
Plasma membrane blebbing and pore formation requires P2X7 receptor 
activation 
Despite BzATP being considered a highly effective P2X7 receptor agonist, it 
can bind to a number of other P2 receptors, including the human P2Y1 receptor 
(North, 2002) that is also expressed in osteoprogenitor cells (Maier et al., 1997; 
Noronha-Matos et al., 2012 and Figure 15A). Preincubation of the cells with 
A438079 (3 µM) abolished the late component of BzATP (100 µM)-induced [Ca2+]i 
response, while keeping a residual fast [Ca2+]i rise (Figure 15B). Conversely, the 
selective P2Y1 receptor antagonist, MRS 2179, applied in a concentration (0.3 µM) 
that significantly attenuated the initial [Ca2+]i rise of the ATP (100 µM) response 
(Noronha-Matos et al., 2012), kept largely unrestrained the late component of the 
BzATP (100 µM) [Ca2+]i response (Figure 15B). These results suggest that ATP 
operates a biphasic [Ca2+]i response in cultured postmenopausal MSCs, which is 
mediated by fast desensitizing P2Y1 receptors and by slow activating 
(nondesensitizing) P2X7 receptors, respectively (e.g., see Noronha-Matos et al., 
2012); the latter receptors are more likely to be activated by BzATP. Given that 
MRS 2179 also partially depressed the late component of BzATP-induced [Ca2+]i 
response, one may speculate that P2X7-induced [Ca2+]i rises may depend on prior 
activation of coexistent P2Y1 receptors (Bowler et al., 1999; Buckley et al., 2001 
and Figure 15A).  
This scenario was different when considering BzATP-induced pore formation 
and plasma membrane blebbing in MSCs from postmenopausal women. The 
selective P2X7 receptor antagonist, A438079 (3 µM), abolished both TO-PRO-3   
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 dye uptake (Figure 15C) and plasma membrane blebbing (Figure 15D) caused by 
Figure 15. Blebbing and pore formation in MSCs from postmenopausal women requires P2X7 
receptor activation. (A) Immunocytochemical detection of P2X7 and P2Y1 receptors on 7 day 
cultures of MSCs. Confocal micrograph images representative of 3 individual experiments. Scale 
bars  150 µm. B–D) Fluorescent [Ca2+]i oscillations (B), TO-PRO-3 dye uptake (C), and plasma 
membrane blebbing (D) were monitored simultaneously by confocal microscopy in the time-lapse 
mode. After loading the cells with Fluo-4 NW, the superfusion fluid was supplemented with TO-
PRO-3 (1 µM).  
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BzATP (100 µM), whereas MRS 2179 (0.3 µM) was ineffective. These results 
suggest that despite the role the P2Y1 receptor might play in [Ca2+]i mobilization 
caused by BzATP, this receptor lacks effect on membrane cell dynamics, which 
may justify the lack of action of the P2Y1 receptor ligands, ADP (100 µM) and 
ADPβS (100 µM), on membrane zeiosis (see Figure 13B, C).  
P2X7-induced plasma membrane blebbing is independent of Ca2+, but 
involves activation of phospholipase C (PLC), protein kinase C (PKC), and 
Rho-associated kinase in MSCs from postmenopausal women 
Although the pharmacology and channel properties of the P2X7 receptor have 
been studied extensively, signal transduction pathways are relatively unknown. It 
has been demonstrated that P2X7 receptors signal through phospholipase D 
(PLD) and phospholipase A2 (PLA2) in osteoblasts from newborn rats (Panupinthu 
et al., 2007). These researchers showed that lysophosphatidic acid (LPA) resulting 
from PLD activity acts on specific receptors on osteoblasts to cause membrane 
cell blebbing via a pathway dependent on Rho-associated kinase (Panupinthu et 
al., 2007). The interplay between PKC and Rho-kinase activation has been 
hypothesized, although this interaction has not been experimentally proven. Here, 
we examined whether inhibition of Rho-associated kinase using H1152 (3 µM; 
Sasaki et al., 2002; Tamura et al., 2005) or inhibition of PKC by CHL (5 µM; 
Herbert et al., 1990) affected membrane cell blebbing in cultured postmenopausal 
MSCs challenged with BzATP (100 µM). Figure 16Ai shows that BzATP (100 µM) - 
induced plasma membrane blebbing was prevented by both H1152 (3 µM, Figure 
16Aii) and CHL (5 µM, Figure 16Aiii); statistical analysis of these experiments is 
shown in Figure 16B. Despite their effect on membrane cell blebbing, the two 
Figure 15. (Continued) Cells were challenged with BzATP (100 µM, for 6 min) in the 
absence and in the presence of A438079 (3 µM, a selective P2X7 receptor antagonist) or 
MRS 2179 (0.3 µM, a selective P2Y1 receptor antagonist). (B) Each point represents pooled 
data from 3–5 individuals for a total of 32 cells (BzATP), 80 cells (BzATP plus A438079), 
and 50 cells (BzATP plus MRS 2179). [Ca2+]i transients were calibrated to the maximal 
calcium load produced by ionomycin (5 µM, 100% response). (C) Bars represent pooled 
data from 3 individuals for n cells. Values are in arbitrary fluorescence units. *P<0.05 vs. 
BzATP alone. (D) Percentage of cells exhibiting plasma membrane blebs within each cell 
populations. Bars represent pooled data from n cells. Error bars = S.E.M. *P<0.05 vs. 
control (before addition of drugs); **P<0.05 vs. BzATP alone.  
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enzyme inhibitors differently affected BzATP (100 µM)-induced [Ca2+]i response. 
Figure 16. P2X7-induced membrane cell dynamics require activation of PLC, PKC and Rho-
associated kinase in MSCs from postmenopausal women. [Ca2+]i oscillations and membrane 
blebs were monitored by confocal microscopy in the time-lapse mode in MSCs loaded with 
Fluo-4 NW, at culture day 7. (A) Left panels: [Ca2+]i transients calibrated to the maximal 
calcium load produced by ionomycin (5 μM, 100% response).  
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Inhibition of Rho-associated kinase by H1152 (3 µM) globally depressed [Ca2+]i 
transients caused by BzATP (100 µM; Figure 16Aii). Conversely, CHL (5 µM) 
prevented the sustained component of BzATP (100 µM)-induced [Ca2+]i response, 
while keeping almost unaltered the initial [Ca2+]i rise (Figure 16Aiii). To confirm the 
PKC involvement in zeiosis, we tested the effect of a phorbol ester activator of 
PKC, PMA (5 µM; Castagna et al., 1982). PMA mimicked the effect of BzATP on 
the total number of cells exhibiting membrane blebbing, while producing a smaller 
[Ca2+]i response than the nucleotide (Figure 16Aiv, B). Data suggest that PKC and 
Rho-associated kinase effectively mediate membrane cell blebbing downstream 
P2X7 receptor activation.  
As mentioned above, P2X7 activation may lead to the production of LPA and 
subsequent activation of the Gq-coupled LPA1 receptor, which may mediate 
blebbing in osteoblasts and, thus, osteogenic differentiation during skeletal 
development in rats (Panupinthu et al., 2007). Stimulation of Gq-coupled receptors 
leads, most commonly, to PLC activation and increases in plasma membrane 
diacylglycerol (DAG) and cytosolic IP3 levels (Bleasdale et al., 1990). DAG would 
otherwise activate PKC. Pretreatment of the cells with U73122 (3 µM) significantly 
reduced BzATP-induced [Ca2+]i response, as well as membrane cell blebbing; 
under these conditions, only 35±1% of the cells exposed to the nucleotide showed 
blebbing (Figure 16Av, B). Overall, these results suggest that P2X7-induced 
plasma membrane blebbing involves activation of PLC, PKC, and Rho-associated 
kinase in MSCs from postmenopausal women.  
Figure 16. (Continued) [Ca2+]i oscillations and membrane blebs were monitored by confocal 
microscopy in the time-lapse mode in MSCs loaded with Fluo-4NW, at culture day 7. (A) Left 
panels: [Ca2+]i transients calibrated to the maximal calcium load produced by ionomycin (5 μM, 
100% response). Each point represents pooled data from 3-5 different individuals for a total of 
30 cells (BzATP 100 μM, Ai), 61 cells (BzATP 100 μM plus H1152 3 μM, Aii), 80 cells (BzATP 
100 μM plus CHL 5 μM, Aiii), 36 cells (PMA 10 μM, Aiv) and 65 cells (BzATP 100 μM plus 
U73122 3 μM, Av). Error bars = S.E.M. Right panels: pseudocolor micrographs obtained before 
and during drug treatment. Arrows indicate membrane blebs formed during perfusion with 
BzATP (100 μM) and PMA (10 μM). Scale bars = 50 μm. (B) Percentage of cells exhibiting 
membrane blebs within each situation, along with the effect of BzATP (100 μM) in a Ca2+-free 
solution (CaØ + 1mM EGTA) obtained in the absence or in the presence of thapsigargin (2 
μM), used to deplete intracellular Ca2+ reservoirs. Bars represente pooled data from n cells (3-5 
individuals). Error bars = S.E.M. *P<0.05 vs. control (before addition of drugs); **P<0.05 vs. 
BzATP or PMA alone. 
3. Original Research Papers 
 
PhD thesis – José Bernardo Noronha Matos (2011-2014) 141  
Taking into consideration that BzATP (100 µM) elicits plasma membrane 
blebbing irrespective of the pattern obtained for the [Ca2+]i response, we decided 
to perform similar experiments in the absence of external Ca2+ (plus EGTA, 1 mM) 
and after depleting the intracellular Ca2+ stores with thapsigargin (2 µM). BzATP 
(100 µM)-induced membrane cell blebbing was still observed in 57±1% of the cells 
tested in Ca2+-free Tyrode’s solution supplemented with the Ca2+ chelator, EGTA 
(1 mM; Figure 16B). BzATP (100 µM) accelerated Ca2+ influx from the extracellular 
milieu on readmission of CaCl2 to control levels (1.8 mM) in the Tyrode’s solution. 
Under control conditions, [Ca2+]i peaked to 74±3% (n=48 cells) of the ionomycin 
response in 200 sec, while the maximal [Ca2+]i load (76±2% of the ionomycin 
response, n=44 cells) was anticipated by 80 sec (P<0.05) when the cells were 
preincubated with the P2X7 receptor agonist. The specific inhibitor of endoplasmic 
reticulum Ca2+-ATPase, thapsigargin (2 µM; Thastrup et al., 1990), failed to affect 
the formation of membrane cell blebs caused by BzATP (100 µM), which were 
observed in 65±1% of tested cells (Figure 16B). This reinforces the idea that 
P2X7-induced membrane cell blebbing is a Ca2+-independent phenomenon in 
MSCs from postmenopausal women. 
P2X7-induced changes in the morphology of MSCs from postmenopausal 
women depend on PLC, PKC, and Rho-associated kinase 
The mechanism underlying membrane cell blebbing is thought to involve 
actomyosin contraction, but the initiating events are poorly understood. 
Interestingly, cell shape and cytoskeletal tension generated by actomyosin have 
been shown to regulate osteogenic differentiation of human MSCs (McBeath et al., 
2004). In the same set of previous experiments, we were able to measure the 
changes in cell area on application of BzATP (100 µM) in the absence and in the 
presence of the selective P2X7 antagonist A438079 (3 µM), the PLC inhibitor 
U73122 (3 µM), the PKC inhibitor CHL (5 µM), and the Rho-associated kinase 
inhibitor H1152 (3 µM). Figure 17A shows a representative image of a cell loaded 
with the Ca2+ indicator, Fluo-4NW, and the corresponding differential interference 
contrast (DIC) image, just before and during BzATP (100 µM) application. One can 
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appreciate a clear retraction of the cell synchronous to application of the 
nucleotide along with the formation of plasma membrane blebs (Figure 17A, 
magnified inset). On average, the total area of the cells shrank by 316±93 µm2 
(n=67) after exposure to BzATP (100 µM) for 6 min. Contraction of the cells 
caused by BzATP (100 µM) was significantly attenuated in the presence of 
A438079 (3 µM), H1152 (3 µM), chelerythrine (5 µM), and U73122 (3 µM) (Figure 
17B). These results suggest that P2X7-induced changes in the morphology of 
MSCs from postmenopausal women depend on PLC, PKC, and Rho-associated 
kinase. The involvement of PKC in cell shrinkage was confirmed using PMA (10 
µM). Like that observed for membrane cell blebbing, PMA (10 µM) also mimicked 
the effect of BzATP (100 µM) on cell retraction. A reduction of the total cell area by 
425±133 µm2 (n=32) was observed in the presence of PMA (10 µM), an effect that 
was completely reverted by CHL (5 µM, n=41), strengthening the involvement of 
PKC in cell shape changes (Figure 17B). P2X7-induced morphological changes in 
MSCs from postmenopausal women are mostly Ca2+-independent, because the 
cell shrinkage effect of BzATP (100 µM) was enhanced, rather than reduced, to 
511±56 µm2 (n=97) in the absence of extracellular Ca2+ (plus 1 mM EGTA) and 
depletion of internal Ca2+ stores with thapsigargin (2 µM) had no significant effect 
(316±74 µm2, n=79). 
Osteogenic commitment of MSCs from postmenopausal women is impaired 
as compared to younger females 
Cell viability/proliferation (given by the MTT assay) of postmenopausal MSCs 
grown in osteogenesis-inducing conditions gradually increase until day 28, a 
situation that was not different from that observed with the cells isolated from 
younger females (e.g., see Noronha-Matos et al., 2012). Significant (P<0.05) 
differences were, however, observed regarding the osteogenic differentiation 
profile between the two groups (Figure 18). Cell cultures from the younger group 
(age 14 yr, n=3) exhibited higher ALP activity normalized by the number of viable 
cells (MTT value) than the postmenopausal group (age 71±3 yr, n=18). ALP 
activity in the younger group of patients reached a maximum at day 14 (Figure 
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Figure 17. PLC, PKC and Rho-associated kinase are involved in cell retraction induced by 
activation of the P2X7 receptor in MSCs from postmenopausal women. (A) Representative 
confocal micrographs of postmenopausal MSCs loaded with Fluo-4NW, obtained at culture day 
7 just before and during perfusion with BzATP (100 μM). Arrows indicate high magnification 
plasma membrane blebs. Scale bars = 50 μm. Pseudocolor images represent [Ca2+]i levels; cell 
boundaries are best appreciated by differential interference contrast (DIC) microscopy. (B) 
Variation of cell area (μm2) after application of drugs as compared to the control situation 
(negative values indicate cell retraction). Bars represents pooled data from 3-5 individuals for a 
total of 67 cells (BzATP 100 μM), 57 cells (BzATP 100 μM plus A438079 3 μM), 59 cells 
(BzATP 100 μM plus CHL 5 μM), 42 cells (BzATP 100 μM plus U73122 3 μM), 29 cells (BzATP 
100 μM plus H1152 3 μM), 32 cells (PMA 10 μM), and 41 cells (PMA 10 μM plus CHL 5 μM). 
Error bars = S.E.M. *P<0.05 vs. control (before addition of drugs); **P<0.05 vs. BzATP or PMA 
alone. 
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18A), whereas in the postmenopausal group, ALP activity increased slowly, yet 
progressively, with incubation time until day 28.  
 
Activation of the P2X7 receptor on postmenopausal MSCs resumes the 
osteogenic differentiation profile detected in younger females 
The effects of the P2X7 receptor activation on osteoblast cell cultures have 
been addressed in several studies, often with conflicting results (for a review, see 
Burnstock et al., 2013). For instance, the P2X7 receptor has been implicated in 
osteogenesis promotion in newborn rats (Panupinthu et al., 2007) and mediates 
shockwave-induced osteogenic differentiation of MSCs from healthy human 
volunteers (Sun et al., 2013). Conversely, other researchers observed reductions 
in ALP activity and bone mineralization in osteoblast cultures isolated from 2-days-
old neonatal rats (Orriss et al., 2012). In SaOS-2 cells, a human osteosarcoma cell 
line, BzATP favoured osteoblast apoptosis (Gartland et al., 2001). This dispute 
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Figure 18. Activity of ALP in cell lysates of bone marrow-derived MSCs from young females 
(A) and postmenopausal women (B) exposed to BzATP (100 μM), A438079 (3 μM) and 
H1152 (3 μM) for 28 days. Ordinates are nanomoles of p-nitrophenol (pNP; at 405 nm) 
produced per minute from p-nitrophenylphosphate (pNPP) catalysed by ALP normalized by 
MTT values at given time points. Bone marrow samples were obtained from 3 young female 
patients (age 14 yr) and 5 postmenopausal women (age 71±3 yr); 3-8 replicas were performed 
in each individual experiment. Error bars = S.E.M. *P<0.05 vs. control. 
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prompted us to investigate the role of the P2X7 receptor on osteogenic 
differentiation of MSCs from postmenopausal women, given that the gain of 
function of this receptor has been associated with increased bone mass (Husted et 
al., 2013). 
Treatment of MSCs with BzATP (100 µM) significantly increased the ALP 
activity above the control level. This was verified in MSC cultures from 
postmenopausal women (Figure 18B), but not in those from younger females 
(Figure 18A). On the contrary, the P2X7 receptor antagonist, A438079, failed to 
modify the ALP activity in MSC cultures from postmenopausal women (Figure 
18B), when it was applied in a concentration (3 µM) that almost prevented 
osteogenic differentiation in cells from younger female patients (Figure 18A). 
Inhibition of Rho-kinase with H1152 (3 µM) significantly decreased the ALP activity 
measured in MSC cultures from both age groups (Figure 18A, B). The 
enhancement of ALP activity caused by BzATP (100 µM) in postmenopausal 
MSCs was significantly attenuated by blocking the P2X7 receptor with A438079 (3 
µM). Coapplication of BzATP (100 µM) with the Rho-associated kinase inhibitor, 
H1152 (3 µM), abolished the increase in ALP activity observed with the nucleotide 
alone in cells from both age groups (Figure 18A, B). These findings suggest that 
P2X7 receptor activation promotes osteogenic differentiation in MSCs from 
postmenopausal women through a mechanism that involves stimulation of Rho 
associated kinase. Data also indicate that P2X7 receptors are tonically activated 
by endogenous ATP in cells from young females, but the osteogenic differentiating 
tone of the P2X7 receptor seems to be impaired in MSC cultures from 
postmenopausal women, probably because the nucleotide does not reach high 
enough concentrations in the cell microenvironment to activate this receptor.  
Runx-2 and Osterix are important transcription factors involved in bone 
formation. Runx-2 is involved in osteoblastic differentiation and skeletal 
morphogenesis; it is essential for the maturation of osteoblasts and ossification, 
both intramembranous and endochondral. It binds to a number of enhancers and 
promoters, including osteocalcin, osteopontin, bone sialoprotein and type I 
collagen (Ducy et al., 1997; Kern et al., 2001). Osterix acts downstream of Runx-2 
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and is a zinc-finger-containing transcription factor, which is essential for embryonic 
osteoblast differentiation and bone formation (Nakashima et al., 2002). In this 
study, we collected total cell lysates for Runx-2 and osterix protein quantification 
by Western blot analysis. Western blot gels (Figure 19A, B) show that 
postmenopausal MSCs at culture day 7 and 21 express the two osteogenic 
differentiation markers, Runx-2 and Osterix. BzATP (100 µM) increased the 
expression of Runx-2 and osterix proteins from day 7 to 21 by ~452 and 226%, 
respectively (Figure 19C). In addition to the increments in ALP activity observed 
with BzATP, the ATP analogue increased the expression of important bone 
transcription factors, Runx-2 and Osterix, indicating that P2X7 receptor promotes 
osteogenic commitment of MSCs from postmenopausal women.  
P2X7 receptor activation promotes mineralization of postmenopausal MSC 
cultures 
The ultimate goal of bone-forming osteoprogenitors is the ability to mineralize 
the extracellular matrix via ALP activity. In this context, we performed 
histochemical assays using the Alizarin red staining at culture day 43 in order to 
identify extracellular calcium deposits corresponding to areas of mineralization of 
the cultures. We compared data obtained in the absence and in the presence of 
BzATP (100 µM) in MSCs from postmenopausal women and younger females. In 
control conditions, the total mineralized area (Figure 20A) and the total number of 
bone nodules formed per culture well (Figure 20B) were significantly higher in the 
young female group as compared to MSC cultures from postmenopausal women. 
Continuous application of BzATP (100 µM) significantly increased the total 
mineralized area and the total number of bone nodules formed per culture well in 
both age groups (Figure 20). The mineralization effect of the P2X7 receptor 
agonist was more notorious in the young female group, but BzATP (100 µM) was 
still capable of increasing by ~4-fold mineralization of MSCs cultures from 
postmenopausal women as compared to the control level. It is also worth noting 
that both total mineralized area and bone nodule formation in postmenopausal 
MSC cultures treated with BzATP (100 µM) overcame mineralization parameters 
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determined in control conditions (no drugs added) for the young female group 
(Figure 20). BzATP (100 µM)-induced mineralization of MSCs cultures was fully 
prevented in the presence of the selective P2X7 antagonist, A438079 (3 µM). 
Likewise, inhibition of the Rho-associated kinase with H1152 (3 µM) also 
abolished mineralization of the cultures caused by BzATP (100 µM). Interestingly, 
mineralization of the cultures was slightly reduced when A438079 (3 µM) and 
H1152 (3 µM) were applied alone (Figure 20); differences reached statistical 
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Figure 19. (A), (B) Western blot analysis of Osterix (58 KDa; A) and Runx-2 (59 KDa; B) 
transcription factors in MSCs from 3 postmenopausal women (age 75±8 yr) at culture day 7 
and 21: influence of BzATP (100 μM). β-Actin (45 KDa) was used as control. (C) Relative 
expression of Osterix and Runx-2 in postmenopausal MSCs as a percentage of control values 
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control values obtained in the absence of BzATP.  
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significance in the young female group, thus coinciding with the findings obtained 
for the ALP activity (see Figure 18). Data suggest that tonic activation of the P2X7 
receptor by endogenously released ATP favours mineralization of MSCs, via a 
mechanism involving downstream activation of Rho-associated kinase. 
DISCUSSION 
We present here data showing that activation of the P2X7 receptor in 
postmenopausal MSCs causes plasma membrane blebbing and the formation of 
large pores permeable to high-molecular-mass (up to 900 Da) compounds in a 
Ca2+-independent manner. Most notably, P2X7 receptors activation favoured 
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Figure 20. P2X7 receptor activation promotes mineralization of bone marrow-derived MSCs 
cultures from young females (age 14 yrold, n=3) and postmenopausal women (age 71±3 yr, 
n=18). Cultures were continuously exposed to BzATP (100 μM) in the absence and in the 
presence of A438079 (3 μM) or H1152 (3 μM), for 43 days; effects of H1152 (3 μM) and 
A438079 (3 μM) applied alone are also shown. Calcium deposition was assessed by the 
Alizarin red test. Results are expressed as total mineralized area (μm2) (A) and total number 
of bone nodules per culture well (B). Bars represent pooled data from n individual 
experiments. Error bars = S.E.M. *P<0.05 vs. control (no drugs added); **P<0.05 vs. BzATP 
alone; aP<0.05; bP<0.05 
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osteogenic commitment of postmenopausal MSCs measured as increases in 
alkaline phosphatase activity and in the expression of Runx-2 and Osterix 
transcription factors. Mineralization of postmenopausal MSC cultures in the 
presence of the P2X7 agonist, BzATP, resumed the pattern observed in MSC 
cultures from younger (14-yr-old) females. Results also support the involvement of 
PLC, PKC, and Rho-associated kinase downstream the P2X7 receptor activation 
as important mediators of osteogenic differentiation and mineralization of MSCs 
from both young females and postmenopausal women. Our findings emphasize 
the putative clinical implications of the P2X7 receptor and its downstream 
PLC/PKC/Rho kinase pathway in bone loss disorders.  
Previous reports implicate ATP, via the P2X7 receptor, in membrane zeiosis 
observed in hepatocyte (Nicotera et al., 1986), thymocyte (Zheng et al., 1991), and 
macrophage (Pelegrin and Surprenant, 2006; Verhoef et al., 2003) cell lines. This 
was more recently detected in osteoblasts from newborn rats (Panupinthu et al., 
2007). Here, we add compelling evidence showing that ATP and the preferential 
P2X7 receptor agonist, BzATP, favour the uptake of the high-molecular mass dye 
TO-PRO-3 (671 Da) in parallel to the formation of plasma membrane blebs and 
cell shrinkage in postmenopausal MSCs. Involvement of the nondesensitizing 
P2X7 receptor (Pelegrin and Surprenant, 2006; Verhoef et al., 2003) was 
confirmed by selectively blocking the effects of BzATP with A438079. In contrast 
to changes in [Ca2+]i transients (Soulet et al., 2005), blockade of the P2Y1 receptor 
with MRS 2179 was devoid of effect on BzATP-induced membrane cell blebbing 
and TOPRO-3 dye uptake, thus rejecting the involvement of ADP-sensitive 
receptors (namely the P2Y1 receptor) on postmenopausal MSCs membrane 
plasticity.  
Using osteoblasts from newborn rats, Panupinthu et al. (Panupinthu et al., 
2007) showed that blebbing was fully reversible on removal of BzATP and that 
cells respread with extension of pseudopods and peripheral ruffling. These 
observations imply a clearcut distinction between P2X7-induced blebbing in 
osteoprogenitors and apoptotic blebbing seen in osteoclasts. Moreover, reversible 
membrane plasticity most likely involves cytoskeletal tension generated by 
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actomyosin filaments, which has been implicated in osteogenic commitment of 
human MSCs (McBeath et al., 2004). Here, we proved that reversible P2X7-
induced membrane plasticity phenomena are also relevant in postmenopausal 
MSCs undergoing osteogenic differentiation.  
Our data support the hypothesis that P2X7-induced membrane blebbing and 
cell shrinkage involve downstream activation of PLC, PKC, and Rho-associated 
kinase in MSCs from postmenopausal women. Notably, BzATP-induced [Ca2+]i 
transients were also modified by inhibitors of PLC, PKC, and Rho-kinase, 
respectively U73122, CHL, and H1152. Inhibition of PKC with CHL affected 
predominantly the late component of BzATP induced [Ca2+]i response, which 
coincides with the timing expected for the occurrence of large-conductance pore 
formation due to prolonged exposure to P2X7 receptor agonists, as suggested 
previously (Faria et al., 2010). Data from this study are in agreement with previous 
findings demonstrating that Rho-kinase inhibition prevents membrane cell blebbing 
(Morelli et al., 2003; Panupinthu et al., 2007). Dependency on Rho-associated 
kinase activity has been detected in other cell types (Davies et al., 2000; Morelli et 
al., 2003; Verhoef et al., 2003), showing that this pathway has a broad influence 
spectrum on P2X7-induced zeiosis besides osteogenic differentiation. It has been 
demonstrated that PKC and Rho-kinase coexist on the same intracellular 
signalling pathway in porcine coronary artery (Kandabashi et al., 2003). Rho-A 
was also shown to be involved in PTH-stimulated PKC translocation and in IL-6 
promoter expression in the rat osteosarcoma cell line, UMR-106 (Radeff et al., 
2004). Focal adhesion and stress fibre formation stimulated by Thy-1 was PKC-α 
and Rho-A dependent in a rat astrocytic cell line (Avalos et al., 2009). Others 
showed the involvement of both P2X7 and PKC on large-conductance channel 
formation in 2BH4 cells and peritoneal macrophages using a patch-clamp 
technique (Faria et al., 2010). Regarding our belief that PLC functions downstream 
of P2X7 receptor activation, as it could be blocked by U73122, other researchers 
suggested the involvement of Gq-coupled receptor LPA1 in membrane cell 
blebbing that results from increases in DAG levels and PKC activation (Panupinthu 
et al., 2007). 
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Interestingly, we found that P2X7-induced morphological changes were largely 
independent of Ca2+ in postmenopausal MSCs, given that removal of extracellular 
Ca2+ (plus EGTA) and prevention of intracellular Ca2+ recruitment with thapsigargin 
failed to prevent blebbing. Previous reports detected a similar percentage of cells 
exhibiting membrane blebbing in the presence of physiological concentrations of 
Ca2+ and in a Ca2+-free buffer, but higher concentrations of BzATP were required 
in the former case, since low concentration of divalent cations favour the P2X7 
receptor activation (Panupinthu et al., 2007). The lack of Ca2+ involvement on 
morphological changes triggered by the P2X7 receptor in human MSCs differs 
from that observed in rats (Panupinthu et al., 2007), most probably because the 
human receptor lacks the calmodulin binding domain at the C terminus (Roger et 
al., 2010). Thus, most probably, membrane plasticity phenomena resulting from 
activation of the P2X7 receptor rely on the release of LPA from cell membranes 
through the action of PLD and PLA2 (Panupinthu et al., 2007 and 2008).  
Rho-associated kinase has been shown to cause phosphorylation of myosin 
regulatory light chain, which in turn controls actomyosin filament assembly and 
contraction (Coleman et al., 2001; Leverrier and Ridley, 2001). Here, we showed 
that postmenopausal MSCs undergoing osteogenic differentiation depend on 
morphological changes triggered by the P2X7–Rho-associated kinase axis. PKC 
and PLC are equally involved, since inhibition of these enzymes attenuates cell 
shrinkage. Other researchers have shown that rat osteoclast cell retraction 
induced by calcitonin is PKC dependent (Cheewatrakoolpong et al., 2005). In fact, 
PMA was able to induce postmenopausal MSC retraction, reinforcing the PKC 
involvement in this phenomenon. Contraction of cortical actomyosin filaments 
causes their focal detachment from the plasma membrane and increases 
cytoplasmic pressure, both of which lead to the formation of blebs. Since blebbing 
reflects vigorous actomyosin contraction, it is plausible that there may be a role for 
this phenomenon in cell migration or assembly of extracellular matrix by MSCs 
underlying osteogenic commitment in the bone microenvironment. Interestingly, 
most prevalent variants of P2X7 receptor resulting from alternative splicing have 
large deletions in the long C-terminal tail, which is critical for receptor 
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oligomerization, translocation to the plasma membrane, and functional coupling to 
intracellular signalling cascades (e.g., phospholipases, RhoA/ROCK, and epithelial 
membrane protein 2) and actin cytoskeleton involved in cell blebbing and pore 
formation (Cheewatrakoolpong et al., 2005). Variation of the P2X7 receptor 
structure may explain differential sensitivity to agonists, membrane permeability 
kinetics, and blebbing displayed by receptors expressed in different cell types. For 
the human receptor, a prevalent C-terminal truncated splice variant, P2X7B, has 
been described, which fails to trigger membrane permeabilization to large 
molecules (Adinolfi et al., 2010; Cheewatrakoolpong et al., 2005). While its 
association with bone remodelling is still controversial, data from the present study 
encourage further investigation, as truncated splice variants of the P2X7 receptor 
in MSCs might serve as fine descriptors of risk for bone mass loss and 
osteoporotic fractures, in parallel to the association described for single-nucleotide 
polymorphisms of the P2X7 receptor gene.  
Our findings clearly indicate that long-term activation of the P2X7 receptor with 
BzATP anticipates osteogenic differentiation and promotes mineralization of 
postmenopausal MSCs in culture. This was proven at early culture time points 
(e.g., day 4 and 7), as increases in ALP activity and in the amount of osteogenic 
transcription factors, such as Runx-2 and Osterix, led to increased formation of 
mineralized bone nodules afterward (culture day 43). This correlates with data 
using newborn rats to study skeletal development (Panupinthu et al., 2008). 
Likewise, increases of Runx-2 expression and osteogenic differentiation of murine 
MSCs were observed subsequent to mechanical stimulation (e.g., oscillatory fluid 
flow; Arnsdorf et al., 2009), via a RhoA-dependent mechanism involving 
deformation of the nuclear envelope and loosening of the chromatin. Participation 
of RhoA/ROCK and cytoskeletal dynamics also seems to be required for stretch-
induced tenogenic differentiation of human MSCs (Xu et al., 2011). Evidence 
gathered in this study links P2X7 receptor-induced osteogenic differentiation and 
mineralization of postmenopausal MSCs to Rho associated kinase, since both 
phenomena were abrogated by preincubation with the highly potent and specific 
Rho kinase inhibitor, H1152 (e.g., see Sasaki et al., 2002).  
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BzATP also promoted mineralization of cultured MSCs from young (14-yr-old) 
females through the P2X7 receptor/Rho-kinase pathway, although the effect in the 
younger group was much more exuberant than in postmenopausal women. 
Immunoreactivity against the P2X7 receptor was detected at early time points on 
MSCs from postmenopausal women, declining thereafter (7>21 days), whereas 
the opposite was found in MSCs from younger females (7<21 days) (Noronha-
Matos et al., 2012). The same was verified regarding ATP-induced [Ca2+]i 
transients (Noronha-Matos et al., 2012) and BzATP-evoked membrane blebbing 
(unpublished observations), which decreased significantly in postmenopausal 
MSCs from culture day 7 to 21. Differences in the P2X7 receptor expression and 
function might explain the changes in the mineralization potency of BzATP among 
the two age groups. One cannot, however, exclude the fact that the actions of 
adenine nucleotides are balanced through concurrent expression of specific 
NTPDases, namely NTPDase1, -2, and -3, whose levels raise in postmenopausal 
MSCs, as these cells differentiate (7<21 days; Noronha-Matos et al., 2012). 
Preliminary data from our group demonstrate that extracellular inactivation of 
BzATP is faster in more differentiated MSC populations. The regulatory potential 
of subtype specific NTPDases on P2X7 receptor commitment of MSCs to 
osteogenic differentiation deserves attention in future studies (see paper 3 below). 
Despite this constraint, we were able to show that activation of the P2X7–Rho-
kinase axis enables MSCs from postmenopausal women to differentiate into 
osteoblasts, resuming mineralization to levels observed in young females.  
Controlled ATP release from human osteoblasts was first described by 
Romanello et al. (Romanello et al., 2001), and since then, it has been a widely 
investigated area. Evidence now suggests that stimuli inducing bone formation 
and accelerated fracture healing (like mechanical loading, ultrasound, 1,25(OH)2 
vitamin D3, and bisphosphonates) promote ATP release from osteoblast-like cells 
(Alvarenga et al., 2010; Biswas and Zanello, 2009; Hayton et al., 2005; Romanello 
et al., 2006; Rumney et al., 2012). Interestingly, the amount of ATP released from 
osteoblasts depends on their differentiation state, with mature bone-forming cells 
releasing up to 7-fold more than proliferative immature cells (Orriss et al., 2009). 
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Despite the controversy regarding the mechanisms controlling ATP release from 
osteoprogenitor cells, our data indicate that these provide enough ATP to activate 
P2X7 receptors in young women, but the P2X7 receptor tonus may be severely 
affected in postmenopausal MSC cultures.  
In summary, this study provided valuable information concerning the role of the 
P2X7 receptor on osteogenic differentiation of MSCs from postmenopausal 
women, which, together with previous findings from our group, led us to propose 
that adenine and uracil nucleotides (Noronha-Matos et al., 2012) and their 
derivatives (such as adenosine; Costa et al., 2011) may act as potential targets for 
therapeutic management of bone disorders leading to increased bone loss, 
osteoporosis, and fracture risk. 
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Inhibition of NTPDase3 on bone marrow-derived mesenchymal stem cells 
may be a novel therapeutic strategy to increase bone formation in 
postmenopausal women 
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ABSTRACT 
The ability of bone marrow-derived mesenchymal stem cells (MSCs) to 
differentiate into bone-forming osteoblasts is compromised in postmenopausal 
women. Nucleotides, via several P2 purinoceptors, are important regulators of 
osteogenic differentiation of MSCs. The endogenous actions of nucleotides may 
be counteracted by breakdown through specific NTPDases. Here, we investigated 
the expression and function of specific NTPDases on osteogenic differentiation 
and mineralization of MSCs from young females and postmenopausal women. In 
the younger group, nucleotides progressively increased intracellular [Ca2+]i and 
osteogenic differentiation of MSCs with the time in culture (7<21 days); parallel 
increases in alkaline phosphatase activity and in the expression of osteogenic 
transcription factors (Runx-2 and Osterix) and P2 purinoceptors (e.g, P2X7 and 
P2Y6), were also observed. Conversely, we found that intracellular [Ca2+]i and 
osteogenic differentiation markers became less evident with time (7<21 days) in 
cultures of MSCs from postmenopausal women. The extracellular hydrolysis of the 
nucleotides was faster in less proliferative and more differentiated cell populations, 
in agreement with increases in the expression of NTPDases1, -2 and -3 in 
differentiating postmenopausal MSCs (7<21 days). A major difference was found 
in the expression of NTPDase3 among MSCs from young females and 
postmenopausal women. Selective blockade of overexpressed NTPDase3 in 
postmenopausal MSCs with PSB 06126 (3 µM) or with the antibody hN3-B3s (0.5 
µg/ml) led to increases in extracellular ATP levels and to osteogenic differentiation 
and mineralization of the cultures, via the activation of P2X7 and P2Y6 receptors. 
Data suggest that inhibition of NTPDase3 on MSCs may be a novel therapeutic 
strategy to increase bone formation in postmenopausal women. 
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INTRODUCTION 
Bone marrow-derived mesenchymal stem cells (MSCs) present an extensive 
proliferative potential and are characterized by their ability to differentiate into 
various cell lineages (e.g., osteoblasts, adipocytes and chondrocytes). Among 
bone marrow stromal cells, mesenchymal stem cells (MSCs) are a rare population 
of non-haematopoietic stromal cells, which have the potential to differentiate into 
the osteoblast lineage, when incubated under proper stimuli (Bobis et al., 2006; 
Conget et al., 1999; Costa el al., 2011; Pittenger et al., 1999). However, their 
ability to differentiate into osteoblasts is compromised in postmenopausal women 
as compared to younger female patients (Noronha-Matos et al., 2012), leading to 
unbalanced bone resorption by osteoclasts. 
Extracellular adenine nucleotides, like ATP, play important roles in the 
differentiation and function of osteoblasts. Both MSCs and differentiated 
osteoblasts constitutively release ATP when submitted to mechanical stress like 
weight bearing load, ultrasound stimulation or under pathological conditions, such 
as hypoxia and inflammation (Alvarenga et al., 2010; Brandao-Burch et al., 2012; 
Orriss et al., 2009). Their specific targets include several subtypes of P2Y (G-
protein coupled) and P2X (ligand-gated ion channels) purinoceptors (Romanello et 
al., 2005). We provided evidence showing that, besides ATP, uracil nucleotides 
are also important regulators of osteogenic differentiation of MSCs through the 
activation of UDP-sensitive P2Y6 receptors (Noronha-Matos et al., 2012). This 
study also confirmed that the actions of adenine and uracil nucleotides were 
balanced through specific NTPDases, which regulate their extracellular breakdown 
and, thereby, determine whether osteoblast progenitors are driven into 
proliferation or differentiation. Our findings showed that MSCs from 
postmenopausal women express ecto-NTPDase1 and -3 at all differentiation time 
points, whereas NTPDase2 only becomes evident in less proliferative and more 
differentiated cells.  
Regarding the substrate preference, human NTPDase1 (also called CD39 or 
apyrase, EC 3.6.1.5) dephosphorylates ATP directly into AMP, with little 
accumulation of ADP. NTPDase2 (CD39LI, EC 3.6.1.3) is a preferential nucleoside 
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triphosphatase, leading to minimal accumulation of monophosphates, because it 
hydrolyses diphosphates 10-15 less efficiently than triphosphates (Kukulsky et al., 
2005). NTPDase3 (CD39L3 or HB6) and NTPDase8 (hepatic ATPDase) are 
functional intermediates between NTPDase1 and NTPDase2 (Kukulsky et al., 
2005). With the exception of NTPDase8, the apparent Km values of human 
NTPDases for adenine nucleotides as substrates are in the low micromolar range; 
higher Km values are obtained for the hydrolysis of uracil nucleotides, which may 
influence the relative potency of UTP/UDP compared to ATP/ADP. Among human 
MSCs, osteoprogenitors are distinguished because they express high amounts 
(>95%) of ecto-5’-nucleotidase/CD73 (Liu et al., 2009; see also Noronha-Matos et 
al., 2012), the rate limiting enzyme for adenosine formation from the catabolism of 
relased adenine nucleotides  (Costa et al., 2011). Adenosine is also an important 
regulator of osteogenic differentiation of human MSCs through the activation of A1, 
A2A and A2B receptors depending on the proliferation status of the cells (Costa et 
al., 2011). Because of their involvement in physiological processes, namely blood 
clotting, vascular inflammation, immune reactions and certain types of cancer, 
NTPDases are now considered as potential drug targets (Gendron et al., 2002).  
Taking into consideration our findings on the kinetics of the extracellular 
catabolism of adenine/uracil nucleotides and adenosine formation via ecto-
nucleotidases in human MSCs from postmenopausal women (Costa et al., 2011; 
Noronha-Matos et al., 2012), we hypothesized that differential expression and/or 
activity of specific NTPDases could contribute to the differences in osteogenic 
differentiation detected between young females and postmenopausal women. 
Membrane compartmentalization of ecto-enzymes, nucleotide releasing sites and 
purinoceptors has been demonstrated (reviewed by Yegutkin, 2008). This feature 
emphasizes the value of gathering information concerning extracellular 
metabolism and subsequent delivery of nucleotides to specific P1 and P2 
purninoceptors in order to antecipate their pathophysiological relevance on 
osteogenesis, prompting for new pharmacological targets to control bone loss. 
Therefore, we consider worth to investigate the expression of NTPDase1, -2 and -
3 and ecto-5’-nucleotidase along with certain P2 purinoceptors subtypes, by 
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immunofluorescence confocal microscopy in cultured MSCs derived from the bone 
marrow of thirteen postmenopausal women (56-83 years old) undergoing total hip 
arthroplasty and nine younger females (13-40 years old). We also studied the 
variations of extracellular ATP accumulation and breakdown of adenine and uracil 
nucleotides during osteogenic differentiation of MSCs from both age groups. The 
effects of selective P2 purinoceptor agonists and NTPDase inhibitors on 
osteogenic differentiation and mineralization of MSCs from postmenopausal 
women as compared to younger females were inferred by changes in (1) alkaline 
phosphatise (ALP) activity, (2) the expression of osteogenic transcription factors, 
Runx-2 and Osterix, and (2) calcium deposition in mineralized bone nodules 
(Alizarin Red staining). The ability of ATP, UTP and UDP to trigger intracellular 
[Ca2+]i transients with respect to the growth state of primary MSCs was evaluated 
by confocal microscopy using the fluorescent Ca2+ indicator, Fluo4-NW.  
MATERIALS AND METHODS 
Reagents and antibodies 
Adenosine (ADO), ADP, ATP, 3,4-dihydroxy-9,10-dioxo-2-anthracenesulfonic 
acid sodium salt (Alizarin Red Staining), apyrase (Grade VI from potato, EC 
3.6.1.5), 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), 4-
nitrophenyl phosphate, uridine, UDP and UTP were obtained from Sigma-Aldrich 
(St. Louis, MO, USA). 3-[[5-(2,3-Dichlorophenyl)-1H-tetrazol-1-yl]methyl]pyridine 
hydrochloride (A438079), 6-N,N-Diethyl-β-γ-dibromomethylene-D-adenosine-5′-
triphosphate trisodium salt hydrate (ARL 67156), N,N’’-1,4-butanediyl-bis-[N’-(3-
isothiocyanatophenyl) thiourea (MRS 2578), 1-Amino–4-(1-naphthyl) 
aminoanthraquinone-2-sulfonic acid sodium salt (PSB 06126) were obtained from 
Tocris Cookson Inc. (Bristol, UK). 2-Methoxy-6-chloro-9-(4-bis[β-chloroethyl] 
amino-1-methylbutylamino) acridine dihydrochloride (quinacrine mustard 
dihydrochloride) was obtained from Fluka (Buchs, Switzerland). The ATP 
Bioluminescence Assay Kit HS II was obtained from Roche Applied Science 
(Mannhelm, Germany). Dimethylsulphoxide (DMSO) and Folin phenol reagent 
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were from Merck (Darmstadt, Germany). Tetrabutylammonium was obtained from 
Waters Corporation (Milford, MA, USA).  
All primary antibodies used in this study have previously been validated: anti-
P2Y1,  anti-Runx-2 (M-70) and anti-Osterix (M-15) were from Santa Cruz (Santa 
Cruz, CA); anti-P2Y2, anti-P2Y4, anti-β-Actin and horseradish-peroxidase-
conjugated secondary antibodies were from AbCam (Cambridge, UK); anti-P2Y6 
and anti-P2X7 were purchased from Alomone (Jerusalem, Israel); anti-osteocalcin 
and anti-Type I collagen were from AbD Serotec (Kidlington, Oxford, UK). The 
development and specificity of anti-human NTPDase2 and NTPDase3 has been 
reported previously (Dranoff et al., 2004; Munkonda et al., 2009). Genetic 
immunization protocol was carried out with plasmids (pcDNA3 for human 
NTPDase1 and pcDNA3.1 for human CD73) encoding each protein using New 
Zealand rabbits for antibodies against human NTPDase1 and Hartley guinea pigs 
for human CD73 antibodies; Hartley guinea pigs and New Zealand rabbits were 
obtained from Charles River Laboratories (Quebec City, Canada). NTPDase and 
CD73 antibodies were developed in the Centre de Recherche en Rhumatologie et 
Immunologie, University of Laval, Québec, QC, Canada (see 
http://ectonucleotidases-ab.com for further details). Alexa Fluor 488-labeled anti-
rabbit, Alexa Fluor 568-labeled anti-mouse, Alexa Fluor 653-labeled anti-goat and 
the fluorescent calcium indicator Fluo-4NW were supplied by Molecular Probes 
(Invitrogen, Carlsbad, CA).  
Cell cultures and phenotypic characterization 
Human bone marrow samples were obtained from the neck of the femur of 
consecutive female patients (56-83 years old, n=13) undergoing total hip 
arthroplasty as a result of primary osteoarthrosis, and from younger female 
patients (13-40 years old, n=9) requiring bone engraftment for spinal fusion to 
correct scoliosis or fracture osteosynthesis. Handling of bone marrow samples and 
culture of adherent cells was performed during 10-15 days (until near confluence), 
as previously described (Noronha-Matos et al., 2012; 2014). First subcultures 
were maintained for 43 days in standard culture medium [α-minimal essential 
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medium (α-MEM) plus 10% foetal bovine serum, 100 U/mL penicillin, 100 μg/mL 
streptomycin and 2.5 μg/mL amphotericin B] supplemented with 50 μg/mL 
ascorbic acid, 10 mM β-glycerophosphate and 10 nM dexamethasone to promote 
osteogenic differentiation. Bone marrow-derived mesenchymal stem cells (MSCs) 
cell cultures were established for 35 to 43 days in the absence (control) or in the 
presence of the test drugs that were added to the culture medium at day 1 (Costa 
el al., 2011; Noronha-Matos et al., 2012). Drugs were renewed in the culture at 
each medium change, i.e. twice a week.  
Phenotypic characterization of the cells (first subculture) was performed by flow 
cytometry (Noronha-Matos et al., 2012). These cells exhibited positive 
immunoreactivity against CD105 (SH2), CD29 (integrin ß1) and CD117 (tyrosine-
protein kinase Kit), which have been identified as surface markers of bone 
marrow-derived MSCs (Baddoo et al., 2003; Bobis et al., 2006; Boiret et al., 2005; 
Cognet and Minguell, 1999; Dennis et al., 2002; Gronthos et al., 2003; Pittenger et 
al., 1999). Conversely, the cells were negative for haematopoietic surface 
markers, like CD14 and CD45, which have been extensively used as a good 
argument to distinguish bone marrow haematopoietic cells from mesenchymal 
stem cells (Baddoo et al., 2003; Pittenger et al., 1999). Thus, first passage plastic-
adherent human bone marrow cells obtained under the present experimental 
conditions are highly enriched in multipotent MSCs. 
Viability/proliferation and osteogenic differentiation of bone marrow MSCs 
Cell viability/proliferation was evaluated by the MTT assay (Costa el al., 2011; 
Noronha-Matos et al., 2012; 2014). Data from the MTT assay correlates positively 
with the results measuring cell proliferation from total DNA quantification per 
culture well (see e.g. Noronha-Matos et al., 2012). Osteogenic differentiation of 
bone marrow-derived MSCs was inferred as increases in alkaline phosphatase 
(ALP) activity and in the expression of osteogenic transcription factors, namely 
Runx-2 and Osterix. ALP activity was determined in cell lysates by colorimetric 
determination of p-nitrophenyl phosphate (PNP) hydrolysis, as described 
previously (Costa et al., 2011; Hoemann et al., 2009; Noronha-Matos et al., 2012; 
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2014); obtained values were expressed in nmol of PNP per minute normalized by 
the MTT absorbance (nmol min−1 MTT−1) (Noronha-Matos et al., 2012). Levels of 
Runx-2 and Osterix proteins were determined by Western blot analysis at culture 
days 7 and 21 (Noronha-Matos et al., 2014). Equal protein amounts (10 µg) 
loaded into SDS-PAGE (10%) gels were transferred onto a polyvinylidenifluoride 
membrane using a Mini-Protean Tetra Cell coupled to a Mini-Trans-Blot module 
(Bio-Rad, Hercules, CA, USA). Blocked membranes were incubated with anti-
human primary antibodies [1:200: anti-Runx-2 (M-70, rabbit), anti-Osterix (M-15, 
goat)]. β-Actin (rabbit) was used as control.  The peroxidase detection system 
(1.25 mM luminol, 0.2 mM coumaric acid, 0.1M Tris pH 8.5, 0.032% hydrogen 
peroxide) was used for visualization of the immunoreactivity. Gels were analysed 
using a gel blot imaging system (ChemiDoc MP, Bio-Rad, Hercules, CA, USA). At 
culture day 43, calcium deposition in mineralized nodules was revealed by the 
Alizarin Red staining and photographed using a microscope (Zeiss Axiophot, 
Oberkochen, Germany) equipped with CCD camera (CoolSnap HQ, Ropers Inc., 
Tucson, AZ, USA) running an image acquisition software (MetaFluor 6.3, 
Photometrics, Tuczon, AZ, USA) (Costa el al., 2011; Noronha-Matos et al., 2014). 
Images were exported to Image J 1.37c software (NIH, Bethesda, MD, USA) for 
quantification of the area of bone-nodules. Results were expressed in total 
mineralized area per μm2 and total number of bone nodules per culture well 
(Brandao-Burch et al., 2005; Noronha-Matos et al., 2012; 2014).  
Single-cell [Ca2+]i transients by confocal microscopy 
Primary human MSCs were seeded into 35 mm dishes at a density of 2×104 
cells/mL and allowed to grow for 7 and 21 days in supplemented -MEM medium. 
Intracellular [Ca2+]i oscillations were evaluated in cells loaded with the fluorescent 
Ca2+ indicator, Fluo-4NW (2.5 µM), as previously described (Noronha-Matos et al., 
2012; 2014). Briefly, culture dishes were mounted on the stage of a laser-scanning 
confocal microscope (Olympus FV1000, Tokyo, Japan) and perfused continuously 
(1 mL/min) with gassed (95% O2 + 5% CO2) Tyrode’s solution (pH=7.4) containing 
(mM): NaCl 137, KCl 2.7, CaCl2 1.8, MgCl2 1, NaH2PO4 0.4, NaHCO3 11.9 and 
3. Original Research Papers 
 
PhD thesis – José Bernardo Noronha Matos (2011-2014) 163  
glucose 11.2, at 37ºC. Test drugs were delivered using a multichannel perfusion 
system (ValveLink8.2; Digitimer, Welwyn Garden City, UK). [Ca2+]i transients were 
calibrated to the maximal calcium load produced by the Ca2+ ionophore, ionomycin 
(5 µM, 100% response) (Henriksen et al., 2006; Noronha-Matos et al., 2012; 
2014).  
Immunofluorescence staining 
Human bone marrow-derived MSCs were allowed to grow in chamber slides for 
7 or 21 days. Paraformaldehyde fixed cells were incubated, in the dark for 2 hours, 
with the following primary antibodies: NTPDase1 1:150 (hN1-9LI4, rabbit), 
NTPDase2 1:200 (hN2-Kw3I4, rabbit), NTPDase3 1:200 (hN3-B3S, mouse), ecto-
5’-nucleotidase 1:300 (h50NT-2CI4, guinea-pig), P2Y2 1:150 (rabbit), P2Y4 1:75 
(rabbit), P2Y6 1:75 (rabbit), P2X7 1:75 (rabbit), osteocalcin 1:75 (rabbit), and 
collagen type I 1:50 (rabbit). Alexa Fluor 488 (anti-rabbit), Alexa Fluor 568 (anti-
mouse) and Alexa-Fluor 649 (anti-guinea pig) were applied as secondary 
antibodies for 1 h in the dark. Glass slides were mounted with VectaShield 
medium and stored at 4ºC. Observations were performed and analysed with a 
laser-scanning confocal microscope (Olympus FV1000, Tokyo, Japan) (Alqallaf et 
al., 2009; Costa et al., 2011; Noronha-Matos et al., 2012; 2014).  
Kinetic experiments and HPLC analysis 
The kinetics of inactivation of ATP, UTP and UDP in human primary MSC 
cultures was studied at days 7 and 21, at 37ºC (three replicas were performed in 
each individual experiment) (see e.g., Costa et al., 2011; Noronha-Matos et al., 
2012). After a 30-min equilibration period, cells were incubated with 100 µM of 
ATP, UTP, or UDP added to the culture medium in the conditions referred above 
(zero time). Samples (75 μl) were collected from each well at different times up to 
30 min for high-performance liquid chromatography (HPLC, LaChrom Elite, Merck, 
Frankfurt, Germany) analysis of the variation of substrate disappearance and 
product formation. Aliquots of 20 µl of collected samples were used for nucleotide 
analysis. Concentrations of the substrates were plotted as a function of time 
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(progress curves). Half-degradation times of ATP, UTP, or UDP were calculated 
as previously described (Costa et al., 2011, Noronha-Matos et al., 2012). The 
enzymatic activity was normalized to the amount of viable cells given by the MTT 
assay (see e.g., Noronha-Matos et al., 2012). The spontaneous degradation of 
adenine and uracil nucleotides at 37ºC in the absence of the cells was negligible 
over 30 min. At the end of the experiments, the remaining incubation medium was 
collected and used to quantify the lactate dehydrogenase (LDH, EC 1.1.1.27) 
activity (Keiding et al., 1974). The negligible activity of LDH in the samples 
collected at the end of the experiments is an indication of the integrity of the cells 
during the experimental period. 
Intracellular ATP staining with quinacrine 
Quinacrine is a weak-base acridine derivative that binds ATP with high affinity 
and specificity. When excited by light at 476 nm it emits fluorescence in the 500-
540 nm range and it has been widely used to visualize ATP-containing subcellular 
compartments in living cells (Irvin and Irvin, 1954; Orriss et al., 2009). MSCs were 
seeded on 35 mm glass bottom dishes (FluoroDish®, World Precision 
Instruments), at a density of 2x104 cells/mL, and maintained in culture for 7 days. 
On the day of the experiment, cultured cells were washed twice with PBS before 
incubation with 30 μM quinacrine for 1 h, at 37ºC; cells were washed twice more 
and 150 µL of PBS were added per culture dish. Culture dishes were then 
mounted on a thermostatized perfusion chamber at the stage of an inverted laser-
scanning confocal microscope (Olympus FV1000, Tokyo, Japan) equipped with a 
20× magnification objective lens (LUCPLFL 20xPH; N.A. 0.45). Quinacrine 
fluorescence was detected in the time-lapse mode with FluoView Advanced 
Software (Olympus). Quinacrine was excited with the 488 nm Multi-line Ar laser. 
The emitted fluorescence was detected at 510-560 nm using the scanner of the 
confocal microscope (Olympus FV1000, Tokyo, Japan) (Brandao-Burch et al., 
2012; Pinheiro et al., 2013). 
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Extracellular ATP quantification by bioluminescence 
Extracellular ATP was detected with the luciferin-luciferase ATP 
bioluminescence assay kit HS II (Roche Applied Science, Indianapolis, Indiana, 
USA) using a multi detection microplate reader (Synergy HT, BioTek Instruments, 
Vermont, USA), as described elsewhere (Pinheiro et al., 2013). Briefly, cells were 
seeded into 96-well microplates, at 2x104 cells/mL density, for 7 or 21 days (three 
replicas were performed in each individual experiment). At the beginning of the 
experiment, cells were washed twice with Tyrode’s solution and allowed to 
equilibrate for 30 min, at 37ºC. After equilibrium, the cells were washed again and 
incubated with Tyrode’s solution in the absence or in the presence of test drugs. 
After a 30-min time period, the incubation fluid was removed and snap-frozen in 
liquid nitrogen. Before adding the luciferin-luciferase mixture, collected samples 
were defrosted till 25ºC according to the manufacturer instructions. Sample 
bioluminescence was compared to external ATP standards prepared daily within 
the same concentration range; all samples were run in duplicate. Results are 
expressed as pmol of ATP per 30 min per well. The remaining incubation medium 
was used to quantify the lactate dehydrogenase (LDH, EC 1.1.1.27) activity 
(Keiding et al., 1974), in order to evaluate cell integrity during the experimental 
period (see e.g. Pinheiro et al., 2013). 
Presentation of data and statistical analysis 
Results presented in this study are from bone marrow samples obtained from 
thirteen postmenopausal women (56 - 83 years old, n=13) and from nine younger 
females (13-40 years old, n=9). For each experiment and assay, 3-8 replicas were 
accomplished. Data are expressed as mean ± S.E.M. from an n number of 
individual experiments. Data from different individuals (from the same age group) 
were evaluated using one-way analysis of variance (ANOVA) and no significant 
differences in the pattern of cell behaviour were found. Statistical differences found 
between control and drug-treated cultures were determined by Bonferroni´s 
method. Values of P<0.05 were considered to represent significant differences. 
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Declaration of ethical approval 
Informed consent to use the biological material, that would be otherwise 
discarded, was obtained. All procedures were approved by the Ethics Committees 
of Centro Hospitalar de Vila Nova de Gaia – Espinho (University Hospital), 
Gabinete Coordenador de Investigação / DEFI – Centro Hospitalar do Porto (CHP) 
and of Instituto de Ciências Biomédicas Abel Salazar (Medical School) of the 
University of Porto. The investigation conforms to the principles outlined in the 
Declaration of Helsinki.  
RESULTS 
Osteogenesis is compromised in MSC cultures from postmenopausal 
women 
Human MSCs (first subculture) from young females (13-40 years) and 
postmenopausal women (56-79 years) were allowed to grow for 28 days in an 
osteoblast-inducing medium. During this period, cell cultures were characterized 
for osteogenic differentiation measured as increases in ALP activity (Figure 21A) 
and in the expression of osteogenic transcription factors, such as Runx-2 and 
Osterix (Figure 21B and 21C). Calcium deposits corresponding to areas of 
mineralization of the extracellular matrix were evaluated by the Alizarin red 
histochemical staining at culture day 43 (Figure 21D).   
Cell cultures from the younger group (13-40 years, n=9) exhibited much higher 
ALP activity than the postmenopausal group (56-79 years, n=9) (Figure 21A). The 
divergence in ALP activity found between the two age groups do not reflect 
differences in cell proliferation, since cell growth rate profiles of patients with 
different ages were very similar (see e.g. Noronha-Matos et al., 2012). 
Total cell lysates from MSC cultures of the two age groups were collected for 
Runx-2 and Osterix protein quantification by Western blot analysis at culture day 
21. The typical Western blot gels depicted in Figure 21 show that Runx-2 and 
osterix proteins were less abundant in postmenopausal women (60-83 years) as 
compared to younger females (31-39 years) (Figure 21B and 21C). This difference 
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Figure 21. Osteogenic differentiation of human bone marrow-derived mesenchymal stem cells 
(MSCs, first subculture) grown in an osteoblastic-inducing medium during 43 days. Bone 
marrow specimens were obtained from female patients with 56-79 years (postmenopausal 
group, n=9, gray bars) and 13-40 years (control group, n=9, white bars) (see Materials and 
Methods section). 
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(28 and 38% for Runx-2 and Osterix, respectively) reached statistical significance 
(P<0.05) in the case of the Osterix. Decreases in the expression of Runx-2 and 
osterix osteogenic transcription factors may explain the reduction of ALP activity 
measured in postmenopausal MSC cultures (Ducy et al., 1997; Franceschi and 
Xiao, 2003; Kern et al., 2001; Nakashima et al., 2002; Paredes et al., 2004; 
Selvamurugan et al., 1998) (see Figure 21A). 
The ability to mineralize the extracellular matrix, via ALP activity, measured as 
the total mineralized area per culture well given by the Alizarin red histochemical 
staining at day 43, was reduced (P<0.05) in postmenopausal women (59-83 years, 
n=6) as compared to MSC cultures from younger females (13-39 years, n=4)   
(Figure 21D). Overall, these results show that the osteogenic commitment of 
MSCs from postmenopausal women is impaired as compared to that observed in 
cells from younger females.  
Differences in the expression of ionotropic P2X7 and metabotropic P2Y2-6 in 
MSCs from young females and postmenopausal women 
MSCs were allowed to grow in chamber slices for 7 and 21 days in osteogenic-
inducing medium. Figure 22A shows that, in younger females, the expression of 
osteogenic-promoting receptors, like P2X7 and P2Y6, increase with the time (7<21 
days) as cells differentiate in culture. On the contrary, immunoreactivity for P2Y2 
and P2Y4 receptors decreased from day 7 onwards, becoming practically 
undetectable on culture day 21 (Figure 22A). This pattern changed dramatically in 
Figure 21. (Continued) Panel (A) represents the activity of alkaline phosphatase (ALP) in cell 
lysates; results are expressed in nanomoles of p-nitrophenol produced per min per µg of total 
protein at certain time points. Panel (B) shows typical Western blot gels for Runx-2 (59 KDa) 
and Osterix (58 KDa) transcription factors in MSCs from young females (31-39 years) and 
postmenopausal women (60-83 years) at culture day 21; β-Actin (45 KDa) was used as an 
internal control.  Panel (C), relative expression of Runx-2 and Osterix as a percentage of 
control detected in young females and postmenopausal women. Panel (D) represents matrix 
mineralization of MSC cultures (first subculture) at day 43. Bone marrow samples were 
obtained from female patients with 59-83 years (postmenopausal group, n=6, gray bar) and 13-
39 years (control group, n=4, white bar). Calcium deposition was assessed by the Alizarin red 
test; typical micrographs evidencing bone nodules formation (red-brownish spots) are shown in 
the two right hand side panels (scale bar is 100 µm). Results are expressed as total 
mineralized area per culture well in μm2. Bar graphs represent mean ± S.E.M. *P<0.05 
represent significant differences between the two age groups. 
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MSCs from postmenopausal women (Figure 22B). Although the expression of 
P2X7 and P2Y6 remained fairly constant as cultures progress (a slight decrease 
was observed in the case of the P2X7 receptor), the immunoreactivity against 
P2Y2 and P2Y4 receptors was more evident on day 21 compared to culture day 7. 
The preferential expression of the ATP- and UTP-sensitive inhibitory P2Y2 and 
Figure 22. Immunocytochemical detection of P2X7, P2Y2, P2Y4 and P2Y6 receptors on human 
primary bone marrow-derived mesenchymal stem cells (MSCs, 1st subculture) from female 
patients with (A) 13-36 years (control group, n=3) and (B) 56-79 years (postmenopausal group, 
n=5-6). Shown is the time-related immunoreactivity fluorescence detection by confocal 
microscopy of MSCs allowed to grow for 7 and 21 days in an osteoblast-inducing medium. 
Cells grown in eight-well chamber slides were processed for immunocytochemistry in parallel 
and were visualized keeping unaltered the settings of the confocal microscope throughout the 
procedure. For further details on immunofluorescence labelling see Materials and Methods 
section. Images are representative of three to five independent experiments. Scale bar is 150 
µm. 
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P2Y4 receptors on differentiated postmenopausal MSCs resembles that observed 
in rat primary osteoblasts (Orriss et al., 2006).    
Age-related changes in intracellular [Ca2+]i signals caused by ATP and uracil 
nucleotides (UTP and UDP) in MSCs  
Taking into consideration the variation of P2 purinoceptors expression along 
osteogenic differentiation of MSCs from both age groups, we tested whether these 
differences impacted on cells function. MSCs from young females (13-36 years) 
and postmenopausal women (56-79 years) cultured for 7 or 21 days were loaded 
with the intracellular fluorescence calcium indicator, Fluo4-NW, before being 
challenged with 100 µM ATP, UTP and UDP on the stage of the confocal 
microscope (Figure 23).  
At culture day 7, all nucleotides tested significantly (P<0.05) increased [Ca2+]i in 
MSCs from postmenopausal women, but these compounds were much less 
effective in the cells collected from younger females. Superfusion of 7-day MSC 
cultures from postmenopausal women with ATP (100 µM, Figure 23A) elicited a 
fast [Ca2+]i rise, which typically peaked 40 sec after nucleotide addition and 
decayed back to baseline within 1-2 min; a second progressive, but of much lower 
amplitude, ATP-induced [Ca2+]i rise was observed following the initial high-
magnitude [Ca2+]i transient (see also Noronha-Matos et al., 2012). Under similar 
experimental conditions, both UTP (100 µM, Figure 23B) and UDP (100 µM, 
Figure 23C) triggered sustained increases in [Ca2+]i that typically peaked 2-3 min 
after application of uracil nucleotides and decayed back to baseline after drug 
washout. It is worth noting that UDP-induced [Ca2+]i rise had a higher magnitude 
than that caused by UTP when both signals were calibrated for the maximum 
[Ca2+]i load produced by ionomycin (5 µM).        
In MSCs from postmenopausal women, intracellular [Ca2+]i responses caused 
by ATP, UTP and UDP were strikingly decreased with time in culture (7>21 days) 
(cf. Noronha-Matos et al., 2012), yet the opposite was verified in cells from 
younger females (Figure 23). That is, more differentiated MSCs from 
postmenopausal women were less responsive to stimulation by ATP and uracil 
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Figure 23. Effects of ATP, UTP and UDP (100 µM) on intracellular [Ca2+]i oscillations in human 
primary bone marrow-derived mesenchymal stem cells (MSCs, 1st subculture) from female 
patients with 13-36 years (control group) and 56-79 years (postmenopausal group). Cells were 
allowed to grow in culture for 7 and 21 days in an osteoblast-inducing medium. Cells were 
loaded with the fluorescent calcium indicator, Fluo-4NW (2.5 µM, in PBS plus 2.5% pluronic 
acid) for 45 min at 37ºC.  
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nucleotides, despite the fact that these cells express higher amounts of P2 
purinoceptors (see Figure 22B). In contrast to the divergence between nucleotide-
induced [Ca2+]i responses and P2 receptors expression in MSCs from 
postmenopausal women, we observed that [Ca2+]i transients produced by 100 µM 
ATP, UTP and, in particular, UDP, corresponded to evident gains of expression of 
P2X7 and P2Y6 receptors responding to ATP and UDP, respectively, when 
comparing 7-day and 21-day cultures from younger females.        
Nucleotide-induced modifications in the osteogenic differentiation pattern of 
MSCs from young females and postmenopausal women  
First passage MSCs from young females (14-16 years) and postmenopausal 
women (56-76 years) were cultured for 28 days in conditions that favour 
osteogenic differentiation in the absence and in the presence of 100 µM ATP, UTP 
and UDP. Continuous application of these nucleotides to the culture medium was 
devoid of effect on the proliferation of MSCs measured by the MTT assay (data 
not shown). Table 5 shows the variation of ALP activity of the cells exposed 
continuously to adenine and uracil nucleotides compared to the control cultures 
grown in the absence of test drugs.  
In MSC cultures from postmenopausal women, ATP (100 µM) caused a 
biphasic effect decreasing ALP activity until a maximum was reached on culture 
day 14, returning back to baseline thereafter (Table 5). On the contrary, UTP (100 
µM) and UDP (100 µM) significantly (P<0.05) increased the ALP activity of 
postmenopausal MSCs during the first week, but the effect of uracil nucleotides 
decreased progressively thereafter (Table 5). At days 21 and 28, the activity of 
ALP was about the same in the presence of UTP (100 µM) and UDP (100 µM), as 
compared to control cultures. The lack of effect on ALP activity contrast with the 
Figure 23. (Continued) Changes in fluorescence were detected by laser-scanning confocal 
microscopy (Olympus FV1000, Tokyo, Japan) in the time-lapse mode. ATP (100 μM, A), UTP 
(100 μM, B) and UDP (100 μM, C) were applied during 6 min. Intracellular [Ca2+]i transients 
were calibrated to the maximal calcium load produced by ionomycin (5 μM, 100 % response). 
The black bars at the bottom of each graph indicate the period of drug exposure. Each point 
represents pooled data from 3 (control group) and 6 (postmenopausal group) different 
individuals. The vertical bars represent S.E.M from an n number of evaluated cells. 
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increased expression of uracil nucleotide-sensitive P2Y2, P2Y4 and P2Y6 receptors 
as cells differentiate (see Figure 22B). 
At culture day 21, ATP (100 µM) increased, rather than decreased, ALP activity 
in MSCs from young female patients (14-16 years). Whilst UTP (100 µM) and UDP 
(100 µM) progressively increased the ALP activity as MSCs from the younger 
female group maturate (maximum ALP activity was reached on culture day 28), 
the differentiating effect of both uracil nucleotides decreased from the first week 
onwards in postmenopausal MSC cultures. The timing of the osteogenic 
differentiation promotion caused by ATP, UTP and UDP on MSCs from young 
females coincides with the highest expression levels of P2X7 and P2Y6 receptors 
(see Figure 22A), which activation is known to favour osteogenesis and bone 
formation in human osteoprogenitor cell cultures (Noronha-Matos et al., 2012; 
2014).  
Table 5. Variation of alkaline phosphatase (ALP) activity of human primary bone marrow-
derived mesenchymal stem cells (MSCs, first subculture) from young females (14-16 years old) 
and postmenopausal women (59-76 years old) exposed continuously (during 28 days) to ATP 
(100 µM), UTP (100 µM) and UDP (100 µM). 
Values represent changes in the activity of ALP (nmol/min/µg protein) as compared to control 
cultures grown in the absence of test drugs at the same time points (see Figure 21A). Zero 
represents identity between the two values (drug vs. control); positive and negative values 
represent facilitation or inhibition of osteogenic cell differentiation relative to control data 
obtained at the same time points. Each value represents pooled data from three to six different 
individuals (Mean ± SEM); 6-8 replicas were performed for each individual experiment. *P<0.05 
represents significant differences from control values obtained in the absence of test drugs. 
14 - 16 yr
59 -76 yr
14 - 16 yr
59 -76 yr
14 - 16 yr
59 -76 yr
UDP (100 µM)
-0.04±0.06 -0.08±0.03 0.09±0.1 0.35±0.06*
0.03±0.01
28
-0.05±0.03
-0.11±0.02*
ATP (100 µM)
UTP (100 µM)
-0.02±0.04 -0.1±0.01* 0.02±0.11 0.24±0.08*
0.13±0.04* 0.07±0.02* 0.01±0.03 0.01±0.01
nmol/min/µg protein 
(Drug-Ctr)
-0.12±0.07* -0.16±0.04*
7 14
0.80±0.19*
0.00±0.01 -0.32±0.01* -0.22±0.01*
21
Days in culture
0.12±0.05* 0.08±0.03* 0.05±0.03
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Differences in NTPDase1, -2, -3 and ecto-5’-nucleotidase/CD73 
immunoreactivity in the plasma membrane of MSCs from young females and 
postmenopausal women 
P2 purinoceptors activation leading to osteogenic differentiation of human 
MSCs may be balanced through specific NTPDases whose expression varies 
along maturation of the cells (see e.g. Noronha-Matos et al., 2012). These findings 
may explain the disparity between subtype-specific P2 receptors expression in 
MSCs and the effects of adenine and uracil nucleotides on intracellular [Ca2+]i and 
ALP activity at the same differentiation time points. Therefore, we allowed MSCs 
from young females (13-36 years) and postmenopausal women (59-76 years) to 
grow in chamber slides for 7 and 21 days in supplemented -MEM before 
immulabelling the cells with specific primary antibodies against human NTPDase1, 
-2 and -3, and ecto-5’-nucleotidase/CD73. Fluorescence immunoreactivity against 
these enzymes shows a cytoplasmic/membrane-staining pattern that is typical for 
ecto-enzymes (Figure 24).  
In MSCs from postmenopausal women, fluorescence immunoreactivity for 
NTPDase1, -2 and -3 increased with time (7<21 days in culture) (Figure 24B). 
Interestingly, the immunoreactivity against NTPDase2 was almost unapparent in 
MSCs cultured for 7-days, but it became stronger in more differentiated (21-day) 
cultures. Interestingly, we did not observe such maturation changes along the time 
of the cells in culture in the expression of NTPDase1 and -2 in MSCs from younger 
females (Figure 24A). We found a remarkable major difference concerning the 
expression of NTPDase3 among the cells from women of the two age groups, as 
this enzyme was totally absent in MSCs from younger females whilst its 
expression was increasingly more evident in maturating cells from 
postmenopausal women (Figure 24A).     
The immunoreactivity against ecto-5’-nucleotidase/CD73, an enzyme that is 
typically expressed (>95%) by osteoprogenitor cells (see e.g. Lu et al., 2010), was 
detected at all maturation stages of MSCs from both young females and 
postmenopausal women. These findings suggest that adenosine formation, via 
ecto-5’-nucleotidase/CD73, does not account for the changes in the osteogenic 
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7 days 
21 days 
59 - 76 yr 
NTPDase 1 NTPDase 2 NTPDase 3 5’-NTase 
Scale bars: 150 µm 
A 
13 - 36 yr 
7 days 
21 days 
NTPDase 1 NTPDase 2 NTPDase 3 5’-NTase 
Av 
Scale bars: 150 µm 
Figure 24. Immunocytochemical detection of NTPDase1, -2 and -3 and ecto-5’-nucleotidase on 
human primary bone marrow-derived mesenchymal stem cells (MSCs, 1st subculture) from 
female patients with (A) 13-36 years (control group) and (B) 59-76 years (postmenopausal 
group). Shown is the time-related immunoreactivity fluorescence detection by confocal 
microscopy of MSCs allowed to grow for 7 and 21 days in an osteoblast-inducing medium. 
Cells grown in eight-well chamber slides were processed for immunocytochemistry in parallel 
and were visualized keeping unaltered the settings of the confocal microscope throughout the 
procedure. For further details on immunofluorescence labelling see Materials and Methods 
section. Images are representative of three to five independent experiments. Scale bar is 150 
µm. 
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differentiation potential of these cells in the two age groups, unless otherwise 
deficits occur upstream AMP substrate production from released adenine 
nucleotides. 
Age related-changes in the pattern of the extracellular catabolism of ATP 
and uracil nucleotides (UTP and UDP) in cultured MSCs by HPLC 
Figure 25 illustrates the time course of the extracellular catabolism of ATP and 
uracil nucleotides (UTP and UDP) in MSCs from young females (13-36 years) and 
postmenopausal women (59-76 years), which were allowed to grow in culture for 7 
(Figure 25Ai, 25Bi and 25Ci) and 21 (Figure 25Aii, 25Bii and 25Cii) days in an 
osteogenic-inducing medium. Because enzymatic activity is usually represented 
as a function of the total protein content of the samples, yet in osteoblast 
differentiating cultures type I collagen accounts to 85-90% of the organic matrix, 
we decided to normalize the NTPDase activity by the amount of viable cells given 
by the MTT assay (Figure 25Aiii, Biii and Ciii) (cf. Noronha-Matos et al., 2012).  
In MSCs from young females, ATP (100 µM) was hydrolysed with a half-
degradation time of 121±71 min and 32±7 min at culture days 7 (Figure 25Ai) and 
21 (Figure 25Aii), respectively; the half-degradation times calculated for 
postmenopausal MSCs were respectively 24±2 min and 12±1 min at culture days 
7 (Figure 25Ai) and 21 (Figure 25Aii).  Normalization of the ATP hydrolytic activity 
to the amount of viable MSCs from both age groups demonstrates that speed up 
of ATP (100 µM) catabolism as cultures progressed is due predominantly to the 
concurrent increase in the number of cells, since the net enzymatic activity 
decreased by 25-50% (Figure 25A). Comparing the normalized NTPDase activity 
of MSCs from both age groups, we show here that MSCs from postmenopausal 
women hydrolyse ATP (100 µM) 2.1 times faster than younger females, if one 
considers data obtained at culture day 21 (Figure 25Aiii). 
Extracellular UTP (100 µM) was hydrolysed with half-degradation times of 
124±27 and 34±5 min in MSCs from young females grown in culture for 7 (Figure 
25Bi) and 21 (Figure 25Bii) days, respectively. In postmenopausal MSC cultures, 
UTP (100 µM) was hydrolysed with half-degradation times of 142±29 and 12±1 
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Figure 25. Time course of extracellular ATP (100 µM) (A), UTP (100 µM) (B) and UDP (100 
µM) (C)   metabolism   and   total   NTPDase   activity in    human primary bone marrow-derived  
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min at corresponding time periods, days 7 (Figure 25Bi) and 21 (Figure 25Bii), 
respectively. The progress curves of UDP (100 µM) disappearance in MSC 
cultures from young females and postmenopausal women at days 7 and 21 are 
shown in Figure 25C. The results show that extracellular UDP (100 µM) is slowly 
inactivated in less differentiated cells (Figure 25Ci), but the rate of UDP catabolism 
speeds up significantly (P<0.05) as cultures progressed to more differentiated 
status (Figure 25Cii). In MSCs from young females, UDP (100 µM) was 
metabolised with half-degradation times of 151±48 and 41±5 min at culture day 7 
(Figure 25Ci) and 21 (Figure 25Cii), respectively, whereas in the postmenopausal 
group it was hydrolysed with half-degradation times of 69±16 and 6±1 min at 
corresponding time periods, days 7 (Figure 25Ci) and 21 (Figure 25Cii), 
respectively. The normalized NTPDase activity at culture day 21 shows that 
postmenopausal MSCs hydrolyse UTP (100 µM, Figure 25Biii) and UDP (100 µM, 
Figure 25Ciii) respectively 3 and 4.6 times faster than cultured cells from younger 
females.  
The presence of a saturating concentration (10 mM) of β-glycerophosphate in 
the culture medium did not alter the degradation kinetics of ATP and uracil 
nucleotides (UTP and UDP), indicating that the contribution of non-specific 
phosphatases, namely ALP (EC 3.1.3.1) to the extracellular catabolism of 
nucleotides applied in a 100-µM concentration is negligible (data not shown).  
Figure 25. (Continued) mesenchymal stem cells (MSCs, 1st subculture) from female patients 
with 13-36 years (control group) and 59-76 years (postmenopausal group). Cells were allowed 
to grow for 7 (Ai, Bi, Ci) and 21 (Aii, Bii, Cii) days in an osteoblast-inducing medium. 
Nucleotides (100 µM) were added to the culture medium at zero time. Samples (75 µl) were 
collected from each well at the indicated times in the abscissa. Each collected sample was 
analyzed by HPLC to separate and quantify ATP, UTP or UDP in MSCs from young females 
(open circles) and postmenopausal women (filled squares). The NTPDase activity (Aiii, Biii, 
Ciii) was determined 15 minutes after exposure of the cells to the nucleotides; the activity of 
NTPDases was normalized by the amount of viable cells given by the MTT assay (control 
group, day 7: 0.35±0.05 A/cm2 vs day 21: 1.08±0.20 A/cm2,
 
n=7; postmenopausal group, day 7: 
0.48±0.02 A/cm2 vs day 21: 0.89±0.05 A/cm2,
 
n=6). Each point represents pooled data from 
three individuals; two replicas were performed in each individual experiment. The vertical bars 
represent S.E.M. and are shown when they exceed the symbols in size. *P<0.05 represent 
significant differences between the two age groups. 
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Extracellular ATP accumulation in MSC cultures from young females and 
postmenopausal women  
Human MSCs and osteoblast-like cells release ATP constitutively without cell 
damage (see e.g. Brandao-Burch et al., 2012; Buckley et al., 2003; Genetos et al., 
2005; Riddle et al., 2007; Romanello et al., 2001). Given that maturation of 
metabolizing enzymes and purinoceptors may determine divergent effects of 
released nucleotides in differentiating cell populations, we designed experiments 
to measure the accumulation of ATP in the extracellular fluid collected from MSCs 
from young females (13-36 years) and postmenopausal women (59-82 years) 
grown in culture for 7 and 21 days in an osteogenic-inducing medium (Figure 26).  
Quinacrine fluorescence cell staining has been widely used to visualize ATP-
containing sub-cellular compartments in living cells (Irvin and Irvin, 1954; Orriss et 
al., 2009). Figure 26A shows that quinacrine (30 µM)-loaded MSCs exhibit a clear 
granular-vesicular staining pattern in the cytosol corresponding to intracellular ATP 
stores. Confirmation that MSCs constitutively release ATP was obtained 
measuring the nucleotide content in the fluid collected from MSCs cultures (Figure 
26B). In 7-day cultures, accumulation of ATP in culture media during 30 min was 
about the same in samples collected from young females (0.24±0.04 pmol per 
well) and postmenopausal women (0.26±0.07 pmol per well). Whilst the ATP 
content of the samples decreased significantly (P<0.05) from culture day 7 to 21 in 
MSCs from young female patients (0.24±0.04 vs 0.11±0.06 pmol per well, 
respectively), the opposite was verified in cells isolated from postmenopausal 
women (0.26±0.07 vs 0.35±0.06 pmol per well, respectively) (Figure 26B). In order 
to confirm that these differences were not due to cell damage, we measured the 
lactate dehydrogenase (LDH) activity in the same samples. Cell membrane 
integrity was confirmed in all cell populations analysed because no significant 
(P<0.05) divergence was observed in LDH activity values (Figure 26B).  
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Inhibition of NTPDase3 favours extracellular ATP accumulation and 
promotes osteogenic differentiation and mineralization of MSCs from 
postmenopausal women 
Considering that overexpression of NTPDase3 may account to faster nucleotide 
inactivation and to the partial loss of osteogenic potential of MSCs from 
Figure 26. Constitutive ATP release from bone marrow-derived mesenchymal stem cells 
(MSCs, 1st subculture) from female patients with 13-36 years (control group) and 59-82 years 
(postmenopausal group). The cells were allowed to grow in an osteoblast-inducing medium. 
Panel (A) represents 7-day cells loaded with quinacrine exhibiting a clear granular-vesicular 
staining pattern in the cytosol corresponding to intracellular ATP stores (Ai, scale bar is 150 
µm; Aii, scale bar is 75 µm). Panel (B), comparison of ATP accumulation in culture media of 
MSCs from young females (13-36 years) and postmenopausal women (59-82 years), which 
were allowed to grow for 7 and 21 days. Samples were collected 30 min after changing the 
culture medium. The ATP content of the samples was quantified by the luciferin-luciferase 
bioluminescence assay. In parallel, we measured the lactate dehydrogenase activity (LDH, 
filled squares) of the same samples to evaluate the integrity of the cells. Represented is pooled 
data from three individuals; two replicas were performed in each individual experiment. The 
vertical bars represent S.E.M. are shown when they exceed the symbols in size. *P<0.05 
represent significant differences between the two age groups. 
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postmenopausal women compared to younger female patients, we decided to test 
whether selective inhibition of the activity of this enzyme could restore the 
osteogenic potential of postmenopausal MSCs. To this end we evaluated the 
effect of PSB 06126 (3 µM), an anthraquinone derivative that selectively inhibit 
NTPDase3 (Baqi et al., 2009) on osteogenic differentiation and mineralization of 
MSCs from postmenopausal women, which were cultured for 43 days in an 
osteogenic-inducing medium. Inhibition of NTPDase3 with PSB 06126 (3 µM) 
increased (by 3.6 fold, P<0.05) ATP accumulation in culture media of MSCs from 
postmenopausal women. On culture day 21, PSB 06126 (3 µM) significantly 
(P<0.05) increased (1) the ALP activity of MSCs by 43±17% above baseline 
(Figure 27A) and (2) the expression of Runx-2 by more than 5-fold the control 
level, without affecting downstream Osterix transcription factor (Figure 27B). 
Continuous application of the selective NTPDase3 inhibitor, PSB 06126 (3 µM), to 
the culture medium was devoid of effect on MSCs proliferation measured by the 
MTT assay. These findings contrast with those obtained with ARL 67156, a 
bromaminic acid derivative that preferentially inhibits NTPDase1 at 50 µM (Baqi et 
al., 2009), and sodium polyoxotungstate (POM-1, 10-100 µM), the non-selective 
inhibitor of NTPDases1, -2 and -3 (Wall et al., 2008), which decreased both MSCs 
proliferation and ALP activity (data not shown).   
Figure 28 shows that selective inhibition of NTPDase3, either with PSB 06126 
(3 µM) or with the monoclonal anti-human NTPDase3 antibody (hN3-B3S, 0.5 
µg/ml) (Munkonda et al., 2009), significantly (P<0.05) increased matrix 
mineralization of MSCs cultures from postmenopausal women at culture day 43. 
The mineralization effect caused by PSB 06126 (3 µM) and hN3-B3S (0.5 µg/ml) 
was prevented after pretreatment with A438079 (3 µM) and MRS 2578 (100 nM), 
which selectively antagonize osteogenic promoting P2X7 and P2Y6 receptors, 
respectively (see e.g. Noronha-Matos et al., 2012; 2014; Panupinthu et al., 2008). 
At the concentrations used in this study, neither A438079 (3 µM) nor MRS 2578 
(100 nM) modified the total mineralized area of the cultures when used alone, thus 
indicating that endogenously produced nucleotides may not reach concentrations 
high enough to activate P2X7 and P2Y6 in postmenopausal MSCs unless 
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NTPDase3 is inhibited. In contrast, apyrase (2.5 U/mL, EC 3.6.1.5, also called 
NTPDase1/CD39 or ATP diphosphohydrolase), the enzyme that catalyses 
inactivation of nucleoside triphosphates into their monophosphate derivatives with 
little or none accumulation of diphosphates, significantly (P<0.05) decreased bone 
nodule formation when applied alone and prevented PSB 06126 (3 µM)-induced 
mineralization of MSC cultures (Figure 28B). These results suggest that inhibition 
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Figure 27. Selective inhibition of NTPDase3 with PSB 06126 increase osteogenic 
differentiation of postmenopausal bone marrow-derived mesenchymal stem cells (MSCs, 1st 
subculture) cultured for 28 days in an osteogenic-inducing medium. Panel (A), represented is 
the variation of alkaline phosphatase (ALP) activity of cultured MSCs exposed continuously to 
PSB 06126 (3 µM) as compared to control cultures grown in the absence of the NTPDase3 
inhibitor (see Figure 21A). Zero represents identity between the two values (drug vs. control); 
positive and negative values represent facilitation or inhibition of osteogenic differentiation 
relative to control data obtained at the same time points. Each column represents pooled data 
from three individuals; 3-8 replicas were performed for each individual experiment. Panel (B), 
represented is the relative expression of the osteogenic transcription factors, Runx-2 (59 kDa) 
and Osterix (58 kDa), detected by Western blot analysis in MSCs from postmenopausal women 
(60-83 years) grown in culture for 7 and 21 days in the presence of PSB 06126 (3 µM) as 
compared to control values without adding the NTPDase3 inhibitor (dashed horizontal line). β-
Actin (45 kDa) was used as control. Bars represent means ± S.E.M from three individuals. 
*P<0.05 represent significant differences from control values obtained in the absence of PSB 
06126. 
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of NTPDase3 activity with PSB 06126 (3 µM) or hN3-B3S (0.5 µg/ml) in 
postmenopausal MSCs recapitulates the mineralization potential of younger 
females (see Noronha-Matos et al., 2014), whose cells lack NTPDase3 (Figure 
24A), an effect that requires the activation of P2X7 or P2Y6 respectively by ATP 
and UDP. We also considered the use of siRNA to selectively prevent NTPDase3 
expression in order to confirm the results obtained with PSB 06126 and hN3-B3s. 
Unfortunately maximum knockdown of a gene transcript usually occurs 48 hours 
after transfection. The duration of knockdown depends on a number of factors, 
including the transcription rate of the gene within the cell, but rarely lasts beyond 
96 hours. Given that our study involves long term cultures, which go beyond 40 
days, it is highly unlikely that full silencing of the gene transcript would occur under 
such experimental conditions. 
DISCUSSION 
This study was designed to investigate age-dependent changes in the 
“purinome” (Volonté and D’Ambrosi, 2009), comprising nucleotide release sites, 
extracellular metabolizing enzymes and purinoceptors expression/activation, in 
order to understand the mechanisms underlying impairment of osteogenic 
differentiation and matrix mineralization of primary cultures of MSCs from 
postmenopausal women as compared to younger females. Our results show that 
there is a notorious discrepancy between the expression time course and function 
of osteogenic-inducing P2 purinoceptors in differentiating MSCs from 
postmenopausal women. In contrast to younger females, nucleotide-induced 
intracellular [Ca2+]i signals and osteogenic commitment of MSCs (measured as 
Figure 28. (Continued) in culture. Calcium deposition was assessed by the Alizarin red test. 
Panel (A), shows typical micrographs evidencing the formation of bone nodules (red-brownish 
spots) in MSC cultures exposed continuously for 43 days to PSB 06126 (3 µM) applied either 
alone or in the presence of A438079 (3 µM, a P2X7 selective antagonist), MRS 2578 (100 µM, 
a P2Y6 selective antagonist), or apyrase (2.5 U/ml). Scale bar is 100 µm.  Panel (B), results are 
expressed as total mineralized area per culture well. Each column represents pooled data from 
three to eight individuals; 3-6 replicas were performed for each individual experiment. The 
vertical bars represent S.E.M. *,**P<0.05 represent significant differences compared to control 
values (no drugs added) or with the effects of PSB 06126 or hN3-B3S applied alone, 
respectively. 
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ALP activity, expression of Runx-2 and Osterix transcription factors and matrix 
mineralization) declined along maturation of the cells in culture. The loss of 
purinergic signalling in postmenopausal MSCs is positively correlated with gains in 
the expression and activity of extracellular nucleotide metabolizing enzymes, in 
particular the NTPDase3; this enzyme is absent in cells from younger females but 
it becomes highly expressed in postmenopausal MSCs. Here, we provided the first 
evidence demonstrating that inhibition of NTPDase3, either with PSB 06126 (Baqi 
et al., 2009) or with a monoclonal antibody against the human enzyme (hN3-B3S) 
(Munkonda et al., 2009), rescued the osteogenic potential of postmenopausal 
MSCs to levels observed in younger females by promoting the activation of P2X7 
and P2Y6 receptors by endogenous ATP and UDP, respectively. In view of this, we 
recommend inhibition of NTPDase3 as a novel therapeutic strategy to increase the 
osteogenic commitment of MSCs leading to bone formation in postmenopausal 
women.             
Our data unequivocally indicate that osteogenic differentiation of MSCs is 
compromised in postmenopausal women as compared to younger females. This 
was inferred considering that postmenopausal MSCs present lower ALP activity 
and reduced levels of the osteogenic transcription factors, Runx-2 and Osterix 
(Ducy et al., 1997; Franceschi and Xiao, 2003; Kern et al., 2001; Nakashima et al., 
2002; Paredes et al., 2004; Selvamurugan et al., 1998). This trait anticipates a 
reduced matrix mineralization capability that was confirmed in the postmenopausal 
group at later culture stages. In fact, previous studies using Runx-2-deficient mice 
revealed a complete absence of differentiated osteoblasts (leading to low ALP 
expression) and bone nodule formation (Komori et al., 1997; Otto et al., 1997). 
Likewise, mouse embryos lacking Osterix, a zinc-containing transcription factor 
essential for osteoblast differentiation and bone formation that acts downstream 
Runx-2, do not express osteoblast differentiation markers, like osteocalcin and 
alkaline phosphatase (ALP) (Nakashima et al., 2002). In addition, gene expression 
analysis revealed down-regulation of Runx-2 in MSCs from patients with 
osteoporosis (Dalle Carbonare et al., 2009).  
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Previous studies from our group demonstrated that postmenopausal MSCs in 
culture express ionotropic P2X7 receptors (Noronha-Matos et al., 2012). Our 
findings showed that immunoreactivity against P2X7 receptor was higher at early 
time points (culture day 7), but declined slightly thereafter (see also Figure 22). 
These findings are in agreement with the RT-PCR analysis performed by Orriss 
and col. (2006) in rat primary osteoblasts and suggest that P2 purinoceptors 
expression in osteoprogenitor cells is differentiation-dependent. We showed that 
activation of the P2X7 receptor favours osteogenic commitment of human MSCs 
and bone mineralization through a mechanism involving plasma membrane zeiosis 
and cytoskeleton rearrangements triggered by a Rho kinase-dependent pathway 
(Noronha-Matos et al., 2014). These findings fully support the increase in the 
postmenopausal fracture risk observed in women presenting loss of function 
polymorphisms of the P2X7 receptor (Jorgensen et al., 2012; Ohlendorff et al., 
2007). Despite our findings proving that activation of the P2X7 receptor with 
BzATP promotes osteogenesis of MSCs derived both from young females and 
postmenopausal women (Noronha-Matos et al., 2014), endogenous ATP might not 
reach high enough levels to activate P2X7 receptors in MSCs from 
postmenopausal women unless cultures were treated with selective inhibitors of 
NTPDase3, like PSB 06126 (3 µM) or hN3-B3S (this study).       
Besides the recognized role of ATP in bone remodelling via ionotropic P2X7 
among other P2 receptors, we presented compelling evidences that uracil 
nucleotides facilitate osteogenic differentiation of postmenopausal MSCs 
predominantly through the activation of UDP-sensitive P2Y6 receptor (Noronha-
Matos et al., 2012). This was observed despite P2Y2 and P2Y4 receptors 
recognizing both ATP and UTP have also been localized in human bone-forming 
cells (Bowler et al., 1995; Maier et al., 1997), where they may be involved in the 
inhibition of bone mineralization particularly when the nucleotides were used in low 
concentrations (Hoebertz et al., 2002; Orriss et al., 2007). These intriguing 
observations, together with the lack of information regarding the relative 
abundance of each receptor subtype and their exact role during osteogenic 
differentiation of human osteoprogenitor cells, prompted us to investigate changes 
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in the expression of specific P2 purinoceptors with impact on bone formation in 
differentiating MSC cultures obtained from young females and postmenopausal 
women.  
In younger females, the expression of osteogenic-promoting receptors, P2X7 
and P2Y6, progressively increase towards more differentiated cells, whereas P2Y2 
and P2Y4 receptors become practically undetectable on culture day 21. Curiously, 
an opposite P2 receptors maturation pattern was observed in MSCs from 
postmenopausal women; whilst P2X7 and P2Y6 receptors expression remained 
fairly constant as cultures progress, the immunoreactivity against P2Y2 and P2Y4 
receptors became more evident in more mature cells. Differences in P2 receptors 
expression among postmenopausal and younger females, namely the growing 
expression of inhibitory ATP- and UTP-sensitive P2Y2 and P2Y4 receptors, may 
partially counteract the bone-promoting effect of P2X7 and P2Y6 receptors 
(Hoebertz et al., 2002; Orriss et al., 2007). Our data also demonstrate that 
variation of P2 purinoceptors expression during maturation of MSCs impact on 
intracellular [Ca2+]i signals and osteogenic differentiation of these cells. In contrast 
to MSCs from young females where appearance of osteogenic-promoting 
receptors, P2X7 and P2Y6, positively correlates with the magnitude of intracellular 
[Ca2+]i signals and ALP activity of the cultures, we observed an age-related 
divergence between P2 purinoceptors expression and osteogenic commitment 
induced by adenine and uracil nucleotides in MSCs from postmenopausal women 
leading to impairment of bone formation.     
P2 purinoceptors activation leading to osteogenic differentiation of human 
MSCs may be balanced through specific nucleotide metabolizing enzymes (e.g. 
NTPDases) whose expression may also vary along maturation of the cells 
(Noronha-Matos et al., 2012). This argument may explain the disparity between 
subtype-specific P2 receptors expression in MSCs and the effects of adenine and 
uracil nucleotides on intracellular [Ca2+]i and ALP activity at the same 
differentiation time points. In contrast to data obtained regarding the ATP 
catabolism which largely depended on the amount of cells at a given stage, 
normalization of MSCs ability to hydrolyse uracil nucleotides (UTP and UDP) per 
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viable cell (MTT assay) indicates that the net enzymatic activity of MSCs from 
postmenopausal, but not from younger females, increases 3 to 5 fold as cultures 
progress from day 7 to 21. Given that the number of viable cells did not increase 
proportionally in the same time period, the results suggest that more differentiated 
MSCs exhibit higher NTPDase activity implicated in the extracellular inactivation of 
both UTP and UDP. The presence of NTPDase3 in postmenopausal MSCs and its 
absence in the cells from younger females may give a good explanation for the 
discrepancy between the two age groups concerning the ability to hydrolyse uracil 
nucleotides and their impact on intracellular [Ca2+]i signalling and commitment to 
osteogenic differentiation. Interestingly, 7-day cultures of MSCs from 
postmenopausal women metabolise significantly (P<0.05) less UTP than that 
observed in cultures from younger patients (Figure 25Biii). This may be 
attributable to the relatively low expression levels of NTPDase2 (CD39LI, EC 
3.6.1.3) in 7-day cultures of postmenopausal MSCs (see Figure 24B), as this 
enzyme is a preferential nucleoside triphosphatase hydrolysing diphosphates 10-
15 less efficiently than triphosphates (Kukulsky et al., 2005). Taking into 
consideration that NTPDases prefer adenine nucleotides to uracil nucleotides as 
substrates, the presence of low amounts of NTPDase1 and -3 may not be enough 
to compensate UTP hydrolysis by absent NTPDase2 in 7-day postmenopasual 
MSCs. 
Increases in the ATP content of the samples collected from postmenopausal 
MSCs grown for 21 days in culture clearly contrasts with the faster extracellular 
inactivation kinetics of the nucleotide upon cells maturation (7<21 days) (Figure 
25A), which was also predicted by the concomitant gain of expression of 
NTPDases in more differentiated cells (Figure 24B). This apparent discrepancy 
can only be resolved assuming that differentiated MSCs from postmenopausal 
women release constitutively more ATP than cells from younger females by a yet 
unknown mechanism, excluding a priori cells damage considering the low levels of 
LDH activity measured in the same samples. Human MSCs and osteoblast-like 
cells release ATP constitutively without cell damage (see e.g. Brandao-Burch et 
al., 2012; Buckley et al., 2003; Genetos et al., 2005; Riddle et al., 2007; 
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Romanello et al., 2001). There are two main mechanisms underlying nonlytic 
release of nucleotides from cells: (a) Exocytic release specifically concentrated 
within secretory granules or vesicles; and (b) controlled release of cytosolic 
nucleotides via intrinsic plasma membranes channels or pores, which includes 
ABC transporters, connexin hemichannels voltage-dependent anion channels and 
the P2X7 receptor itself (Donahue, 2000; Orriss et al., 2009; Riddle et al., 2007; 
reviewed in Burnstock, 2006). Evidence now suggests that stimuli inducing bone 
formation and accelerated fracture healing (like mechanical loading, ultrasound, 
1,25/OH)2 vitamin D3, and biphosphonates) promote ATP release from osteoblast-
like cells (Alvarenga et al., 2010; Biswas and Zanello, 2009; Hayton et al., 2005; 
Riddle et al., 2007; Romanello et al., 2006; Rumney et al., 2012). Interestingly, the 
amount of ATP released from osteoblasts also depends on their differentiation 
status (Orriss et al., 2009). Using rat osteoblasts, these authors demonstrated that 
mature bone-forming cells release up to 7-fold more ATP than proliferative 
immature cells, yet we could not reproduce the same tendency in MSCs from 
young females. As a matter of fact, we found higher endogenous levels of ATP in 
the culture medium of more differentiated MSCs from postmenopausal women. 
Despite this, we were unable to demonstrate any tonic activity of the P2X7 
receptor in postmenopausal MSCs using the selective receptor antagonist 
A438079 in a concentration (3 µM) that almost prevented ALP activity in cells from 
younger females (Noronha-Matos et al., 2014). This difference may be attributable 
(1) to a slight decline in the P2X7 receptor expression, and/or (2) to an increase in 
the breakdown of ATP by highly expressed NTPDases in the close proximity of 
P2X7 receptors expressed in more differentiated postmenopausal MSCs.  
Like ATP, the ability of various cell types (e.g. murine airway epithelial cells, 
human cardiomyocytes) to release UTP has been directly confirmed using an 
enzymatic assay; estimated UTP release was approximately 10-30% of all 
detected nucleotides (Lazarowski and Harden, 1999; Lazarowski et al., 2003). In 
addition, UDP-sugars, like UDP-glucose (P2Y14 receptor activator), may be 
released from cells together with ATP under certain conditions (Kreda et al., 2007, 
2008; Lazarowski et al., 2003). UDP itself is an end product of glycogen synthesis 
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that may be released to the extracellular fluid. It is important to stress that the 
extracellular accumulation of nucleotides such as UTP and UDP may not 
necessarily involve a requirement for their selective release from intracellular 
pools. Rather these nucleotides may accumulate as a secondary consequence of 
extracellular metabolism (degradation or synthesis) of nucleotide precursors that 
are directly released in various physiological and pathological conditions (Burrell et 
al., 2005; Buxton et al., 2001; Joseph et al., 2004; Yegutkin et al., 2001; 2002). 
Thus, ADP or UDP may either be released directly or be generated via the 
extracellular hydrolysis of released ATP and UTP by NTPDases. 
Interestingly, UTP is a much better substrate than UDP for NTPDase1 and 
NTPDase3 (Kukulski et al., 2005), which may influence the real potency of UTP on 
P2Y2 and P2Y4 receptors expressed on MSCs in culture. Distinctively from 
adenine nucleotides, all membrane-bound NTPDases dephosphorylate UTP with a 
transient formation of UDP, thus favouring P2Y6 receptor activation (Kukulski et 
al., 2005; see Figure 23 and Table 5). Expression of NTPDase2 in more 
differentiated MSCs from postmenopausal women is expected to terminate ATP 
and UTP actions on P2X7 and P2Y2,4 receptors, respectively. Simultaneously, 
increased NTPDase2 activity provide the generation of UDP for stimulation of 
P2Y6 receptors, which may be balanced through the concomitant increase in the 
expression of NTPDase1 and -3, which efficiently hydrolyse UDP. These changes 
may determine the decay of ATP, UTP and UDP actions on intracellular [Ca2+]i 
signals and ALP activity in more differentiated postmenopausal MSCs in culture, 
despite the presence of available P2 purinoceptors. At this stage, one could not 
completely rule out the influence of adenosine accumulation (or its lack) originated 
from the extracellular catabolism of adenine nucleotides via ecto-5’-
nucleotidase/CD73, since the nucleoside is also an important regulator of 
osteogenic differentiation through the activation of subtype-specific P1 receptors, 
namely the most abundant A2B receptor in human MSCs (Costa et al., 2011). 
Comparing the expression and activity of NTPDases in young females and 
postmenopausal women it became clear that high NTPDase3 activity determines 
down-modulation of the activity of bone-promoting P2X7 and P2Y6 receptors, 
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which could be readmitted by selectively inhibiting its activity with PSB 06126 or 
with a monoclonal antibody against the human enzyme, hN3-B3S. Inhibition of 
NTPDase3 rescued osteogenic transcription factors (Runx-2 and Osterix), ALP 
activity, and matrix mineralization of postmenopausal MSCs to the levels observed 
in younger females, suggesting that age-dependent expression of this enzyme 
may be implicated in bone mass loss due to unbalance of the purinergic 
commitment of MSCs to osteogenic differentiation in postmenopausal women. The 
exact trigger and the timing associated with age-related expression of NTPDase3 
in MSCs remains uncertain. Preliminary data from our laboratory, show that 
NTPDase3 was also absent from cultured MSCs isolated from a 39-years old man 
requiring bone engraftment due to traumatic bone fracture, as well as from a 50-
years old male undergoing total hip replacement due to osteoarthrosis (data not 
shown). In these patients, the expression pattern of NTPDase1 and -2 resemble 
that found in the younger female group. It, thus, appears that oestrogen deficiency 
after menopause may be a trigger worth to investigate concerning bone loss linked 
to overexpression of NTPDase3 and P2 receptor activity impairment in 
postmenopausal women. 
 In conclusion, inhibition of NTPDase3 on MSCs may be a novel therapeutic 
strategy to increase bone formation in postmenopausal women, which together 
with activation of bone-forming P2X7 and P2Y6 receptors may increase 
osteogenesis and matrix mineralization in situations where bone destruction 
exceeds bone formation (e.g. osteoporosis, rheumatoid arthritis, osteogenesis 
imperfect, fracture mal-union). 
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4. DISCUSSION AND CONCLUSIONS 
Bone is a dynamic tissue that is constantly being remodelled. This allows it to 
maintain its healthy condition, which is crucial for the efficient and lifelong 
execution of important skeletal functions (see Introduction, section 1.3). The 
development of novel therapies to overcome bone loss is of utmost importance. 
Some of the current therapeutic approaches (see Introduction, section 1.3.3) lack 
specificity and/or present countless side effects. Among bone diseases, 
osteoporosis has become a major public health problem in most developed 
countries. Only in USA, it affects at least 10 million citizens over the age of 50, and 
an additional 33–34 million Americans complain from osteopenia. Moreover, 
twenty-six percent of women over age 65 have osteoporosis (Feng and McDonald, 
2011). 
Bone tissue engineering (BTE) arose as a promising strategy to prevent bone 
loss, given the possibility of using osteoprogenitor cells supplemented with growth 
factors to promote new bone formation at defective sites. This presents an elegant 
approach, which includes minimal-invasive surgical approaches for the 
management of bone loss. However, some important issues must be taken into 
consideration. For obvious reasons, the use of the patient’s own cells is most 
attractive in order to avoid the potential for immune rejection. Usually, 
osteoprogenitor cells (mesenchymal stem cells, MSCs) derive from the patient’s 
own bone marrow. These are easily isolated and have a high proliferative 
capacity, while retaining their undifferentiated state (Banfi et al., 2002; Bruder et 
al., 1997). These cells, under the appropriate conditions, can differentiate into 
osteoblasts, the bone forming cells (Bobis et al., 2006). However, such ability 
becomes compromised in elderly individuals, which may result in bone disorders 
such as osteoporosis (see Introduction, section 1.2.3), thus limiting their usage in 
the context of bone tissue engineering (BTE) and cell transplantation procedures 
(Raggi and Berardi, 2012). Some of these alterations have been previously 
explored reinforcing the idea that ageing is partly due to a decline of stem cell 
function. As mentioned previously in this work (see section 1.2.3), possible 
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explanations for this fact may lie at the molecular level. Ageing is associated to an 
accumulation of cells damage affecting DNA, proteins, membranes and organelles 
(Ju and Rudoplh, 2008). Regarding bone cells, it was previously mentioned that a 
decline in oestrogen levels after menopause affects osteogenic differentiation; 
interestingly, oestrogen decline and telomere shortening (and so DNA damage) 
have been linked (Bayne et al., 2011). Another intriguing possibility that may 
explain stem cell loss of function is an alteration at local factors constitutively 
released by these cells. These molecules are required, together with multiple 
systemic factors, as important regulators of cell proliferation and/or differentiation 
fate. Purines and pyrimidines belong to such a group of local signalling molecules 
that are released to bone microenvironment under physiological conditions (e.g. 
mechanical loading, circulating hormones), but whose levels dramatically increase 
in response to bone injury (e.g. inflammation, hypoxia) (see sections 1.1.3 and 
1.4). 
In order to improve stem cell usage in BTE, it is crucial to understand the 
mechanisms underlying the decline of stem cells function and to explore the local 
mediators that may help to ameliorate this condition. Purinergic signalling has 
emerged as a promising field in the context of bone remodelling. Nucleotides (e.g. 
ATP, UTP) are important local regulators of osteogenic differentiation of MSCs 
(see section 1.4). These are constitutively released by cells under basal and/or 
stressful conditions and by binding to multiple P2 purinoceptors (P2Y and P2X) on 
osteoblasts and osteoclasts, may act as autocrine/paracrine regulators of bone 
remodelling (Burnstock et al., 2013). Purinergic signalling effects are influenced by 
multiple factors including the receptor subtype, the extracellular nucleotides 
present locally and the expression of ecto-nucleotidases which will, in turn, 
regulate nucleotide levels (see Burnstock et al., 2013). However, fine-tuning of 
such a complex set of interactions among the various players of the purinergic 
system is still highly controversial. The interplay between purinoceptor subtypes 
and ecto-enzymes on bone cells is still largely unknown leading to a gap in our 
knowledge regarding how they are organized to control bone remodelling. In 
addition, we must be aware that most of the highlights on this subject that are 
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available from the literature derive from using animal models and immortalized 
human cell lines, whilst only a few studies were carried out in non-modified human 
osteoprogenitors / osteoblasts.  
For the reasons stated above, this work emerged to clarify some previously 
unknown molecular mechanisms operating upstream and downstream of P2 
receptors in human osteogenesis, in both health and disease, in order to disclose 
new potential therapeutic targets. So, this work focused on three major goals: (1) 
to investigate the expression and function of uracil nucleotide-sensitive receptors 
(P2Y2, P2Y4, and P2Y6) in human bone marrow MSCs; (2) to study the expression 
and function of P2X7 receptors on osteogenic differentiation of bone marrow 
MSCs in culture, exploring the underlying mechanism involved; (3) to disclose the 
importance of NTPDases in the management of cell differentiation and/or 
proliferation of human MSCs. 
In this study, we demonstrated that isolated human bone marrow-derived MSCs 
express important stem cell markers, namely CD29, CD105, CD117 and CD73. 
Conversely, these cells were negative for haematopoietic surface markers, like 
CD14 and CD45 (Noronha-Matos et al., 2012). These findings suggest that our 
cultures were enriched in MSCs. MSCs allowed to grow in culture with an 
osteogenic-inducing medium synthetize type I collagen and osteocalcin, exhibit 
alkaline phosphatase (ALP) activity, express osteogenic transcription factors like 
Runx-2 and Osterix, and, finally, form bone-nodules of mineralized matrix at latter 
culture stages. This osteogenic differentiation capability is compromised in 
postmenopausal woman when compared to younger females, without being 
accompanied by changes in proliferation (Noronha-Matos et al., 2012).  
Exploitation of the role of purinergic signalling between younger females and 
postmenopausal women revealed previously unknown information. Data show that 
the expression of P2 receptors is age and differentiation-dependent, as it was 
shown in rat osteoprogenitor cells (Orriss et al. 2006). In young females, 
immunoreactivity against P2X7 and P2Y6 increases with time of the cells in culture 
(7<21 days); the opposite was observed regarding the expression of P2Y2 and 
P2Y4 receptors. In the postmenopausal group, the P2Y2 and P2Y4 receptors 
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immunoreactivity increase with time of the cells in culture (7<21 days), whereas 
the P2X7 receptor expression decrease slightly as cells differentiate and P2Y6 
receptor remains fairly constant throughout the culture period (7~21 days). Such 
differences necessarily implicate functional consequences in the context of 
purinergic signalling. Higher expression levels of osteogenic inducing receptors, 
such as P2Y6 and P2X7 receptors, in MSCs from younger females predict 
enhanced osteogenic potential as compared with the cells from postmenopausal 
women (Noronha-Matos et al., 2012; 2014). In contrast, the latter express higher 
levels of P2Y2 and P2Y4 receptors upon maturation, which are known to inhibit 
bone formation when exposed to both ATP and UTP (Hoebertz et al., 2002), thus 
counteracting bone formation induced by UDP and ATP via co-expressed P2Y6 
and P2X7 receptors, respectively. On its own, this receptor pattern might explain 
the differences in the osteogenic potential found between cells from the two age 
groups. We observed in the postmenopausal group that the expression of the 
P2X7 receptor declines slightly throughout the culture period, which may 
additionally contribute to the osteogenic differentiation impairment of MSCs from 
postmenopausal women compared to younger females.  
From data presented in this study, it became evident that UDP-sensitive P2Y6 
and ATP-activated P2X7 receptors are important promoters of osteogenesis and 
matrix mineralization. Unrestrained activation of P2Y6 receptors with a stable UDP 
analogue (PSB 0474), but not with the non-hydrolysable UTP analogue (UTPγS) 
favoured intracellular [Ca2+]i oscillations and increased ALP activity in MSC 
cultures. Nevertheless, the actions of native uracil nucleotides (UDP and UTP) 
declined significantly as MSC cultures progress to a less proliferative and more 
differentiated stage, because their effects may be balanced through nucleotide 
metabolizing enzymes (NTPDases), which determine whether osteoblast 
progenitors are driven into proliferation or differentiation (Noronha-Matos et al., 
2012). Our data regarding the action of the P2X7 receptor on the osteogenic 
commitment of MSCs confirmed epidemiological studies suggesting that loss of 
function polymorphisms of the P2X7 receptor has been associated with increased 
risk of fractures in postmenopausal women. Results presented here demonstrate 
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that activation of the P2X7 receptor increase [Ca2+]i accumulation in parallel to the 
formation of reversible plasma membrane blebs and pores permeable to high-
molecular weight fluorescent dyes (e.g. TO-PRO-3). The way P2X7 receptors 
promote osteogenic differentiation (increase in ALP activity and in the expression 
of osteogenic transcription markers, Runx-2 and Osterix) and mineralization of 
postmenopausal MSCs in culture is independent of [Ca2+]i, but involves 
cytoskeleton rearrangements secondary to the activation of a PLC/PKC/Rho-
kinase pathway. These findings contributed to clarify previously obtained results 
regarding the role of the P2X7 receptor in osteogenic differentiation of human 
osteoprogenitor cells, which have been extrapolated from data obtained in 
different species often with conflicting results (see e.g. Roger et al., 2010). Most 
importantly, our findings point towards new pharmacological targets (the P2X7 
receptor and downstream signalling cascade) for the therapeutic management of 
bone disorders leading to increased bone loss, osteoporosis and fracture risk.   
Activation of P2 purinoceptors may be balanced through the catabolism of 
nucleotides by extracellular enzymes, namely NTPDases. Our findings show, for 
the first time, that the actions of both adenine and uracil nucleotides on the 
osteogenic commitment of MSCs largely depend on the kinetics of their 
extracellular hydrolysis by NTPDases. Thus, beyond age and differentiation-
dependent P2 receptors activity, a second degree of complexity emerges due to 
the differential expression of certain NTPDase subtypes between young females 
and postmenopausal women, which ultimately determines the amount and type of 
nucleotides reaching P2 receptors depending on the maturation stage of the cells. 
We show here, for the first time, that MSCs from young females do not express 
NTPDase3, but this enzyme is highly expressed in more differentiated cells from 
postmenopausal women (Figure 29). On the other hand, while young females 
express consistently both NTPDase1 and 2 along the differentiation process, 
these enzymes only gain significant expression in less proliferative and more 
differentiated cells from postmenopausal women. These differences, together with 
the reported changes with age and differentiation status of MSCs among young 
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Figure 29. Osteogenic differentiation of bone marrow-derived mesenchymal stem cells (MSCs) 
is compromised in postmenopausal woman. (A) Representative diagram of a MSC under 
osteogenic differentiation from a young and healthy female. Nucleotides (like ATP and UTP) 
are constitutively released to the extracellular medium and converted into different metabolites 
throughout the NTPDase cascade, allowing the activation of different P2 receptors, namely 
P2X7 and P2Y6 receptors. Such activation promotes [Ca2+]i oscillations (P2Y6 and P2X7 
receptor) as well as reversible plasma membrane zeiosis (P2X7 receptor), increases the ALP 
activity (P2X7 and P2Y6 receptors) and the expression of transcription factors like Runx-2 and 
Osterix (P2X7 receptor), which are involved in osteogenic differentiation of MSCs. Such 
mechanism(s) causes the commitment of the MSC to become a mature osteoblast, a cell 
capable of new bone formation (mineralization). (B) Representative diagram of a MSC under 
osteogenic differentiation from a postmenopausal woman.  
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females and postmenopausal women, may contribute to explain (at least in part) 
the divergence in the osteogenic potential between the two age groups shedding 
light to find novel putative targets to increase bone formation (Figure 29). The 
most striking difference regarding the purinergic signalling pathway found between 
young females and postmenopausal women was that the lack of NTPDase3 in the 
younger group; the same was recently confirmed in men. This enzyme, as 
mentioned, compromises the activity of the osteogenic inducers P2X7 and P2Y6 
receptors (Figure 29). This difference may give a good explanation for the 
discrepancy between the two age groups concerning the ability to hydrolyse uracil 
nucleotides and their impact on intracellular [Ca2+]i signalling and commitment to 
osteogenic differentiation. In contrast to adenine nucleotides, all membrane-bound 
NTPDases dephosphorylate UTP with a transient formation of UDP, thus favouring 
P2Y6 receptor activation (Kukulski et al., 2005). In younger females, formation of 
nucleotide diphosphates (namely UDP) by NTPDase2 is unrestrained by the 
absence of NTPDase3, a situation that does not occur in postmenopausal women. 
The deleterious influence of overexpression of NTPDase3 on osteogenic 
commitment of postmenopausal MSCs (Figure 29) was confirmed in experiments 
using the selective inhibitor of this enzyme, PSB 06126, or an antibody directed 
against the human enzyme, hN3-B3s. Selective inhibition of NTPDase3 in 
postmenopausal MSCs increased the amount of ATP in the culture medium and 
rescued the osteogenic phenotype observed in younger females concerning 
increases in ALP activity, in the levels of osteogenic factors (Runx-2 and Osterix) 
and in the ability to form mineralized bone-nodules. Using NTPDase3 inhibitors we 
Figure 29. (Continued) Nucleotides (such as ATP and UTP) are constitutively released in 
higher amounts as compared to MSCs from younger individuals (diagram A). Nucleotide 
inactivation (or catabolism) via NTPDases is faster as compared to younger females, since 
these cells over express NTPDase3. This compromises ATP and UDP endogenous levels, and 
so P2X7 and P2Y6 receptors activation, respectively, leading to impairment of osteogenic 
differentiation. In addition, these cells express P2Y2 and P2Y4 receptors which have been 
associated with the inhibition of cell differentiation. This will compromise the formation of new 
bone (mineralization). Grey arrows represent ATP or UTP release (bold arrow means higher 
nucleotide release); black arrows represent nucleotide breakdown (bold arrows means higher 
catabolism rate), P2 receptor’s activation, or cell differentiation; dashed arrows or lines means 
compromised cell differentiation. Mesenchymal stem cell, MSC; NTPDase1, N1; NTPDase2, 
N2; NTPDase3, N3; ecto 5’-nucleotidase/CD73, Ecto 5’. 
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also readmitted tonic activation of P2X7 and P2Y6 receptors by endogenously 
released adenine and uracil nucleotides, which had been lost in postmenopausal 
women as determined by the absence of the effect of specific receptor 
antagonists, respectively A438079 and MRS 2578, in concentrations that 
significantly decreased osteogenic differentiation in younger females (Noronha-
Matos et al., 2012; 2014).  
All together, our results suggest that there are three major potential therapeutic 
targets on the purinergic cascade which may be used for the management of bone 
loss: the UDP-sensitive P2Y6 receptor (Noronha-Matos et al., 2012), the ATP-
sensitive P2X7 receptor (Noronha-Matos et al., 2014), and the ecto-NTPDase3 
enzyme (manuscript in preparation). We strongly believe that these results will 
provide new insights for development of novel therapeutic strategies to increase 
osteogenesis and matrix mineralization in situations where bone destruction 
exceeds bone formation (e.g. osteoporosis, rheumatoid arthritis, osteogenesis 
imperfect, fracture mal-union). In addition, our findings provide the basis to 
promote osteogenic differentiation of postmenopausal MSCs in vitro in the context 
of BTE or cell therapy/transplantation procedures. 
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